<html lang="en" class="js"><head><link rel="preload" href="/static/fonts/HardingText-Regular-Web-cecd90984f.woff2" as="font" type="font/woff2" crossorigin=""><script async="" src="https://scripts.webcontentassessor.com/scripts/93dabb8d80079a87fec7bb6f67b807fce90e1688f8957ad7ad152bfd58ea01c2"></script><script type="text/javascript" async="" src="https://pagead2.googlesyndication.com/tag/js/gpt.js"></script><script async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-MRVXSHQ"></script><script type="text/javascript" src="https://www.nature.com/J2aDduIATYv7HUFVx7d-38dgMmxgffPEAnUowhHPu5Q1c-pY9Z7mKVmj97Q_gxLiqBMDC3RiFJ6Tk4ZIjRcm3Q=="></script><script src="https://cmp.nature.com/production_live/en/consent-bundle-8-85.js" onload="initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')"></script>
    <title>Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial | Nature Medicine</title>
    
        
<link rel="alternate" type="application/rss+xml" href="https://www.nature.com/nm.rss">


    
        

        <script id="save-data-connection-testing">
            function hasConnection() {
                return navigator.connection || navigator.mozConnection || navigator.webkitConnection || navigator.msConnection;
            }

            function createLink(src) {
                var preloadLink = document.createElement("link");
                preloadLink.rel = "preload";
                preloadLink.href = src;
                preloadLink.as = "font";
                preloadLink.type = "font/woff2";
                preloadLink.crossOrigin = "";
                document.head.insertBefore(preloadLink, document.head.firstChild);
            }

            var connectionDetail = {
                saveDataEnabled: false,
                slowConnection: false
            };

            var connection = hasConnection();
            if (connection) {
                connectionDetail.saveDataEnabled = connection.saveData;
                if (/\slow-2g|2g/.test(connection.effectiveType)) {
                    connectionDetail.slowConnection = true;
                }
            }

            if (!(connectionDetail.saveDataEnabled || connectionDetail.slowConnection)) {
                createLink("/static/fonts/HardingText-Regular-Web-cecd90984f.woff2");
            } else {
                document.documentElement.classList.add('save-data');
            }
        </script>
    

<link rel="preconnect" href="https://cmp.nature.com" crossorigin="">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="applicable-device" content="pc,mobile">
<meta name="viewport" content="width=device-width,initial-scale=1.0,maximum-scale=5,user-scalable=yes">
<meta name="360-site-verification" content="5a2dc4ab3fcb9b0393241ffbbb490480">

<script data-test="dataLayer">
    window.dataLayer = [{"content":{"category":{"contentType":"article","legacy":{"webtrendsPrimaryArticleType":"research","webtrendsSubjectTerms":"drug-development;translational-research","webtrendsContentCategory":null,"webtrendsContentCollection":null,"webtrendsContentGroup":"Nature Medicine","webtrendsContentGroupType":null,"webtrendsContentSubGroup":"Article","status":null}},"article":{"doi":"10.1038/s41591-022-02015-7"},"attributes":{"cms":null,"deliveryPlatform":"oscar","copyright":{"open":true,"legacy":{"webtrendsLicenceType":"http://creativecommons.org/licenses/by/4.0/"}}},"contentInfo":{"authors":["Richard D. Carvajal","Marcus O. Butler","Alexander N. Shoushtari","Jessica C. Hassel","Alexandra Ikeguchi","Leonel Hernandez-Aya","Paul Nathan","Omid Hamid","Josep M. Piulats","Matthew Rioth","Douglas B. Johnson","Jason J. Luke","Enrique Espinosa","Serge Leyvraz","Laura Collins","Howard M. Goodall","Koustubh Ranade","Chris Holland","Shaad E. Abdullah","Joseph J. Sacco","Takami Sato"],"publishedAt":1665619200,"publishedAtString":"2022-10-13","title":"Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial","legacy":null,"publishedAtTime":null,"documentType":"aplusplus","subjects":"Drug development,Translational research"},"journal":{"pcode":"nm","title":"nature medicine","volume":"28","issue":"11","id":41591,"publishingModel":"Hybrid Access"},"authorization":{"status":true},"features":[{"name":"furtherReadingSection","present":true}],"collection":null},"page":{"category":{"pageType":"article"},"attributes":{"template":"mosaic","featureFlags":[{"name":"nature-onwards-journey","active":false}],"testGroup":null},"search":null},"privacy":{},"version":"1.0.0","product":null,"session":null,"user":null,"backHalfContent":true,"country":"BR","hasBody":true,"uneditedManuscript":false,"twitterId":["o3xnx","o43y9","o3ef7"],"baiduId":"d38bce82bcb44717ccc29a90c4b781ea","japan":false}];
    window.dataLayer.push({
        ga4MeasurementId: 'G-ERRNTNZ807',
        ga360TrackingId: 'UA-71668177-1',
        twitterId: ['3xnx', 'o43y9', 'o3ef7'],
        baiduId: 'd38bce82bcb44717ccc29a90c4b781ea',
        ga4ServerUrl: 'https://collect.nature.com',
        imprint: 'nature'
    });
</script>

<script>
    (function(w, d) {
        w.config = w.config || {};
        w.config.mustardcut = false;

        
        if (w.matchMedia && w.matchMedia('only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)').matches) {
            w.config.mustardcut = true;
            d.classList.add('js');
            d.classList.remove('grade-c');
            d.classList.remove('no-js');
        }
    })(window, document.documentElement);
</script>
 



     
    
    
        
    
    <style>@media only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark) {  .c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card--major .c-card__title,.c-card__title,.u-h2,.u-h3,h2,h3{font-weight:700;-webkit-font-smoothing:antialiased;font-family:Harding,Palatino,serif;letter-spacing:-.0117156rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card__title,.u-h3,h3{font-size:1.25rem;line-height:1.4rem}.c-reading-companion__figure-title,.u-h4,h4{font-weight:700;-webkit-font-smoothing:antialiased;line-height:1.4rem}html{line-height:1.15;text-size-adjust:100%;box-sizing:border-box;font-size:100%;height:100%;overflow-y:scroll}body{background:#eee;color:#222;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.125rem;line-height:1.76;margin:0;min-height:100%}details,main{display:block}h1{font-size:2em;margin:.67em 0}a,sup{vertical-align:baseline}a{background-color:transparent;color:#069;overflow-wrap:break-word;text-decoration:underline;text-decoration-skip-ink:auto;word-break:break-word}b{font-weight:bolder}sup{font-size:75%;line-height:0;position:relative;top:-.5em}img{border:0;height:auto;max-width:100%;vertical-align:middle}button,input,select{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=submit],button{-webkit-appearance:button}[type=checkbox]{box-sizing:border-box;padding:0}summary{display:list-item}[hidden]{display:none}button{border-radius:0;cursor:pointer;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}h1{font-weight:700;-webkit-font-smoothing:antialiased;font-family:Harding,Palatino,serif;font-size:2rem;letter-spacing:-.0390625rem;line-height:2.25rem}.c-card--major .c-card__title,.u-h2,.u-h3,h2{font-family:Harding,Palatino,serif;letter-spacing:-.0117156rem}.c-card--major .c-card__title,.u-h2,h2{font-weight:700;-webkit-font-smoothing:antialiased;font-size:1.5rem;line-height:1.6rem}.u-h3{font-size:1.25rem}.c-card__title,.c-reading-companion__figure-title,.u-h3,.u-h4,h4,h5,h6{font-weight:700;-webkit-font-smoothing:antialiased;line-height:1.4rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card__title,h3{font-family:Harding,Palatino,serif;font-size:1.25rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,h3{font-weight:700;-webkit-font-smoothing:antialiased;letter-spacing:-.0117156rem;line-height:1.4rem}.c-reading-companion__figure-title,.u-h4,h4{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.125rem;letter-spacing:-.0117156rem}input+label{padding-left:.5em}nav ol,nav ul{list-style:none none}p:empty{display:none}.sans-serif{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.article-page{background:#fff}.c-article-header{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;margin-bottom:40px}.c-article-identifiers{color:#6f6f6f;display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3;list-style:none;margin:0 0 8px;padding:0}.c-article-identifiers__item{border-right:1px solid #6f6f6f;list-style:none;margin-right:8px;padding-right:8px}.c-article-identifiers__item:last-child{border-right:0;margin-right:0;padding-right:0}.c-article-title{font-size:1.5rem;line-height:1.25;margin:0 0 16px}@media only screen and (min-width:768px){.c-article-title{font-size:1.875rem;line-height:1.2}}.c-article-author-list{display:inline;font-size:1rem;list-style:none;margin:0 8px 0 0;padding:0;width:100%}.c-article-author-list__item{display:inline;padding-right:0}.c-article-author-list svg{margin-left:4px}.c-article-author-list__show-more{display:none;margin-right:4px}.c-article-author-list__button,.js .c-article-author-list__item--hide,.js .c-article-author-list__show-more{display:none}.js .c-article-author-list--long .c-article-author-list__show-more,.js .c-article-author-list--long+.c-article-author-list__button{display:inline}@media only screen and (max-width:539px){.js .c-article-author-list__item--hide-small-screen{display:none}.js .c-article-author-list--short .c-article-author-list__show-more,.js .c-article-author-list--short+.c-article-author-list__button{display:inline}}#uptodate-client,.js .c-article-author-list--expanded .c-article-author-list__show-more{display:none!important}.js .c-article-author-list--expanded .c-article-author-list__item--hide-small-screen{display:inline!important}.c-article-author-list__button,.c-button-author-list{background:#ebf1f5;border:4px solid #ebf1f5;border-radius:20px;color:#666;font-size:.875rem;line-height:1.4;padding:2px 11px 2px 8px;text-decoration:none}.c-article-author-list__button svg,.c-button-author-list svg{margin:1px 4px 0 0}.c-article-author-list__button:hover,.c-button-author-list:hover{background:#069;border-color:transparent;color:#fff}.c-article-info-details{font-size:1rem;margin-bottom:8px;margin-top:16px}.c-article-info-details__cite-as{border-left:1px solid #6f6f6f;margin-left:8px;padding-left:8px}.c-article-metrics-bar{display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3}.c-article-metrics-bar__wrapper{margin:16px 0}.c-article-metrics-bar__item{align-items:baseline;border-right:1px solid #6f6f6f;margin-right:8px}.c-article-metrics-bar__item:last-child{border-right:0}.c-article-metrics-bar__count{font-weight:700;margin:0}.c-article-metrics-bar__label{color:#626262;font-style:normal;font-weight:400;margin:0 10px 0 5px}.c-article-metrics-bar__details{margin:0}.c-article-main-column{font-family:Harding,Palatino,serif;margin-right:8.6%;width:60.2%}@media only screen and (max-width:1023px){.c-article-main-column{margin-right:0;width:100%}}.c-article-extras{float:left;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;width:31.2%}@media only screen and (max-width:1023px){.c-article-extras{display:none}}.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{border-bottom:2px solid #d5d5d5;font-size:1.25rem;margin:0;padding-bottom:8px}@media only screen and (min-width:768px){.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{font-size:1.5rem;line-height:1.24}}.c-article-associated-content__container .c-article-associated-content__title{margin-bottom:8px}.c-article-body p{margin-bottom:24px;margin-top:0}.c-article-section{clear:both}.c-article-section__content{margin-bottom:40px;padding-top:8px}@media only screen and (max-width:1023px){.c-article-section__content{padding-left:0}}.c-article-authors-search{margin-bottom:24px;margin-top:0}.c-article-authors-search__item,.c-article-authors-search__title{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.c-article-authors-search__title{color:#626262;font-size:1.05rem;font-weight:700;margin:0;padding:0}.c-article-authors-search__item{font-size:1rem}.c-article-authors-search__text{margin:0}.c-code-block{border:1px solid #eee;font-family:monospace;margin:0 0 24px;padding:20px}.c-code-block__heading{font-weight:400;margin-bottom:16px}.c-code-block__line{display:block;overflow-wrap:break-word;white-space:pre-wrap}.c-article-share-box__no-sharelink-info{font-size:.813rem;font-weight:700;margin-bottom:24px;padding-top:4px}.c-article-share-box__only-read-input{border:1px solid #d5d5d5;box-sizing:content-box;display:inline-block;font-size:.875rem;font-weight:700;height:24px;margin-bottom:8px;padding:8px 10px}.c-article-share-box__button--link-like{background-color:transparent;border:0;color:#069;cursor:pointer;font-size:.875rem;margin-bottom:8px;margin-left:10px}.c-article-editorial-summary__container{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem}.c-article-editorial-summary__container .c-article-editorial-summary__content p:last-child{margin-bottom:0}.c-article-editorial-summary__container .c-article-editorial-summary__content--less{max-height:9.5rem;overflow:hidden}.c-article-editorial-summary__container .c-article-editorial-summary__button{background-color:#fff;border:0;color:#069;font-size:.875rem;margin-bottom:16px}.c-article-editorial-summary__container .c-article-editorial-summary__button.active,.c-article-editorial-summary__container .c-article-editorial-summary__button.hover,.c-article-editorial-summary__container .c-article-editorial-summary__button:active,.c-article-editorial-summary__container .c-article-editorial-summary__button:hover{text-decoration:underline;text-decoration-skip-ink:auto}.c-article-associated-content__container .c-article-associated-content__collection-label{font-size:.875rem;line-height:1.4}.c-article-associated-content__container .c-article-associated-content__collection-title{line-height:1.3}.c-context-bar{box-shadow:0 0 10px 0 rgba(51,51,51,.2);position:relative;width:100%}.c-context-bar__title{display:none}.c-reading-companion{clear:both;min-height:389px}.c-reading-companion__sticky{max-width:389px}.c-reading-companion__scroll-pane{margin:0;min-height:200px;overflow:hidden auto}.c-reading-companion__tabs{display:flex;flex-flow:row nowrap;font-size:1rem;list-style:none;margin:0 0 8px;padding:0}.c-reading-companion__tabs>li{flex-grow:1}.c-reading-companion__tab{background-color:#eee;border:1px solid #d5d5d5;border-image:initial;border-left-width:0;color:#069;font-size:1rem;padding:8px 8px 8px 15px;text-align:left;width:100%}.c-reading-companion__tabs li:first-child .c-reading-companion__tab{border-left-width:1px}.c-reading-companion__tab--active{background-color:#fff;border-bottom:1px solid #fff;color:#222;font-weight:700}.c-reading-companion__sections-list{list-style:none;padding:0}.c-reading-companion__figures-list,.c-reading-companion__references-list{list-style:none;min-height:389px;padding:0}.c-reading-companion__references-list--numeric{list-style:decimal inside}.c-reading-companion__sections-list{margin:0 0 8px;min-height:50px}.c-reading-companion__section-item{font-size:1rem;padding:0}.c-reading-companion__section-item a{display:block;line-height:1.5;overflow:hidden;padding:8px 0 8px 16px;text-overflow:ellipsis;white-space:nowrap}.c-reading-companion__figure-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:16px 8px 16px 0}.c-reading-companion__figure-item:first-child{border-top:none;padding-top:8px}.c-reading-companion__reference-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:8px 8px 8px 16px}.c-reading-companion__reference-item:first-child{border-top:none}.c-reading-companion__reference-item a{word-break:break-word}.c-reading-companion__reference-citation{display:inline}.c-reading-companion__reference-links{font-size:.813rem;font-weight:700;list-style:none;margin:8px 0 0;padding:0;text-align:right}.c-reading-companion__reference-links>a{display:inline-block;padding-left:8px}.c-reading-companion__reference-links>a:first-child{display:inline-block;padding-left:0}.c-reading-companion__figure-title{display:block;margin:0 0 8px}.c-reading-companion__figure-links{display:flex;justify-content:space-between;margin:8px 0 0}.c-reading-companion__figure-links>a{align-items:center;display:flex}.c-reading-companion__figure-full-link svg{height:.8em;margin-left:2px}.c-reading-companion__panel{border-top:none;display:none;margin-top:0;padding-top:0}.c-cod,.c-reading-companion__panel--active{display:block}.c-cod{font-size:1rem;width:100%}.c-cod__form{background:#ebf0f3}.c-cod__prompt{font-size:1.125rem;line-height:1.3;margin:0 0 24px}.c-cod__label{display:block;margin:0 0 4px}.c-cod__row{display:flex;margin:0 0 16px}.c-cod__row:last-child{margin:0}.c-cod__input{border:1px solid #d5d5d5;border-radius:2px;flex-basis:75%;flex-shrink:0;margin:0;padding:13px}.c-cod__input--submit{background-color:#069;border:1px solid #069;color:#fff;flex-shrink:1;margin-left:8px;transition:background-color .2s ease-out 0s,color .2s ease-out 0s}.c-cod__input--submit-single{flex-basis:100%;flex-shrink:0;margin:0}.c-cod__input--submit:focus,.c-cod__input--submit:hover{background-color:#fff;color:#069}.c-pdf-download__link .u-icon{padding-top:2px}.c-pdf-download{display:flex;margin-bottom:16px;max-height:48px}@media only screen and (min-width:540px){.c-pdf-download{max-height:none}}@media only screen and (min-width:1024px){.c-pdf-download{max-height:48px}}.c-pdf-download__link{display:flex;flex:1 1 0%}.c-pdf-download__link:hover{text-decoration:none}.c-pdf-download__text{padding-right:4px}@media only screen and (max-width:539px){.c-pdf-download__text{text-transform:capitalize}}@media only screen and (min-width:540px){.c-pdf-download__text{padding-right:8px}}.c-context-bar--sticky .c-pdf-download{display:block;margin-bottom:0;white-space:nowrap}@media only screen and (max-width:539px){.c-pdf-download .u-sticky-visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}}.c-pdf-container{display:flex;justify-content:flex-end}@media only screen and (max-width:539px){.c-pdf-container .c-pdf-download{display:flex;flex-basis:100%}}.c-pdf-container .c-pdf-download+.c-pdf-download{margin-left:16px}.c-article-extras .c-pdf-container .c-pdf-download{width:100%}.c-article-extras .c-pdf-container .c-pdf-download+.c-pdf-download{margin-left:0}@media only screen and (min-width:540px){.c-context-bar--sticky .c-pdf-download__link{align-items:center;flex:1 1 183px}}@media only screen and (max-width:320px){.c-context-bar--sticky .c-pdf-download__link{padding:16px}}.article-page--commercial .c-article-main-column .c-pdf-button__container .c-pdf-download{display:none}@media only screen and (max-width:1023px){.article-page--commercial .c-article-main-column .c-pdf-button__container .c-pdf-download{display:block}}.c-recommendations-column-switch .c-meta{margin-top:auto}.c-article-recommendations-card__meta-type,.c-meta .c-meta__item:first-child{font-weight:700}.c-article-metrics__heading a,.c-article-metrics__posts .c-card__title a{color:inherit}.c-article-metrics__posts .c-card__title{font-size:1.05rem}.c-article-metrics__posts .c-card__title+span{color:#6f6f6f;font-size:1rem}p{overflow-wrap:break-word;word-break:break-word}.c-ad{text-align:center}@media only screen and (min-width:320px){.c-ad{padding:8px}}.c-ad--728x90{background-color:#ccc;display:none}.c-ad--728x90 .c-ad__inner{min-height:calc(1.5em + 94px)}@media only screen and (min-width:768px){.js .c-ad--728x90{display:none}.js .u-show-following-ad+.c-ad--728x90{display:block}}.c-ad__label{color:#333;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;font-weight:400;line-height:1.5;margin-bottom:4px}.app-author-list{color:#6f6f6f;font-family:inherit;font-size:1rem;line-height:inherit;list-style:none;margin:0;padding:0}.app-author-list>li,.c-breadcrumbs>li,.c-footer__links>li,.js .app-author-list,.u-list-comma-separated>li,.u-list-inline>li{display:inline}.app-author-list>li:not(:first-child):not(:last-child):before{content:", "}.app-author-list>li:not(:only-child):last-child:before{content:" & "}.app-author-list--compact{font-size:.875rem;line-height:1.4}.app-author-list--truncated>li:not(:only-child):last-child:before{content:" ... "}.js .app-author-list__hide{display:none;visibility:hidden}.js .app-author-list__hide:first-child+*{margin-block-start:0}.c-meta{color:inherit;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;line-height:1.4;list-style:none;margin:0;padding:0}.c-meta--large{font-size:1rem}.c-meta--large .c-meta__item{margin-bottom:8px}.c-meta__item{display:inline-block;margin-bottom:4px}.c-meta__item:not(:last-child){border-right:1px solid #d5d5d5;margin-right:4px;padding-right:4px}@media only screen and (max-width:539px){.c-meta__item--block-sm-max{display:block}.c-meta__item--block-sm-max:not(:last-child){border-right:none;margin-right:0;padding-right:0}}@media only screen and (min-width:1024px){.c-meta__item--block-at-lg{display:block}.c-meta__item--block-at-lg:not(:last-child){border-right:none;margin-right:0;padding-right:0}}.c-meta__type{font-weight:700;text-transform:none}.c-skip-link{background:#069;bottom:auto;color:#fff;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;padding:8px;position:absolute;text-align:center;transform:translateY(-100%);z-index:9999}@media (prefers-reduced-motion:reduce){.c-skip-link{transition:top .3s ease-in-out 0s}}@media print{.c-skip-link{display:none}}.c-skip-link:link{color:#fff}.c-status-message{align-items:center;box-sizing:border-box;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;position:relative;width:100%}.c-card__summary>p:last-child,.c-status-message :last-child{margin-bottom:0}.c-status-message--boxed{background-color:#fff;border:1px solid #eee;border-radius:2px;line-height:1.4;padding:16px}.c-status-message__heading{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;font-weight:700}.c-status-message__icon{fill:currentcolor;display:inline-block;flex:0 0 auto;height:1.5em;margin-right:8px;transform:translate(0);vertical-align:text-top;width:1.5em}.c-status-message__icon--top{align-self:flex-start}.c-status-message--info .c-status-message__icon{color:#003f8d}.c-status-message--boxed.c-status-message--info{border-bottom:4px solid #003f8d}.c-status-message--error .c-status-message__icon{color:#c40606}.c-status-message--boxed.c-status-message--error{border-bottom:4px solid #c40606}.c-status-message--success .c-status-message__icon{color:#00b8b0}.c-status-message--boxed.c-status-message--success{border-bottom:4px solid #00b8b0}.c-status-message--warning .c-status-message__icon{color:#edbc53}.c-status-message--boxed.c-status-message--warning{border-bottom:4px solid #edbc53}.c-breadcrumbs{color:#000;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;list-style:none;margin:0;padding:0}.c-breadcrumbs__link{color:#666}svg.c-breadcrumbs__chevron{margin:4px 4px 0;fill:#888;height:10px;width:10px}@media only screen and (max-width:539px){.c-breadcrumbs .c-breadcrumbs__item{display:none}.c-breadcrumbs .c-breadcrumbs__item:last-child,.c-breadcrumbs .c-breadcrumbs__item:nth-last-child(2){display:inline}}.c-card{background-color:transparent;border:0;box-shadow:none;display:flex;flex-direction:column;font-size:14px;min-width:0;overflow:hidden;padding:0;position:relative}.c-card--no-shape{background:0 0;border:0;box-shadow:none}.c-card__image{display:flex;justify-content:center;overflow:hidden;padding-bottom:56.25%;position:relative}@supports (aspect-ratio:1/1){.c-card__image{padding-bottom:0}}.c-card__image img{left:0;min-height:100%;min-width:100%;position:absolute}@supports ((-o-object-fit:cover) or (object-fit:cover)){.c-card__image img{height:100%;object-fit:cover;width:100%}}.c-card__body{flex:1 1 auto;padding:16px}.c-card--no-shape .c-card__body{padding:0}.c-card--no-shape .c-card__body:not(:first-child){padding-top:16px}.c-card__title{letter-spacing:-.01875rem;margin-bottom:8px;margin-top:0}[lang=de] .c-card__title{hyphens:auto}.c-card__summary{line-height:1.4}.c-card__summary>p{margin-bottom:5px}.c-card__summary a{text-decoration:underline}.c-card__link:not(.c-card__link--no-block-link):before{bottom:0;content:"";left:0;position:absolute;right:0;top:0}.c-card--flush .c-card__body{padding:0}.c-card--major{font-size:1rem}.c-card--dark{background-color:#29303c;border-width:0;color:#e3e4e5}.c-card--dark .c-card__title{color:#fff}.c-card--dark .c-card__link,.c-card--dark .c-card__summary a{color:inherit}.c-header{background-color:#fff;border-bottom:5px solid #000;font-size:1rem;line-height:1.4;margin-bottom:16px}.c-header__row{padding:0;position:relative}.c-header__row:not(:last-child){border-bottom:1px solid #eee}.c-header__split{align-items:center;display:flex;justify-content:space-between}.c-header__logo-container{flex:1 1 0px;line-height:0;margin:8px 24px 8px 0}.c-header__logo{transform:translateZ(0)}.c-header__logo img{max-height:32px}.c-header__container{margin:0 auto;max-width:1280px}.c-header__menu{align-items:center;display:flex;flex:0 1 auto;flex-wrap:wrap;font-weight:700;gap:8px 8px;line-height:1.4;list-style:none;margin:0 -8px;padding:0}@media print{.c-header__menu{display:none}}@media only screen and (max-width:1023px){.c-header__menu--hide-lg-max{display:none;visibility:hidden}}.c-header__menu--global{font-weight:400;justify-content:flex-end}.c-header__menu--global svg{display:none;visibility:hidden}.c-header__menu--global svg:first-child+*{margin-block-start:0}@media only screen and (min-width:540px){.c-header__menu--global svg{display:block;visibility:visible}}.c-header__menu--journal{font-size:.875rem;margin:8px 0 8px -8px}@media only screen and (min-width:540px){.c-header__menu--journal{flex-wrap:nowrap;font-size:1rem}}.c-header__item{padding-bottom:0;padding-top:0;position:static}.c-header__item--pipe{border-left:2px solid #eee;padding-left:8px}.c-header__item--padding{padding-bottom:8px;padding-top:8px}@media only screen and (min-width:540px){.c-header__item--dropdown-menu{position:relative}}@media only screen and (min-width:1024px){.c-header__item--hide-lg{display:none;visibility:hidden}}@media only screen and (max-width:767px){.c-header__item--hide-md-max{display:none;visibility:hidden}.c-header__item--hide-md-max:first-child+*{margin-block-start:0}}.c-header__link{align-items:center;color:inherit;display:inline-flex;gap:4px 4px;padding:8px;white-space:nowrap}.c-header__link svg{transition-duration:.2s}.c-header__show-text{display:none;visibility:hidden}.has-tethered .c-header__heading--js-hide:first-child+*{margin-block-start:0}@media only screen and (min-width:540px){.c-header__show-text{display:inline;visibility:visible}}.c-header__dropdown{background-color:#000;border-bottom:1px solid #2f2f2f;color:#eee;font-size:.875rem;line-height:1.2;padding:16px 0}@media print{.c-header__dropdown{display:none}}.c-header__heading{display:inline-block;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.25rem;font-weight:400;line-height:1.4;margin-bottom:8px}.c-header__heading--keyline{border-top:1px solid;border-color:#2f2f2f;margin-top:16px;padding-top:16px;width:100%}.c-header__list{display:flex;flex-wrap:wrap;gap:0 16px;list-style:none;margin:0 -8px}.c-header__flush{margin:0 -8px}.c-header__visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.c-header__search-form{margin-bottom:8px}.c-header__search-layout{display:flex;flex-wrap:wrap;gap:16px 16px}.c-header__search-layout>:first-child{flex:999 1 auto}.c-header__search-layout>*{flex:1 1 auto}.c-header__search-layout--max-width{max-width:720px}.c-header__search-button{align-items:center;background-color:transparent;background-image:none;border:1px solid #fff;border-radius:2px;color:#fff;cursor:pointer;display:flex;font-family:sans-serif;font-size:1rem;justify-content:center;line-height:1.15;margin:0;padding:8px 16px;position:relative;text-decoration:none;transition:all .25s ease 0s,color .25s ease 0s,border-color .25s ease 0s;width:100%}.u-button svg,.u-button--primary svg{fill:currentcolor}.c-header__input,.c-header__select{border:1px solid;border-radius:3px;box-sizing:border-box;font-size:1rem;padding:8px 16px;width:100%}.c-header__select{-webkit-appearance:none;background-image:url("data:image/svg+xml,%3Csvg height='16' viewBox='0 0 16 16' width='16' xmlns='http://www.w3.org/2000/svg'%3E%3Cpath d='m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z' fill='%23333' fill-rule='evenodd' transform='matrix(0 1 -1 0 11 3)'/%3E%3C/svg%3E");background-position:right .7em top 50%;background-repeat:no-repeat;background-size:1em;box-shadow:0 1px 0 1px rgba(0,0,0,.04);display:block;margin:0;max-width:100%;min-width:150px}@media only screen and (min-width:540px){.c-header__menu--journal .c-header__item--dropdown-menu:last-child .c-header__dropdown.has-tethered{left:auto;right:0}}@media only screen and (min-width:768px){.c-header__menu--journal .c-header__item--dropdown-menu:last-child .c-header__dropdown.has-tethered{left:0;right:auto}}.c-header__dropdown.has-tethered{border-bottom:0;border-radius:0 0 2px 2px;left:0;position:absolute;top:100%;transform:translateY(5px);width:100%;z-index:1}@media only screen and (min-width:540px){.c-header__dropdown.has-tethered{transform:translateY(8px);width:auto}}@media only screen and (min-width:768px){.c-header__dropdown.has-tethered{min-width:225px}}.c-header__dropdown--full-width.has-tethered{padding:32px 0 24px;transform:none;width:100%}.has-tethered .c-header__heading--js-hide{display:none;visibility:hidden}.has-tethered .c-header__list--js-stack{flex-direction:column}.has-tethered .c-header__item--keyline,.has-tethered .c-header__list~.c-header__list .c-header__item:first-child{border-top:1px solid #d5d5d5;margin-top:8px;padding-top:8px}.c-header__item--snid-account-widget{display:flex}.c-header__container{padding:0 4px}.c-header__list{padding:0 12px}.c-header__menu .c-header__link{font-size:14px}.c-header__item--snid-account-widget .c-header__link{padding:8px}.c-header__menu--journal{margin-left:0}@media only screen and (min-width:540px){.c-header__container{padding:0 16px}.c-header__menu--journal{margin-left:-8px}.c-header__menu .c-header__link{font-size:16px}.c-header__link--search{gap:13px 13px}}.u-button{align-items:center;background-color:transparent;background-image:none;border:1px solid #069;border-radius:2px;color:#069;cursor:pointer;display:inline-flex;font-family:sans-serif;font-size:1rem;justify-content:center;line-height:1.3;margin:0;padding:8px;position:relative;text-decoration:none;transition:all .25s ease 0s,color .25s ease 0s,border-color .25s ease 0s;width:auto}.u-button--primary{background-color:#069;background-image:none;border:1px solid #069;color:#fff}.u-button--full-width{display:flex;width:100%}.u-display-none{display:none}.js .u-js-hide,.u-hide{display:none;visibility:hidden}.u-hide:first-child+*{margin-block-start:0}.u-visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}@media print{.u-hide-print{display:none}}@media only screen and (min-width:1024px){.u-hide-at-lg{display:none;visibility:hidden}.u-hide-at-lg:first-child+*{margin-block-start:0}}.u-clearfix:after,.u-clearfix:before{content:"";display:table}.u-clearfix:after{clear:both}.u-color-open-access{color:#b74616}.u-float-left{float:left}.u-icon{fill:currentcolor;display:inline-block;height:1em;transform:translate(0);vertical-align:text-top;width:1em}.u-full-height{height:100%}.u-list-reset{list-style:none;margin:0;padding:0}.u-container{margin:0 auto;max-width:1280px;padding:0 16px}.u-justify-content-space-between{justify-content:space-between}.u-mt-32{margin-top:32px}.u-mb-8{margin-bottom:8px}.u-mb-16{margin-bottom:16px}.u-mb-24{margin-bottom:24px}.u-mb-32{margin-bottom:32px}.c-nature-box svg+.c-article__button-text,.u-ml-8{margin-left:8px}.u-pa-16{padding:16px}html *,html :after,html :before{box-sizing:inherit}.c-article-section__title,.c-article-title{font-weight:700}.c-card__title{line-height:1.4em}.c-article__button{background-color:#069;border:1px solid #069;border-radius:2px;color:#fff;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;line-height:1.4;margin-bottom:16px;padding:13px;transition:background-color .2s ease-out 0s,color .2s ease-out 0s}.c-article__button,.c-article__button:hover{text-decoration:none}.c-article__button--inverted,.c-article__button:hover{background-color:#fff;color:#069}.c-article__button--inverted:hover{background-color:#069;color:#fff}.c-header__link{text-decoration:inherit}.grade-c-hide{display:block}.c-nature-box{background-color:#fff;border:1px solid #d5d5d5;border-radius:2px;box-shadow:0 0 5px 0 rgba(51,51,51,.1);line-height:1.3;margin-bottom:24px;padding:16px 16px 3px}.c-nature-box__text{font-size:1rem;margin-bottom:16px}.c-nature-box--access-to-pdf{display:none}@media only screen and (min-width:1024px){.c-nature-box--mobile{display:none}}.c-nature-box .c-pdf-download{margin-bottom:16px!important}.c-nature-box--version{background-color:#eee}.c-nature-box__wrapper{transform:translateZ(0)}.c-nature-box__wrapper--placeholder{min-height:165px}.c-pdf-download__link{padding:13px 24px} } </style>




    
        <link data-test="critical-css-handler" data-inline-css-source="critical-css" rel="stylesheet" href="/static/css/enhanced-article-nature-branded-1dd982e2cc.css" media="only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)" onload="this.media='only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)';this.onload=null">
    
    <noscript>
        <link rel="stylesheet" type="text/css" href="/static/css/enhanced-article-nature-branded-1dd982e2cc.css" media="only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)">
    </noscript>

<link rel="stylesheet" type="text/css" href="/static/css/article-print-c9121fecab.css" media="print">
    



<link rel="apple-touch-icon" sizes="180x180" href="/static/images/favicons/nature/apple-touch-icon-f39cb19454.png">
<link rel="icon" type="image/png" sizes="48x48" href="/static/images/favicons/nature/favicon-48x48-b52890008c.png">
<link rel="icon" type="image/png" sizes="32x32" href="/static/images/favicons/nature/favicon-32x32-3fe59ece92.png">
<link rel="icon" type="image/png" sizes="16x16" href="/static/images/favicons/nature/favicon-16x16-951651ab72.png">
<link rel="manifest" href="/static/manifest.json" crossorigin="use-credentials">
<link rel="mask-icon" href="/static/images/favicons/nature/safari-pinned-tab-69bff48fe6.svg" color="#000000">
<link rel="shortcut icon" href="/static/images/favicons/nature/favicon.ico">
<meta name="msapplication-TileColor" content="#000000">
<meta name="msapplication-config" content="/static/browserconfig.xml">
<meta name="theme-color" content="#000000">
<meta name="application-name" content="Nature">


<script>
    (function () {
        if ( typeof window.CustomEvent === "function" ) return false;
        function CustomEvent ( event, params ) {
            params = params || { bubbles: false, cancelable: false, detail: null };
            var evt = document.createEvent( 'CustomEvent' );
            evt.initCustomEvent( event, params.bubbles, params.cancelable, params.detail );
            return evt;
        }

        CustomEvent.prototype = window.Event.prototype;

        window.CustomEvent = CustomEvent;
    })();
</script>



<!-- Google Tag Manager -->
<script data-test="gtm-head">
    window.initGTM = function() {
        if (window.config.mustardcut) {
            (function (w, d, s, l, i) {
                w[l] = w[l] || [];
                w[l].push({'gtm.start': new Date().getTime(), event: 'gtm.js'});
                var f = d.getElementsByTagName(s)[0],
                        j = d.createElement(s),
                        dl = l != 'dataLayer' ? '&l=' + l : '';
                j.async = true;
                j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl;
                f.parentNode.insertBefore(j, f);
            })(window, document, 'script', 'dataLayer', 'GTM-MRVXSHQ');
        }
    }
</script>
<!-- End Google Tag Manager -->

    <script>
    (function(w,d,t) {
        function cc() {
            var h = w.location.hostname;
            if (h.indexOf('preview-www.nature.com') > -1) return;

            var e = d.createElement(t),
                    s = d.getElementsByTagName(t)[0];

            if (h.indexOf('nature.com') > -1) {
                if (h.indexOf('test-www.nature.com') > -1) {
                    e.src = 'https://cmp.nature.com/production_live/en/consent-bundle-8-85.js';
                    e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')");
                } else {
                    e.src = 'https://cmp.nature.com/production_live/en/consent-bundle-8-85.js';
                    e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')");
                }
            } else {
                e.src = '/static/js/cookie-consent-es5-bundle-cb57c2c98a.js';
                e.setAttribute('data-consent', h);
            }
            s.insertAdjacentElement('afterend', e);
        }

        cc();
    })(window,document,'script');
</script>


<script id="js-position0">
    (function(w, d) {
        w.idpVerifyPrefix = 'https://verify.nature.com';
        w.ra21Host = 'https://wayf.springernature.com';
        var moduleSupport = (function() {
            return 'noModule' in d.createElement('script');
        })();

        if (w.config.mustardcut === true) {
            w.loader = {
                index: 0,
                registered: [],
                scripts: [
                    
                        {src: '/static/js/global-article-es6-bundle-c8a573ca90.js', test: 'global-article-js', module: true},
                        {src: '/static/js/global-article-es5-bundle-d17603b9e9.js', test: 'global-article-js', nomodule: true},
                        {src: '/static/js/shared-es6-bundle-e9d2061c95.js', test: 'shared-js', module: true},
                        {src: '/static/js/shared-es5-bundle-1cbf3a8b56.js', test: 'shared-js', nomodule: true},
                        {src: '/static/js/header-150-es6-bundle-5bb959eaa1.js', test: 'header-150-js', module: true},
                        {src: '/static/js/header-150-es5-bundle-994fde5b1d.js', test: 'header-150-js', nomodule: true}
                    
                ].filter(function (s) {
                    if (s.src === null) return false;
                    if (moduleSupport && s.nomodule) return false;
                    return !(!moduleSupport && s.module);
                }),

                register: function (value) {
                    this.registered.push(value);
                },

                ready: function () {
                    if (this.registered.length === this.scripts.length) {
                        this.registered.forEach(function (fn) {
                            if (typeof fn === 'function') {
                                setTimeout(fn, 0); 
                            }
                        });
                        this.ready = function () {};
                    }
                },

                insert: function (s) {
                    var t = d.getElementById('js-position' + this.index);
                    if (t && t.insertAdjacentElement) {
                        t.insertAdjacentElement('afterend', s);
                    } else {
                        d.head.appendChild(s);
                    }
                    ++this.index;
                },

                createScript: function (script, beforeLoad) {
                    var s = d.createElement('script');
                    s.id = 'js-position' + (this.index + 1);
                    s.setAttribute('data-test', script.test);
                    if (beforeLoad) {
                        s.defer = 'defer';
                        s.onload = function () {
                            if (script.noinit) {
                                loader.register(true);
                            }
                            if (d.readyState === 'interactive' || d.readyState === 'complete') {
                                loader.ready();
                            }
                        };
                    } else {
                        s.async = 'async';
                    }
                    s.src = script.src;
                    return s;
                },

                init: function () {
                    this.scripts.forEach(function (s) {
                        loader.insert(loader.createScript(s, true));
                    });

                    d.addEventListener('DOMContentLoaded', function () {
                        loader.ready();
                        var conditionalScripts;
                        
                            conditionalScripts = [
                                {match: 'div[data-pan-container]', src: '/static/js/pan-zoom-es6-bundle-464a2af269.js', test: 'pan-zoom-js',  module: true },
                                {match: 'div[data-pan-container]', src: '/static/js/pan-zoom-es5-bundle-98fb9b653b.js', test: 'pan-zoom-js',  nomodule: true },
                                {match: 'math,span.mathjax-tex', src: '/static/js/math-es6-bundle-23597ae350.js', test: 'math-js', module: true},
                                {match: 'math,span.mathjax-tex', src: '/static/js/math-es5-bundle-6532c6f78b.js', test: 'math-js', nomodule: true}
                            ];
                        

                        if (conditionalScripts) {
                            conditionalScripts.filter(function (script) {
                                return !!document.querySelector(script.match) && !((moduleSupport && script.nomodule) || (!moduleSupport && script.module));
                            }).forEach(function (script) {
                                loader.insert(loader.createScript(script));
                            });
                        }
                    }, false);
                }
            };
            loader.init();
        }
    })(window, document);
</script><script id="js-position1" data-test="global-article-js" defer="" src="/static/js/global-article-es6-bundle-c8a573ca90.js"></script><script id="js-position2" data-test="shared-js" defer="" src="/static/js/shared-es6-bundle-e9d2061c95.js"></script><script id="js-position3" data-test="header-150-js" defer="" src="/static/js/header-150-es6-bundle-5bb959eaa1.js"></script>










<meta name="robots" content="noarchive">
<meta name="access" content="Yes">


<link rel="search" href="https://www.nature.com/search">
<link rel="search" href="https://www.nature.com/opensearch/opensearch.xml" type="application/opensearchdescription+xml" title="nature.com">
<link rel="search" href="https://www.nature.com/opensearch/request" type="application/sru+xml" title="nature.com">





    
    <script type="application/ld+json">{"mainEntity":{"headline":"Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial","description":"In patients with previously treated metastatic uveal melanoma, the historical 1 year overall survival rate is 37% with a median overall survival of 7.8 months. We conducted a multicenter, single-arm, open-label phase 2 study of tebentafusp, a soluble T cell receptor bispecific (gp100×CD3), in 127 patients with treatment-refractory metastatic uveal melanoma (NCT02570308). The primary endpoint was the estimation of objective response rate based on RECIST (Response Evaluation Criteria in Solid Tumours) v1.1. Secondary objectives included safety, overall survival, progression-free survival and disease control rate. All patients had at least one treatment-related adverse event, with rash (87%), pyrexia (80%) and pruritus (67%) being the most common. Toxicity was mostly mild to moderate in severity but was greatly reduced in incidence and intensity after the initial three doses. Despite a low overall response rate of 5% (95% CI: 2–10%), the 1 year overall survival rate was 62% (95% CI: 53–70%) with a median overall survival of 16.8 months (95% CI: 12.9–21.3), suggesting benefit beyond traditional radiographic-based response criteria. In an exploratory analysis, early on-treatment reduction in circulating tumour DNA was strongly associated with overall survival, even in patients with radiographic progression. Our findings indicate that tebentafusp has promising clinical activity with an acceptable safety profile in patients with previously treated metastatic uveal melanoma, and data suggesting ctDNA as an early indicator of clinical benefit from tebentafusp need confirmation in a randomized trial. In a multicenter, single-arm, open-label phase 2 study of patients with previously treated metastatic uveal melanoma, treatment with tebentafusp, a soluble TCR bispecific (gp100xCD3) showed promising clinical activity with an acceptable safety profile.","datePublished":"2022-10-13T00:00:00Z","dateModified":"2022-10-13T00:00:00Z","pageStart":"2364","pageEnd":"2373","license":"http://creativecommons.org/licenses/by/4.0/","sameAs":"https://doi.org/10.1038/s41591-022-02015-7","keywords":["Drug development","Translational research","Biomedicine","general","Cancer Research","Metabolic Diseases","Infectious Diseases","Molecular Medicine","Neurosciences"],"image":["https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig1_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig2_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig3_HTML.png"],"isPartOf":{"name":"Nature Medicine","issn":["1546-170X","1078-8956"],"volumeNumber":"28","@type":["Periodical","PublicationVolume"]},"publisher":{"name":"Nature Publishing Group US","logo":{"url":"https://www.springernature.com/app-sn/public/images/logo-springernature.png","@type":"ImageObject"},"@type":"Organization"},"author":[{"name":"Richard D. Carvajal","url":"http://orcid.org/0000-0002-3796-1118","affiliation":[{"name":"Columbia University Irving Medical Center","address":{"name":"Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Marcus O. Butler","url":"http://orcid.org/0000-0002-9840-7057","affiliation":[{"name":"University of Toronto","address":{"name":"Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Alexander N. Shoushtari","url":"http://orcid.org/0000-0002-8065-4412","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center","address":{"name":"Memorial Sloan Kettering Cancer Center, New York, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Weill Cornell Medical College","address":{"name":"Weill Cornell Medical College, New York, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Jessica C. Hassel","affiliation":[{"name":"University Hospital Heidelberg","address":{"name":"University Hospital Heidelberg, Heidelberg, Germany","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Alexandra Ikeguchi","url":"http://orcid.org/0000-0002-4448-9755","affiliation":[{"name":"University of Oklahoma","address":{"name":"Stephenson Cancer Center, University of Oklahoma, Oklahoma City, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Leonel Hernandez-Aya","affiliation":[{"name":"Washington University School of Medicine","address":{"name":"Washington University School of Medicine, Saint Louis, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Paul Nathan","affiliation":[{"name":"Mount Vernon Cancer Centre – East and North Herts NHS Trust","address":{"name":"Mount Vernon Cancer Centre – East and North Herts NHS Trust, Northwood, UK","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Omid Hamid","affiliation":[{"name":"The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate","address":{"name":"The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Josep M. Piulats","affiliation":[{"name":"Hospitalet de Llobregat","address":{"name":"Institut Català d’Oncologia l’Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, Barcelona, Spain","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Matthew Rioth","affiliation":[{"name":"University of Colorado","address":{"name":"UC Cancer Center, University of Colorado, Aurora, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Douglas B. Johnson","url":"http://orcid.org/0000-0002-6390-773X","affiliation":[{"name":"Vanderbilt University Medical Center","address":{"name":"Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Jason J. Luke","affiliation":[{"name":"University of Pittsburgh","address":{"name":"UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Enrique Espinosa","affiliation":[{"name":"Hospital Universitario La Paz – CIBERONC","address":{"name":"Hospital Universitario La Paz – CIBERONC, Madrid, Spain","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Serge Leyvraz","affiliation":[{"name":"Charité – Universitätsmedizin Berlin","address":{"name":"Charité Comprehensive Cancer Center, Charité – Universitätsmedizin Berlin, Berlin, Germany","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Laura Collins","affiliation":[{"name":"Immunocore","address":{"name":"Immunocore, Abingdon-on-Thames, UK","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Howard M. Goodall","affiliation":[{"name":"Immunocore","address":{"name":"Immunocore, Abingdon-on-Thames, UK","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Koustubh Ranade","affiliation":[{"name":"Immunocore","address":{"name":"Immunocore, Rockville, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Chris Holland","affiliation":[{"name":"Immunocore","address":{"name":"Immunocore, Rockville, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Shaad E. Abdullah","url":"http://orcid.org/0000-0003-0776-7477","affiliation":[{"name":"Immunocore","address":{"name":"Immunocore, Rockville, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Joseph J. Sacco","url":"http://orcid.org/0000-0003-2591-9796","affiliation":[{"name":"Clatterbridge Cancer Center – NHS Foundation Trust","address":{"name":"Clatterbridge Cancer Center – NHS Foundation Trust, Wirral, UK","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of Liverpool","address":{"name":"University of Liverpool, Liverpool, UK","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Takami Sato","url":"http://orcid.org/0000-0003-2221-0415","affiliation":[{"name":"Jefferson University","address":{"name":"Sidney Kimmel Cancer Center, Jefferson University, Philadelphia, USA","@type":"PostalAddress"},"@type":"Organization"}],"email":"takami.sato@jefferson.edu","@type":"Person"}],"isAccessibleForFree":true,"@type":"ScholarlyArticle"},"@context":"https://schema.org","@type":"WebPage"}</script>




    
    
    


    
    <link rel="canonical" href="https://www.nature.com/articles/s41591-022-02015-7">
    
    
    <meta name="journal_id" content="41591">
    <meta name="dc.title" content="Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial">
    <meta name="dc.source" content="Nature Medicine 2022 28:11">
    <meta name="dc.format" content="text/html">
    <meta name="dc.publisher" content="Nature Publishing Group">
    <meta name="dc.date" content="2022-10-13">
    <meta name="dc.type" content="OriginalPaper">
    <meta name="dc.language" content="En">
    <meta name="dc.copyright" content="2022 The Author(s), under exclusive licence to Springer Nature America, Inc.">
    <meta name="dc.rights" content="2022 The Author(s), under exclusive licence to Springer Nature America, Inc.">
    <meta name="dc.rightsAgent" content="journalpermissions@springernature.com">
    <meta name="dc.description" content="In patients with previously treated metastatic uveal melanoma, the historical 1 year overall survival rate is 37% with a median overall survival of 7.8 months. We conducted a multicenter, single-arm, open-label phase 2 study of tebentafusp, a soluble T cell receptor bispecific (gp100×CD3), in 127 patients with treatment-refractory metastatic uveal melanoma (NCT02570308). The primary endpoint was the estimation of objective response rate based on RECIST (Response Evaluation Criteria in Solid Tumours) v1.1. Secondary objectives included safety, overall survival, progression-free survival and disease control rate. All patients had at least one treatment-related adverse event, with rash (87%), pyrexia (80%) and pruritus (67%) being the most common. Toxicity was mostly mild to moderate in severity but was greatly reduced in incidence and intensity after the initial three doses. Despite a low overall response rate of 5% (95% CI: 2–10%), the 1 year overall survival rate was 62% (95% CI: 53–70%) with a median overall survival of 16.8 months (95% CI: 12.9–21.3), suggesting benefit beyond traditional radiographic-based response criteria. In an exploratory analysis, early on-treatment reduction in circulating tumour DNA was strongly associated with overall survival, even in patients with radiographic progression. Our findings indicate that tebentafusp has promising clinical activity with an acceptable safety profile in patients with previously treated metastatic uveal melanoma, and data suggesting ctDNA as an early indicator of clinical benefit from tebentafusp need confirmation in a randomized trial. In a multicenter, single-arm, open-label phase 2 study of patients with previously treated metastatic uveal melanoma, treatment with tebentafusp, a soluble TCR bispecific (gp100xCD3) showed promising clinical activity with an acceptable safety profile.">
    <meta name="prism.issn" content="1546-170X">
    <meta name="prism.publicationName" content="Nature Medicine">
    <meta name="prism.publicationDate" content="2022-10-13">
    <meta name="prism.volume" content="28">
    <meta name="prism.number" content="11">
    <meta name="prism.section" content="OriginalPaper">
    <meta name="prism.startingPage" content="2364">
    <meta name="prism.endingPage" content="2373">
    <meta name="prism.copyright" content="2022 The Author(s), under exclusive licence to Springer Nature America, Inc.">
    <meta name="prism.rightsAgent" content="journalpermissions@springernature.com">
    <meta name="prism.url" content="https://www.nature.com/articles/s41591-022-02015-7">
    <meta name="prism.doi" content="doi:10.1038/s41591-022-02015-7">
    <meta name="citation_pdf_url" content="https://www.nature.com/articles/s41591-022-02015-7.pdf">
    <meta name="citation_fulltext_html_url" content="https://www.nature.com/articles/s41591-022-02015-7">
    <meta name="citation_journal_title" content="Nature Medicine">
    <meta name="citation_journal_abbrev" content="Nat Med">
    <meta name="citation_publisher" content="Nature Publishing Group">
    <meta name="citation_issn" content="1546-170X">
    <meta name="citation_title" content="Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial">
    <meta name="citation_volume" content="28">
    <meta name="citation_issue" content="11">
    <meta name="citation_publication_date" content="2022/11">
    <meta name="citation_online_date" content="2022/10/13">
    <meta name="citation_firstpage" content="2364">
    <meta name="citation_lastpage" content="2373">
    <meta name="citation_article_type" content="Article">
    <meta name="citation_fulltext_world_readable" content="">
    <meta name="citation_language" content="en">
    <meta name="dc.identifier" content="doi:10.1038/s41591-022-02015-7">
    <meta name="DOI" content="10.1038/s41591-022-02015-7">
    <meta name="size" content="237529">
    <meta name="citation_doi" content="10.1038/s41591-022-02015-7">
    <meta name="citation_springer_api_url" content="http://api.springer.com/xmldata/jats?q=doi:10.1038/s41591-022-02015-7&amp;api_key=">
    <meta name="description" content="In patients with previously treated metastatic uveal melanoma, the historical 1 year overall survival rate is 37% with a median overall survival of 7.8 months. We conducted a multicenter, single-arm, open-label phase 2 study of tebentafusp, a soluble T cell receptor bispecific (gp100×CD3), in 127 patients with treatment-refractory metastatic uveal melanoma (NCT02570308). The primary endpoint was the estimation of objective response rate based on RECIST (Response Evaluation Criteria in Solid Tumours) v1.1. Secondary objectives included safety, overall survival, progression-free survival and disease control rate. All patients had at least one treatment-related adverse event, with rash (87%), pyrexia (80%) and pruritus (67%) being the most common. Toxicity was mostly mild to moderate in severity but was greatly reduced in incidence and intensity after the initial three doses. Despite a low overall response rate of 5% (95% CI: 2–10%), the 1 year overall survival rate was 62% (95% CI: 53–70%) with a median overall survival of 16.8 months (95% CI: 12.9–21.3), suggesting benefit beyond traditional radiographic-based response criteria. In an exploratory analysis, early on-treatment reduction in circulating tumour DNA was strongly associated with overall survival, even in patients with radiographic progression. Our findings indicate that tebentafusp has promising clinical activity with an acceptable safety profile in patients with previously treated metastatic uveal melanoma, and data suggesting ctDNA as an early indicator of clinical benefit from tebentafusp need confirmation in a randomized trial. In a multicenter, single-arm, open-label phase 2 study of patients with previously treated metastatic uveal melanoma, treatment with tebentafusp, a soluble TCR bispecific (gp100xCD3) showed promising clinical activity with an acceptable safety profile.">
    <meta name="dc.creator" content="Carvajal, Richard D.">
    <meta name="dc.creator" content="Butler, Marcus O.">
    <meta name="dc.creator" content="Shoushtari, Alexander N.">
    <meta name="dc.creator" content="Hassel, Jessica C.">
    <meta name="dc.creator" content="Ikeguchi, Alexandra">
    <meta name="dc.creator" content="Hernandez-Aya, Leonel">
    <meta name="dc.creator" content="Nathan, Paul">
    <meta name="dc.creator" content="Hamid, Omid">
    <meta name="dc.creator" content="Piulats, Josep M.">
    <meta name="dc.creator" content="Rioth, Matthew">
    <meta name="dc.creator" content="Johnson, Douglas B.">
    <meta name="dc.creator" content="Luke, Jason J.">
    <meta name="dc.creator" content="Espinosa, Enrique">
    <meta name="dc.creator" content="Leyvraz, Serge">
    <meta name="dc.creator" content="Collins, Laura">
    <meta name="dc.creator" content="Goodall, Howard M.">
    <meta name="dc.creator" content="Ranade, Koustubh">
    <meta name="dc.creator" content="Holland, Chris">
    <meta name="dc.creator" content="Abdullah, Shaad E.">
    <meta name="dc.creator" content="Sacco, Joseph J.">
    <meta name="dc.creator" content="Sato, Takami">
    <meta name="dc.subject" content="Drug development">
    <meta name="dc.subject" content="Translational research">
    <meta name="citation_reference" content="Milam, R. W. &amp; Daniels, A. B. Uveal melanoma. In Melanoma (ed. Riker, A.) pp. 273–312 (Springer, 2018). 
                  https://doi.org/10.1007/978-3-319-78310-9_16
                  
                ">
    <meta name="citation_reference" content="citation_journal_title=Int. J. Cancer; citation_title=International uveal melanoma incidence trends in view of a decreasing proportion of morphological verification; citation_author=A Stang, DM Parkin, J Ferlay, K Jöckel; citation_volume=114; citation_publication_date=2005; citation_pages=114-123; citation_doi=10.1002/ijc.20690; citation_id=CR2">
    <meta name="citation_reference" content="citation_journal_title=Ophthalmology; citation_title=Incidence of uveal melanoma in Europe; citation_author=G Virgili; citation_volume=114; citation_publication_date=2007; citation_pages=2309-2315; citation_doi=10.1016/j.ophtha.2007.01.032; citation_id=CR3">
    <meta name="citation_reference" content="citation_journal_title=Invest. Ophthalmol. Vis. Sci.; citation_title=Very long-term prognosis of patients with malignant uveal melanoma; citation_author=E Kujala, T Makitie, T Kivela; citation_volume=44; citation_publication_date=2003; citation_pages=4651-4659; citation_doi=10.1167/iovs.03-0538; citation_id=CR4">
    <meta name="citation_reference" content="citation_journal_title=Oncol. Ther.; citation_title=Uveal melanoma: a review of the literature; citation_author=M Singh, P Durairaj, J Yeung; citation_volume=6; citation_publication_date=2018; citation_pages=87-104; citation_doi=10.1007/s40487-018-0056-8; citation_id=CR5">
    <meta name="citation_reference" content="citation_journal_title=Ther. Adv. Med. Oncol.; citation_title=Treatment of uveal melanoma: where are we now?; citation_author=J Yang, DK Manson, BP Marr, RD Carvajal; citation_volume=10; citation_publication_date=2018; citation_pages=1758834018757175; citation_doi=10.1177/1758834018757175; citation_id=CR6">
    <meta name="citation_reference" content="citation_journal_title=Br. J. Ophthalmol.; citation_title=Metastatic disease from uveal melanoma: treatment options and future prospects; citation_author=RD Carvajal; citation_volume=101; citation_publication_date=2017; citation_pages=38-44; citation_doi=10.1136/bjophthalmol-2016-309034; citation_id=CR7">
    <meta name="citation_reference" content="citation_journal_title=Science; citation_title=Frequent mutation of BAP1 in metastasizing uveal melanomas; citation_author=JW Harbour; citation_volume=330; citation_publication_date=2010; citation_pages=1410-1413; citation_doi=10.1126/science.1194472; citation_id=CR8">
    <meta name="citation_reference" content="citation_journal_title=Nat. Commun.; citation_title=Molecular profiling of driver events in metastatic uveal melanoma; citation_author=J Karlsson; citation_volume=11; citation_publication_date=2020; citation_doi=10.1038/s41467-020-15606-0; citation_id=CR9">
    <meta name="citation_reference" content="citation_journal_title=Nat. Genet.; citation_title=Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3; citation_author=M Martin; citation_volume=45; citation_publication_date=2013; citation_pages=933-936; citation_doi=10.1038/ng.2674; citation_id=CR10">
    <meta name="citation_reference" content="citation_journal_title=PLoS One; citation_title=Systematic genomic and translational efficiency studies of uveal melanoma; citation_author=CP Johnson; citation_volume=12; citation_publication_date=2017; citation_pages=e0178189; citation_doi=10.1371/journal.pone.0178189; citation_id=CR11">
    <meta name="citation_reference" content="citation_journal_title=Immunotherapy; citation_title=PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma; citation_author=A Javed; citation_volume=9; citation_publication_date=2017; citation_pages=1323-1330; citation_doi=10.2217/imt-2017-0066; citation_id=CR12">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Overall survival benefit with tebentafusp in metastatic uveal melanoma; citation_author=P Nathan; citation_volume=385; citation_publication_date=2021; citation_pages=1196-1206; citation_doi=10.1056/NEJMoa2103485; citation_id=CR13">
    <meta name="citation_reference" content="citation_journal_title=JAMA; citation_title=Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial; citation_author=RD Carvajal; citation_volume=311; citation_publication_date=2014; citation_pages=2397-2405; citation_doi=10.1001/jama.2014.6096; citation_id=CR14">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study; citation_author=MS Pelster; citation_volume=39; citation_publication_date=2021; citation_pages=599-607; citation_doi=10.1200/JCO.20.00605; citation_id=CR15">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402); citation_author=JM Piulats; citation_volume=39; citation_publication_date=2021; citation_pages=586-598; citation_doi=10.1200/JCO.20.00550; citation_id=CR16">
    <meta name="citation_reference" content="citation_journal_title=Ann. Oncol.; citation_title=Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an International Rare Cancers Initiative (IRCI) ocular melanoma study; citation_author=L Khoja; citation_volume=30; citation_publication_date=2019; citation_pages=1370-1380; citation_doi=10.1093/annonc/mdz176; citation_id=CR17">
    <meta name="citation_reference" content="citation_journal_title=Melanoma Res.; citation_title=Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis; citation_author=ES Rantala, M Hernberg, TT Kivelä; citation_volume=29; citation_publication_date=2019; citation_pages=561-568; citation_doi=10.1097/CMR.0000000000000575; citation_id=CR18">
    <meta name="citation_reference" content="citation_journal_title=Cancer Immunol. Immunother.; citation_title=ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells; citation_author=G Bossi, S Buisson, J Oates, BK Jakobsen, NJ Hassan; citation_volume=63; citation_publication_date=2014; citation_pages=437-448; citation_doi=10.1007/s00262-014-1525-z; citation_id=CR19">
    <meta name="citation_reference" content="citation_journal_title=Nat. Med.; citation_title=Monoclonal TCR-redirected tumor cell killing; citation_author=N Liddy; citation_volume=18; citation_publication_date=2012; citation_pages=980-987; citation_doi=10.1038/nm.2764; citation_id=CR20">
    <meta name="citation_reference" content="citation_journal_title=Clin. Cancer Res.; citation_title=Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma; citation_author=MR Middleton; citation_volume=26; citation_publication_date=2020; citation_pages=5869-5878; citation_doi=10.1158/1078-0432.CCR-20-1247; citation_id=CR21">
    <meta name="citation_reference" content="citation_journal_title=Immunology; citation_title=Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells; citation_author=C Boudousquie; citation_volume=152; citation_publication_date=2017; citation_pages=425-438; citation_doi=10.1111/imm.12779; citation_id=CR22">
    <meta name="citation_reference" content="citation_journal_title=Clin. Trials; citation_title=Abstract CT106: a phase I/IIa study of IMCgp100: partial and complete durable responses with a novel first-in-class immunotherapy for advanced melanoma; citation_author=MR Middleton; citation_volume=75; citation_publication_date=2015; citation_pages=CT106; citation_id=CR23">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific T cell redirector with solid tumour activity: results from the FIH study in melanoma (Abstract 3016); citation_author=MR Middleton; citation_volume=34; citation_issue=15 Suppl.; citation_publication_date=2016; citation_pages=3016; citation_doi=10.1200/JCO.2016.34.15_suppl.3016; citation_id=CR24">
    <meta name="citation_reference" content="citation_journal_title=J. Immunother. Cancer; citation_title=Safety, efficacy and biology of the gp100 TCR-based bispecific T cell redirector, IMCgp100 in advanced uveal melanoma in two Phase 1 trials (Poster 208); citation_author=R Carvajal; citation_volume=5; citation_issue=Suppl. 2; citation_publication_date=2017; citation_pages=P208; citation_id=CR25">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T-cell based toxicity and preliminary efficacy in advanced uveal melanoma (Abstract 9531); citation_author=T Sato; citation_volume=35; citation_issue=15 Suppl.; citation_publication_date=2017; citation_pages=9531; citation_doi=10.1200/JCO.2017.35.15_suppl.9531; citation_id=CR26">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma; citation_author=RD Carvajal; citation_volume=40; citation_publication_date=2022; citation_pages=1939-1948; citation_doi=10.1200/JCO.21.01805; citation_id=CR27">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma (Abstract 4); citation_author=S O’Day; citation_volume=28; citation_issue=18 Suppl.; citation_publication_date=2010; citation_pages=4; citation_doi=10.1200/jco.2010.28.18_suppl.4; citation_id=CR28">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab; citation_author=FS Hodi; citation_volume=34; citation_publication_date=2016; citation_pages=1510-1517; citation_doi=10.1200/JCO.2015.64.0391; citation_id=CR29">
    <meta name="citation_reference" content="citation_journal_title=Clin. Cancer Res.; citation_title=Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab; citation_author=R Raja; citation_volume=24; citation_publication_date=2018; citation_pages=6212-6222; citation_doi=10.1158/1078-0432.CCR-18-0386; citation_id=CR30">
    <meta name="citation_reference" content="citation_journal_title=Clin. Cancer Res.; citation_title=Early assessment of lung cancer immunotherapy response via circulating tumor DNA; citation_author=SB Goldberg; citation_volume=24; citation_publication_date=2018; citation_pages=1872-1880; citation_doi=10.1158/1078-0432.CCR-17-1341; citation_id=CR31">
    <meta name="citation_reference" content="citation_journal_title=JCO Precis. Oncol.; citation_title=ctDNA predicts overall survival in patients with NSCLC treated with PD-L1 blockade or with chemotherapy; citation_author=W Zou; citation_volume=5; citation_publication_date=2021; citation_pages=827-838; citation_doi=10.1200/PO.21.00057; citation_id=CR32">
    <meta name="citation_reference" content="citation_journal_title=Nat. Commun.; citation_title=Plasma ctDNA is a tumor tissue surrogate and enables clinical–genomic stratification of metastatic bladder cancer; citation_author=G Vandekerkhove; citation_volume=12; citation_publication_date=2021; citation_doi=10.1038/s41467-020-20493-6; citation_id=CR33">
    <meta name="citation_reference" content="citation_journal_title=JAMA Oncol.; citation_title=Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies; citation_author=JH Lee; citation_volume=4; citation_publication_date=2018; citation_pages=717-721; citation_doi=10.1001/jamaoncol.2017.5332; citation_id=CR34">
    <meta name="citation_reference" content="citation_journal_title=Nat. Cancer; citation_title=Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab; citation_author=SV Bratman; citation_volume=1; citation_publication_date=2020; citation_pages=873-881; citation_doi=10.1038/s43018-020-0096-5; citation_id=CR35">
    <meta name="citation_reference" content="citation_journal_title=Nat. Rev. Cancer; citation_title=The blockade of immune checkpoints in cancer immunotherapy; citation_author=DM Pardoll; citation_volume=12; citation_publication_date=2012; citation_pages=252-264; citation_doi=10.1038/nrc3239; citation_id=CR36">
    <meta name="citation_reference" content="citation_journal_title=Clin. Cancer Res.; citation_title=Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria; citation_author=JD Wolchok; citation_volume=15; citation_publication_date=2009; citation_pages=7412-7420; citation_doi=10.1158/1078-0432.CCR-09-1624; citation_id=CR37">
    <meta name="citation_reference" content="citation_journal_title=Eur. J. Cancer; citation_title=New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1); citation_author=EA Eisenhauer; citation_volume=45; citation_publication_date=2009; citation_pages=228-247; citation_doi=10.1016/j.ejca.2008.10.026; citation_id=CR38">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=Adaptation and modification of the immune related response criteria (IRRC): IrRECIST (Abstract e22121); citation_author=O Bohnsack, A Hoos, K Ludajic; citation_volume=32; citation_issue=15 Suppl.; citation_publication_date=2014; citation_pages=e22121; citation_doi=10.1200/jco.2014.32.15_suppl.e22121; citation_id=CR39">
    <meta name="citation_reference" content="citation_journal_title=Biol. Blood Marrow Transplant.; citation_title=ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells; citation_author=DW Lee; citation_volume=25; citation_publication_date=2019; citation_pages=625-638; citation_doi=10.1016/j.bbmt.2018.12.758; citation_id=CR40">
    <meta name="citation_reference" content="citation_journal_title=Cancer Discov.; citation_title=Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade; citation_author=Q Zhang; citation_volume=10; citation_publication_date=2020; citation_pages=1842-1853; citation_doi=10.1158/2159-8290.CD-20-0047; citation_id=CR41">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=Pseudoprogression and immune-related response in solid tumors; citation_author=VL Chiou, M Burotto; citation_volume=33; citation_publication_date=2015; citation_pages=3541-3543; citation_doi=10.1200/JCO.2015.61.6870; citation_id=CR42">
    <meta name="citation_reference" content="citation_journal_title=Cancer Immunol. Immunother.; citation_title=Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases; citation_author=AMD Giacomo; citation_volume=58; citation_publication_date=2009; citation_pages=1297-1306; citation_doi=10.1007/s00262-008-0642-y; citation_id=CR43">
    <meta name="citation_reference" content="citation_journal_title=Cancer Res.; citation_title=Abstract 517: Tebentafusp induces transient systemic inflammation and modifies the micro-environment to sensitize uveal melanoma tumors to cytotoxic CD8 cells; citation_author=MO Butler; citation_volume=81; citation_issue=13 Suppl.; citation_publication_date=2021; citation_pages=517; citation_doi=10.1158/1538-7445.AM2021-517; citation_id=CR44">
    <meta name="citation_reference" content="citation_journal_title=J. Immunother. Cancer; citation_title=Abstract 819: Radiomic markers associated with clinical benefit in advanced uveal melanoma patients with radiographic progression on tebentafusp; citation_author=V Beylergil; citation_volume=9; citation_issue=2 Suppl.; citation_publication_date=2021; citation_pages=819; citation_id=CR45">
    <meta name="citation_reference" content="citation_journal_title=Clin. Cancer Res.; citation_title=Identification of non-small cell lung cancer sensitive to systemic cancer therapies using radiomics; citation_author=L Dercle; citation_volume=26; citation_publication_date=2020; citation_pages=2151-2162; citation_doi=10.1158/1078-0432.CCR-19-2942; citation_id=CR46">
    <meta name="citation_reference" content="citation_journal_title=Br. J. Cancer; citation_title=Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond; citation_author=L Keller, Y Belloum, H Wikman, K Pantel; citation_volume=124; citation_publication_date=2021; citation_pages=345-358; citation_doi=10.1038/s41416-020-01047-5; citation_id=CR47">
    <meta name="citation_reference" content="citation_journal_title=Cancer Cell; citation_title=Integrative analysis identifies four molecular and clinical subsets in uveal melanoma; citation_author=AG Robertson; citation_volume=32; citation_publication_date=2017; citation_pages=204-220; citation_doi=10.1016/j.ccell.2017.07.003; citation_id=CR48">
    <meta name="citation_reference" content="citation_journal_title=Nat. Genet.; citation_title=The genetic evolution of metastatic uveal melanoma; citation_author=AH Shain; citation_volume=51; citation_publication_date=2019; citation_pages=1123-1130; citation_doi=10.1038/s41588-019-0440-9; citation_id=CR49">
    <meta name="citation_reference" content="citation_journal_title=Rev. Econ. Stat.; citation_title=Nonparametric estimation of average treatment effects under exogeneity: a review; citation_author=GW Imbens; citation_volume=86; citation_publication_date=2004; citation_pages=4-29; citation_doi=10.1162/003465304323023651; citation_id=CR50">
    <meta name="citation_author" content="Carvajal, Richard D.">
    <meta name="citation_author_institution" content="Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, USA">
    <meta name="citation_author" content="Butler, Marcus O.">
    <meta name="citation_author_institution" content="Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada">
    <meta name="citation_author" content="Shoushtari, Alexander N.">
    <meta name="citation_author_institution" content="Memorial Sloan Kettering Cancer Center, New York, USA">
    <meta name="citation_author_institution" content="Weill Cornell Medical College, New York, USA">
    <meta name="citation_author" content="Hassel, Jessica C.">
    <meta name="citation_author_institution" content="University Hospital Heidelberg, Heidelberg, Germany">
    <meta name="citation_author" content="Ikeguchi, Alexandra">
    <meta name="citation_author_institution" content="Stephenson Cancer Center, University of Oklahoma, Oklahoma City, USA">
    <meta name="citation_author" content="Hernandez-Aya, Leonel">
    <meta name="citation_author_institution" content="Washington University School of Medicine, Saint Louis, USA">
    <meta name="citation_author" content="Nathan, Paul">
    <meta name="citation_author_institution" content="Mount Vernon Cancer Centre – East and North Herts NHS Trust, Northwood, UK">
    <meta name="citation_author" content="Hamid, Omid">
    <meta name="citation_author_institution" content="The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, USA">
    <meta name="citation_author" content="Piulats, Josep M.">
    <meta name="citation_author_institution" content="Institut Català d’Oncologia l’Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, Barcelona, Spain">
    <meta name="citation_author" content="Rioth, Matthew">
    <meta name="citation_author_institution" content="UC Cancer Center, University of Colorado, Aurora, USA">
    <meta name="citation_author" content="Johnson, Douglas B.">
    <meta name="citation_author_institution" content="Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, USA">
    <meta name="citation_author" content="Luke, Jason J.">
    <meta name="citation_author_institution" content="UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, USA">
    <meta name="citation_author" content="Espinosa, Enrique">
    <meta name="citation_author_institution" content="Hospital Universitario La Paz – CIBERONC, Madrid, Spain">
    <meta name="citation_author" content="Leyvraz, Serge">
    <meta name="citation_author_institution" content="Charité Comprehensive Cancer Center, Charité – Universitätsmedizin Berlin, Berlin, Germany">
    <meta name="citation_author" content="Collins, Laura">
    <meta name="citation_author_institution" content="Immunocore, Abingdon-on-Thames, UK">
    <meta name="citation_author" content="Goodall, Howard M.">
    <meta name="citation_author_institution" content="Immunocore, Abingdon-on-Thames, UK">
    <meta name="citation_author" content="Ranade, Koustubh">
    <meta name="citation_author_institution" content="Immunocore, Rockville, USA">
    <meta name="citation_author" content="Holland, Chris">
    <meta name="citation_author_institution" content="Immunocore, Rockville, USA">
    <meta name="citation_author" content="Abdullah, Shaad E.">
    <meta name="citation_author_institution" content="Immunocore, Rockville, USA">
    <meta name="citation_author" content="Sacco, Joseph J.">
    <meta name="citation_author_institution" content="Clatterbridge Cancer Center – NHS Foundation Trust, Wirral, UK">
    <meta name="citation_author_institution" content="University of Liverpool, Liverpool, UK">
    <meta name="citation_author" content="Sato, Takami">
    <meta name="citation_author_institution" content="Sidney Kimmel Cancer Center, Jefferson University, Philadelphia, USA">
    <meta name="access_endpoint" content="https://www.nature.com/platform/readcube-access">
    <meta name="twitter:site" content="@naturemedicine">
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:image:alt" content="Content cover image">
    <meta name="twitter:title" content="Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial">
    <meta name="twitter:description" content="Nature Medicine - In a multicenter, single-arm, open-label phase 2 study of patients with previously treated metastatic uveal melanoma, treatment with tebentafusp, a soluble TCR bispecific...">
    <meta name="twitter:image" content="https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig1_HTML.png">
    

    
    
    <meta property="og:url" content="https://www.nature.com/articles/s41591-022-02015-7">
    <meta property="og:type" content="article">
    <meta property="og:site_name" content="Nature">
    <meta property="og:title" content="Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial - Nature Medicine">
    <meta property="og:description" content="In a multicenter, single-arm, open-label phase 2 study of patients with previously treated metastatic uveal melanoma, treatment with tebentafusp, a soluble TCR bispecific (gp100xCD3) showed promising clinical activity with an acceptable safety profile.">
    <meta property="og:image" content="https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig1_HTML.png">
    

    <script>
        window.eligibleForRa21 = 'false'; 
    </script>
<style type="text/css">.cc-banner{background-color:#01324b;border:none!important;bottom:0;box-sizing:border-box;color:#fff!important;left:0;line-height:1.3;margin:auto 0 0;max-width:100%;outline:0;overflow:visible;padding:0;position:fixed;right:0;width:100%;z-index:99999}.cc-banner::backdrop{background-color:#0000004d}.cc-banner *{color:inherit!important}.cc-banner:focus{box-shadow:none;outline:0}.cc-banner a{color:#fff!important;text-decoration:underline}.cc-banner a:active,.cc-banner a:focus,.cc-banner a:hover{color:inherit;text-decoration:none}.cc-banner a:focus{outline:3px solid #08c!important}.cc-banner h2,.cc-banner h3,.cc-banner h4,.cc-banner h5,.cc-banner h6{font-family:sans-serif;font-style:normal;font-weight:700;margin:0 0 .5em}.cc-banner .cc-h2,.cc-banner h2{font-size:18px}.cc-banner .cc-h3,.cc-banner h3{font-size:16px}.cc-banner .cc-h4,.cc-banner .cc-h5,.cc-banner .cc-h6,.cc-banner h4,.cc-banner h5,.cc-banner h6{font-size:14px}.cc-banner .cc-button{font-size:16px}.cc-banner__content{background-color:#01324b;display:flex;flex-direction:column;margin:0 auto;max-height:90vh;max-width:100%;padding:16px;position:relative}.cc-banner__content:focus{outline:0}@media (min-width:680px){.cc-banner__content{padding:12px}}@media (min-width:980px){.cc-banner__content{max-height:60vh;padding-bottom:20px;padding-top:20px}}@media (min-width:1320px){.cc-banner__content{padding-bottom:40px;padding-top:40px}}.cc-banner__container{display:flex;flex-direction:column;margin:auto;max-width:1320px;overflow:auto}.cc-banner__title{background:none!important;border:0;flex-shrink:0;font-size:18px!important;font-size:22px!important;font-weight:700!important;letter-spacing:normal;margin:0 0 12px!important;padding:0}@media (min-width:680px){.cc-banner__title{font-size:24px!important;margin:0 0 16px!important}}@media (min-width:1320px){.cc-banner__title{font-size:26px!important;margin:0 0 24px!important}}.cc-banner__body{display:flex;flex-direction:column;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif!important;overflow-x:hidden;overflow-y:auto;padding:3px 3px 16px}@media (min-width:980px){.cc-banner__body{flex-direction:row}}.cc-banner__policy p{font-size:16px!important;margin:0;max-width:none;padding:0}.cc-banner__policy p:not(:last-child){margin:0 0 16px}@media (min-width:980px){.cc-banner__policy p:not(:last-child){margin:0 0 24px}}.cc-banner__policy p a{font-size:16px!important;font-weight:700}.cc-banner__footer{box-shadow:none;flex-shrink:0;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif !important!important;margin:0;padding:12px 0 3px 3px;position:relative}@media (min-width:380px){.cc-banner__footer{align-items:stretch;display:flex;flex-wrap:wrap}}@media (min-width:680px){.cc-banner__footer{box-shadow:none;flex-wrap:nowrap;width:40%}}.cc-banner__footer .cc-banner__button{flex:1 1 auto;font-weight:700;overflow:hidden;padding:.5em 1em;width:100%}@media (min-width:680px){.cc-banner__footer .cc-banner__button{max-width:275px}}.cc-banner__footer .cc-banner__button:not(:last-child){margin-bottom:12px}@media (min-width:680px){.cc-banner__footer .cc-banner__button:not(:last-child){margin-bottom:0;margin-right:16px}}@media (min-width:980px){.cc-banner__footer .cc-banner__button:not(:last-child){margin-right:24px}}@media (min-width:680px){html[dir=rtl] .cc-banner__footer .cc-banner__button:not(:last-child){margin-left:16px!important;margin-right:0!important}}@media (min-width:980px){html[dir=rtl] .cc-banner__footer .cc-banner__button:not(:last-child){margin-left:24px!important;margin-right:0!important}}.cc-banner__button-preferences{padding-left:0;padding-right:0}@media (min-width:380px){.cc-banner__button-preferences{flex:0 0 auto;margin:auto}}@media (min-width:680px){.cc-banner__button-preferences{margin:0}}@media (min-width:380px) and (max-width:680px){.cc-banner__button-break{display:block}}@media (min-width:680px){.cc-banner--is-tcf .cc-banner__footer{width:auto}}@media (min-width:980px){.cc-banner--is-tcf .cc-banner__footer{padding-right:48px;width:66%}}.cc-banner--is-tcf .cc-banner__stacks-intro{font-size:16px!important}.cc-banner--is-tcf .cc-banner__stacks{margin:16px 0 0}@media (min-width:980px){.cc-banner--is-tcf .cc-banner__stacks{display:flex;flex:0 0 33%;flex-direction:column;margin:0 0 0 48px;overflow:auto}}.cc-banner--is-tcf .cc-banner__stacks-intro{font-size:16px;margin:0 0 12px}.cc-banner--is-tcf .cc-banner__stacks-details{padding:0 3px}.cc-banner--is-tcf .cc-banner .cc-details{border-color:#fff3!important}.cc-box{border-radius:10px;padding:12px}.cc-box--info{background-color:#eff6fb}.cc-box--light{background-color:#faf9f6}.cc-button{border:2px solid #0000;border-radius:32px!important;color:inherit;cursor:pointer;font-size:14px;font-weight:700!important;left:auto;line-height:1.2;margin:0;padding:.5em 1em;right:auto;text-transform:none!important;transition:all .2s}@media (min-width:680px){.cc-button{font-size:14px;padding:.75em 1em}}.cc-button--sm{font-size:12px;padding:2px 8px!important}.cc-button--primary{background-color:#025e8d!important;border-color:#025e8d!important;color:#fff!important}.cc-button--primary:focus{outline:3px solid #08c}.cc-button--primary:focus,.cc-button--primary:hover,.cc-button--secondary{background-color:#fff!important;border-color:#025e8d!important;color:#025e8d!important}.cc-button--secondary:focus{background-color:#025e8d!important;border-color:#fff!important;color:#fff!important;outline:3px solid #08c!important}.cc-button--secondary:hover{background-color:#025e8d!important;border-color:#025e8d!important;color:#fff!important}.cc-button--secondary:active{border:2px solid #01324b!important}.cc-button--secondary.cc-button--contrast{border-color:#fff!important}.cc-button--secondary.cc-button--contrast:hover{background-color:initial!important;color:#fff!important}.cc-button--tertiary{background-color:#f0f7fc!important;background-image:none;border:2px solid #f0f7fc;color:#025e8d!important;text-decoration:underline!important;text-underline-offset:.25em}.cc-button--tertiary:focus{outline:3px solid #08c!important}.cc-button--tertiary:hover{text-decoration-thickness:.25em}.cc-button--tertiary:active{color:#013c5b}.cc-button--link{background-color:initial!important;border-color:#0000!important;border-radius:0!important;color:inherit!important;padding:0!important;text-decoration:underline!important;width:inherit!important}.cc-button--link:focus{outline:3px solid #08c}.cc-button--link:hover{background-color:initial!important;box-shadow:none;text-decoration:none}.cc-button--text{border-radius:0;padding:0}.cc-button--details{padding-right:24px!important;position:relative;width:auto}.cc-button--details:after,.cc-button--details:before{background-color:currentColor;content:"";position:absolute;transition:transform .25s ease-out}.cc-button--details:before{height:10px;margin-top:-5px;right:12px;top:50%;width:2px}.cc-button--details:after{height:2px;margin-top:-1px;right:8px;top:50%;width:10px}.cc-button--details.cc-active:before{transform:rotate(90deg);transform-origin:center}.cc-button--details.cc-active:after{display:none}.cc-details{border-bottom:1px solid #0000001a;padding:12px 0;position:relative;width:100%}.cc-details__summary{align-items:center;display:flex;font-size:14px;font-weight:700;list-style-type:none}.cc-details__summary:focus,.cc-details__summary:focus-visible{outline:3px solid #08c!important;will-change:auto}.cc-details__title{align-items:baseline;display:flex}.cc-details__title h2,.cc-details__title h3,.cc-details__title h4,.cc-details__title h5{line-height:1.4;margin:0!important;padding:0!important}.cc-details__title svg{flex-shrink:0;height:auto;margin-right:8px;position:relative;top:-1px;transition:all .2s;width:auto}.cc-details[open] .cc-details__title svg{top:2px;transform:rotate(90deg)}.cc-details__switch{margin-left:auto}.cc-details__section{padding:16px 0 0 18px}.cc-details__section p{margin:0}.cc-details__section p:not(:last-child){margin-bottom:12px}details summary::-webkit-details-marker{display:none}.cc-radio{align-items:center;display:flex;position:relative}.cc-radio *{cursor:pointer}.cc-radio__input{height:22px;left:0;position:absolute;top:0;width:22px}.cc-radio__input:focus{outline:none}.cc-radio__label{color:inherit;font-size:14px;font-weight:700;line-height:23px;margin:0;padding-left:28px}.cc-radio__label:after,.cc-radio__label:before{background-color:#fff;content:"";display:block;position:absolute;transition:transform .25s ease-out}.cc-radio__label:before{border:1px solid #777;border-radius:50%;height:22px;left:0;top:0;width:22px}.cc-radio__label:after{border:7px solid #025e8d;border-radius:50%;height:0;left:4px;opacity:0;top:4px;width:0}.cc-radio__input:focus+.cc-radio__label:before{box-shadow:0 0 0 2px #08c;outline:none}.cc-radio__label--hidden{display:none}.cc-radio__input:checked+.cc-radio__label:after{opacity:1}.cc-radio__input:disabled{cursor:default}.cc-radio__input:disabled+.cc-radio__label{cursor:default;opacity:.5}.cc-switch *{cursor:pointer}.cc-switch{align-items:center;display:flex;line-height:1}.cc-switch__label{cursor:pointer;display:inline-block;font-size:14px;font-weight:700;margin:0;-webkit-user-select:none;user-select:none}.cc-switch__input[type=checkbox]{-webkit-appearance:none;appearance:none;background-color:#fff!important;background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='rgba(0, 0, 0, 0.25)'/%3E%3C/svg%3E")!important;background-position:0!important;background-repeat:no-repeat!important;border:1px solid #777!important;border-radius:16px!important;height:18px!important;margin:0 8px 0 0!important;transition:background-position .2s ease-in-out!important;width:32px!important}.cc-switch__input[type=checkbox]:focus{background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='%2380b3cc'/%3E%3C/svg%3E")!important}.cc-switch__input[type=checkbox]:checked{background-color:#025e8d!important;background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='%23fff'/%3E%3C/svg%3E")!important;background-position:100%!important}.cc-switch__input[type=checkbox]:checked~.cc-switch__label>.cc-switch__text-off,.cc-switch__input[type=checkbox]:not(:checked)~.cc-switch__label>.cc-switch__text-on{display:none}.cc-switch__input[type=checkbox]:hover{cursor:pointer;outline:none}.cc-switch__input[type=checkbox]:focus-visible{cursor:pointer;outline:3px solid #fc0}.cc-switch__input[type=checkbox]:checked:before{background-color:none!important;color:#0000!important}html[dir=rtl] .cc-switch__input[type=checkbox]{margin-left:8px!important;margin-right:0!important}.cc-list>ul,ul.cc-list{list-style-type:disc;margin-left:0;padding-left:0}.cc-list>ul>li,ul.cc-list>li{margin-left:1em}.cc-list>ul>li:not(:last-child),ul.cc-list>li:not(:last-child){margin-bottom:4px}.cc-list__title{margin-bottom:8px!important}.cc-list--inline>ul,ul.cc-list--inline{display:flex;flex-wrap:wrap;list-style-type:none}.cc-list--inline>ul>li,ul.cc-list--inline>li{margin:0 .5em .5em 0}.cc-overlay{background-color:#0000004d;z-index:99998}.cc-overlay,.cc-preferences{bottom:0;left:0;position:fixed;right:0;top:0}.cc-preferences{background-color:#050a14f2!important;border:0;box-sizing:border-box;color:#111;font-family:sans-serif!important;line-height:1.4;margin:auto;max-height:100vh;overflow:auto;padding:0;z-index:100000}.cc-preferences:focus{outline:none}.cc-preferences *,.cc-preferences :after,.cc-preferences :before{box-sizing:inherit!important}.cc-preferences h2,.cc-preferences h3,.cc-preferences h4,.cc-preferences h5,.cc-preferences h6{font-family:sans-serif;font-style:normal;font-weight:700;margin:0 0 .5em}.cc-preferences .cc-h2,.cc-preferences h2{font-size:18px}.cc-preferences .cc-h3,.cc-preferences h3{font-size:16px}.cc-preferences .cc-h4,.cc-preferences .cc-h5,.cc-preferences .cc-h6,.cc-preferences h4,.cc-preferences h5,.cc-preferences h6{font-size:14px}.cc-preferences a{color:#025e8d;text-decoration:underline}.cc-preferences a:hover{color:inherit;text-decoration:none}.cc-preferences h3{background:none;color:#111;padding:0;text-transform:none}dialog.cc-preferences{background-color:initial}dialog.cc-preferences::backdrop{background-color:#000000e6}.cc-preferences__dialog{display:flex;flex-direction:column;margin:auto;max-height:100vh;max-width:860px;padding:12px;position:relative}.cc-preferences__dialog>:last-child{border-bottom-left-radius:10px;border-bottom-right-radius:10px}@media (min-width:980px){.cc-preferences__dialog{padding:16px}}.cc-preferences__close{background:#0000!important;border:1px solid #ececec;border-radius:50%;color:#111!important;cursor:pointer;font-family:Times New Roman,serif;font-size:40px;height:40px;left:auto;line-height:1;margin-top:-20px;padding:0!important;position:absolute;right:20px;top:50%;width:40px}.cc-preferences__close:focus{outline:3px solid #08c}.cc-preferences__close-label{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.cc-preferences__header{background:#fff!important;border-bottom:1px solid #0000001a;border-top-left-radius:10px;border-top-right-radius:10px;padding:16px;position:relative;text-align:center}.cc-preferences__title{background:none!important;color:#111!important;font-family:sans-serif!important;font-size:18px!important;font-weight:700!important;margin:0!important;padding:0 16px 0 0!important}@media (min-width:480px){.cc-preferences__title{padding-right:0!important}}@media (min-width:980px){.cc-preferences__title{font-size:22px!important}}.cc-preferences__body{background:#fff!important;flex:1 1 auto;min-height:200px;overflow-x:hidden;overflow-y:auto;padding:16px}.cc-preferences__footer{background:#fff!important;border-top:1px solid #d0d0d0;box-shadow:0 0 5px 0 #0003;margin-bottom:0;padding:12px;position:relative}@media (min-width:480px){.cc-preferences__footer{align-items:stretch;display:flex}}.cc-preferences__footer>.cc-button{display:block;width:100%}@media (min-width:480px){.cc-preferences__footer>.cc-button{flex:1 1 auto}}@media (min-width:980px){.cc-preferences__footer>.cc-button{flex-basis:auto}}@media (min-width:480px){.cc-preferences__footer>.cc-button:not(:first-child){margin-left:12px}}.cc-preferences__footer>.cc-button:not(:last-child){margin-bottom:8px}@media (min-width:480px){.cc-preferences__footer>.cc-button:not(:last-child){margin-bottom:0}}.cc-preferences__categories{list-style:none;margin:0;padding:0}.cc-preferences__category:not(:last-child){border-bottom:1px solid #0000001a;margin-bottom:12px;padding-bottom:12px}.cc-preferences__category-description{font-size:14px;margin:0 0 8px;padding:0}.cc-preferences__category-footer{align-items:center;display:flex;justify-content:space-between}.cc-preferences__status{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.cc-preferences__controls{display:flex;margin:0}.cc-preferences__controls>:not(:last-child){margin-right:12px}.cc-preferences__always-on{font-size:14px;font-weight:700;padding-left:26px;position:relative}.cc-preferences__always-on:before{background:#0000!important;border:solid;border-top-color:#0000;border-width:0 0 4px 4px;content:"";display:block;height:10px;left:0;position:absolute;top:2px;transform:rotate(-45deg);width:18px}.cc-preferences__details{background-color:#eff6fb!important;border-radius:10px;font-size:14px;margin:12px 0 0;padding:12px}.cc-preferences__cookie-list,.cc-preferences__provider-list{list-style:none;margin:0;padding:0}.cc-preferences__provider-list{columns:170px}.cc-preferences__cookie-title{font-size:1em;font-style:normal;font-weight:400;margin:0}.cc-preferences__cookie-description{font-size:1em;margin:0 0 8px}.cc-preferences__cookie-domain,.cc-preferences__cookie-lifespan{border-left:1px solid #999;color:#666;margin-left:8px;padding-left:4px}body.cc-has-preferences-open{overflow:hidden;position:relative}.cc-table{border-collapse:collapse;width:100%}.cc-table tbody tr{border-top:1px solid #0000001a}.cc-table td,.cc-table th{font-size:14px;padding:4px 8px;vertical-align:top}.cc-table+.cc-table{margin-top:8px}.cc-table--purposes td:first-child,.cc-table--purposes th:first-child{width:70%}@media (min-width:680px){.cc-table--purposes td:first-child,.cc-table--purposes th:first-child{width:80%}}.cc-table--purposes td:last-child,.cc-table--purposes th:last-child{padding-left:8px;width:40%}@media (min-width:680px){.cc-table--purposes td:last-child,.cc-table--purposes th:last-child{width:30%}}.cc-tabs,.cc-tabs>ul{background-color:#faf9f6;display:flex;list-style:none;margin:0;padding:0}.cc-tabs__panel{border-top:1px solid #ececec;margin-top:-1px}.cc-tabs__button{background-color:initial;border:0;border-left:1px solid #0000;border-right:1px solid #0000;color:#111;font-size:16px;font-weight:700;margin:0;padding:15px 16px 12px;position:relative}.cc-tabs__button:before{background-color:initial;content:"";display:block;height:3px;left:0;position:absolute;top:0;width:100%}.cc-tabs__button.cc-active{background-color:#fff;border-color:#025e8d #ececec #ececec;color:#111}.cc-tabs__button.cc-active:before{background-color:#025e8d}.cc-tabs__content{background-color:#fff;display:none;font-size:14px;padding:16px}.cc-tabs__section:not(:first-child){padding-top:24px}.cc-tcf{font-size:14px;margin-top:16px}.cc-tcf__list{list-style:none;margin:0;padding:0}.cc-vendor-count{color:#666;font-size:16px;margin:0 0 8px}.cc-hide{display:none!important}.cc-show{display:block!important}.cc-external-link{background-color:#ececec;background-image:url("data:image/svg+xml;base64,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");background-position:right 8px center;background-repeat:no-repeat;background-size:10px auto;border-radius:3px;box-shadow:0 1px 0 #0003;color:#111!important;display:inline-block;font-size:12px;padding:4px 26px 4px 8px;text-decoration:none!important}.cc-external-link:hover{text-decoration:underline!important}.cc-m-0{margin:0!important}.cc-grey{color:#666}</style><script async="" type="text/javascript" src="https://injections.readcube.com/nature/inject.fa744f3f.js"></script></head>
<body class="article-page"><dialog class="cc-banner" data-cc-banner="" data-nosnippet="" aria-labelledby="cc-banner-label" open="">
		<div class="cc-banner__content" autofocus="" tabindex="-1">
			<div class="cc-banner__container">
				<div class="cc-banner__header">
					<h2 class="cc-banner__title" id="cc-banner-label">Your privacy, your choice</h2>
				</div>
				<div class="cc-banner__body">
					<div class="cc-banner__policy">
						<p>We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.</p><p>By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.</p><p>See our <a href="https://www.nature.com/info/privacy" data-cc-action="privacy">privacy policy</a> for more information on the use of your personal data.</p><p><button type="button" data-cc-action="preferences" class="cc-button cc-button--link cc-button--text">Manage preferences</button> for further information and to change your choices.</p>
					</div>
					
				</div>
				<div class="cc-banner__footer">
					
			<button data-cc-action="accept" class="cc-button cc-button--secondary cc-button--contrast cc-banner__button cc-banner__button-accept">Accept all cookies</button>
			
		
				</div>
			</div>
		</div>
	</dialog>

<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-MRVXSHQ"
                  height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>



<div class="position-relative cleared z-index-50 background-white" data-test="top-containers">
    <a class="c-skip-link" href="#content">Skip to main content</a>



<div class="c-grade-c-banner u-hide">
    <div class="c-grade-c-banner__container">
        
        <p>Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
            the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
            Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
            and JavaScript.</p>

    </div>
</div>

    

    

    
    
        <div class="u-hide u-show-following-ad"></div>

    <aside class="c-ad c-ad--728x90" style="display: none !important;">
        <div class="c-ad__inner" data-container-type="banner-advert">
            <p class="c-ad__label">Advertisement</p>
            
        
            
    <div id="div-gpt-ad-top-1" class="div-gpt-ad advert leaderboard js-ad text-center hide-print grade-c-hide" data-ad-type="top" data-test="top-ad" data-pa11y-ignore="" data-gpt="" data-gpt-unitpath="/285/medicine.nature.com/article" data-gpt-sizes="728x90" data-gpt-targeting="type=article;pos=top;artid=s41591-022-02015-7;doi=10.1038/s41591-022-02015-7;subjmeta=153,308,575,692;kwrd=Drug+development,Translational+research">
        <noscript>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/medicine.nature.com/article&amp;sz=728x90&amp;c=492027819&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41591-022-02015-7%26doi%3D10.1038/s41591-022-02015-7%26subjmeta%3D153,308,575,692%26kwrd%3DDrug+development,Translational+research">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/medicine.nature.com/article&amp;sz=728x90&amp;c=492027819&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41591-022-02015-7%26doi%3D10.1038/s41591-022-02015-7%26subjmeta%3D153,308,575,692%26kwrd%3DDrug+development,Translational+research"
                     alt="Advertisement"
                     width="728"
                     height="90"></a>
        </noscript>
    </div>

        
    
        </div>
    </aside>


    <header class="c-header" id="header" data-header="" data-track-component="nature-150-split-header" style="border-color:#e40428">
        <div class="c-header__row">
            <div class="c-header__container">
                <div class="c-header__split">
                    
                    
                    <div class="c-header__logo-container">
                        
                        <a href="/nm" data-track="click" data-track-action="home" data-track-label="image">
                            <picture class="c-header__logo">
                                <source srcset="https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg" media="(min-width: 875px)">
                                <img src="https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg" height="32" alt="Nature Medicine">
                            </picture>
                        </a>
                    
                    </div>
                    
                    <ul class="c-header__menu c-header__menu--global">
                        <li class="c-header__item c-header__item--padding c-header__item--hide-md-max">
                            <a class="c-header__link" href="https://www.nature.com/siteindex" data-test="siteindex-link" data-track="click" data-track-action="open nature research index" data-track-label="link">
                                <span>View all journals</span>
                            </a>
                        </li>
                        <li class="c-header__item c-header__item--padding c-header__item--pipe">
                            <a class="c-header__link c-header__link--search" href="javascript:;" data-header-expander="" data-test="search-link" data-track="click" data-track-action="open search tray" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                <svg role="img" aria-hidden="true" focusable="false" height="22" width="22" viewBox="0 0 18 18" xmlns="http://www.w3.org/2000/svg"><path d="M16.48 15.455c.283.282.29.749.007 1.032a.738.738 0 01-1.032-.007l-3.045-3.044a7 7 0 111.026-1.026zM8 14A6 6 0 108 2a6 6 0 000 12z"></path></svg><span>Search</span>
                            </a><div id="search-menu" class="c-header__dropdown c-header__dropdown--full-width has-tethered u-js-hide" data-track-component="nature-150-split-header" hidden="">
    <div class="c-header__container">
        <h2 class="c-header__visually-hidden">Search</h2>
        <form class="c-header__search-form" action="/search" method="get" role="search" autocomplete="off" data-test="inline-search">
            <label class="c-header__heading" for="keywords">Search articles by subject, keyword or author</label>
            <div class="c-header__search-layout c-header__search-layout--max-width">
                <div>
                    <input type="text" required="" class="c-header__input" id="keywords" name="q" value="">
                </div>
                <div class="c-header__search-layout">
                    <div>
                        <label for="results-from" class="c-header__visually-hidden">Show results from</label>
                        <select id="results-from" name="journal" class="c-header__select">
                            
                                
                                    <option value="" selected="">All journals</option>
                                    <option value="nm">This journal</option>
                                
                            
                        </select>
                    </div>
                    <div>
                        <button type="submit" class="c-header__search-button">Search</button>
                    </div>
                </div>

            </div>
        </form>

        <div class="c-header__flush">
            <a class="c-header__link" href="/search/advanced" data-track="click" data-track-action="advanced search" data-track-label="link">
                Advanced search
            </a>
        </div>

        <h3 class="c-header__heading c-header__heading--keyline">Quick links</h3>
        <ul class="c-header__list">
            <li><a class="c-header__link" href="/subjects" data-track="click" data-track-action="explore articles by subject" data-track-label="link">Explore articles by subject</a></li>
            <li><a class="c-header__link" href="/naturecareers" data-track="click" data-track-action="find a job" data-track-label="link">Find a job</a></li>
            <li><a class="c-header__link" href="/authors/index.html" data-track="click" data-track-action="guide to authors" data-track-label="link">Guide to authors</a></li>
            <li><a class="c-header__link" href="/authors/editorial_policies/" data-track="click" data-track-action="editorial policies" data-track-label="link">Editorial policies</a></li>
        </ul>
    </div>
</div>
                        </li>
                        <li class="c-header__item c-header__item--padding c-header__item--snid-account-widget c-header__item--pipe">
                            
                                <a class="c-header__link eds-c-header__link" id="identity-account-widget" data-track="click_login" data-track-context="header" href="https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41591-022-02015-7"><span class="eds-c-header__widget-fragment-title">Log in</span></a>
                            
                        </li>
                    </ul>
                </div>
            </div>
        </div>
        
            <div class="c-header__row">
                <div class="c-header__container" data-test="navigation-row">
                    <div class="c-header__split">
                        <ul class="c-header__menu c-header__menu--journal">
                            
                                <li class="c-header__item c-header__item--dropdown-menu" data-test="explore-content-button">
                                    <a href="javascript:;" class="c-header__link" data-header-expander="" data-test="menu-button--explore" data-track="click" data-track-action="open explore expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                        <span><span class="c-header__show-text">Explore</span> content</span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                    </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="Explore-content" data-test="Explore-content" id="explore" data-track-component="nature-150-split-header" hidden="">
            <div class="c-header__container">
                <h2 id="Explore-content" class="c-header__heading c-header__heading--js-hide">Explore content</h2>
                <ul class="c-header__list c-header__list--js-stack">
                    
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/research-articles" data-track="click" data-track-action="research articles" data-track-label="link" data-test="explore-nav-item">
                                    Research articles
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/reviews-and-analysis" data-track="click" data-track-action="reviews &amp; analysis" data-track-label="link" data-test="explore-nav-item">
                                    Reviews &amp; Analysis
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/news-and-comment" data-track="click" data-track-action="news &amp; comment" data-track-label="link" data-test="explore-nav-item">
                                    News &amp; Comment
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/podcast" data-track="click" data-track-action="podcasts" data-track-label="link" data-test="explore-nav-item">
                                    Podcasts
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/current-issue" data-track="click" data-track-action="current issue" data-track-label="link" data-test="explore-nav-item">
                                    Current issue
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/collections" data-track="click" data-track-action="collections" data-track-label="link" data-test="explore-nav-item">
                                    Collections
                                </a>
                            </li>
                        
                    
                </ul>
                <ul class="c-header__list c-header__list--js-stack">
                    
                        <li class="c-header__item">
                            <a class="c-header__link" href="https://www.facebook.com/Nature-Medicine-193691346949/" data-track="click" data-track-action="facebook" data-track-label="link">Follow us on Facebook
                            </a>
                        </li>
                    
                    
                        <li class="c-header__item">
                            <a class="c-header__link" href="https://twitter.com/naturemedicine" data-track="click" data-track-action="twitter" data-track-label="link">Follow us on Twitter
                            </a>
                        </li>
                    
                    
                    
                        <li class="c-header__item c-header__item--hide-lg">
                            <a class="c-header__link" href="https://www.nature.com/my-account/alerts/subscribe-journal?list-id=5" rel="nofollow" data-track="nav_sign_up_for_alerts" data-track-action="Sign up for alerts" data-track-external="" data-track-label="link (mobile dropdown)">Sign up for alerts<svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill="#fff"></path></svg>
                            </a>
                        </li>
                    
                    
                        <li class="c-header__item c-header__item--hide-lg">
                            <a class="c-header__link" href="https://www.nature.com/nm.rss" data-track="click" data-track-action="rss feed" data-track-label="link">
                                <span>RSS feed</span>
                            </a>
                        </li>
                    
                </ul>
            </div>
        </nav>
                                </li>
                            
                            
                                <li class="c-header__item c-header__item--dropdown-menu">
                                    <a href="javascript:;" class="c-header__link" data-header-expander="" data-test="menu-button--about-the-journal" data-track="click" data-track-action="open about the journal expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                        <span>About <span class="c-header__show-text">the journal</span></span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                    </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="About-the-journal" id="about-the-journal" data-test="about-the-journal" data-track-component="nature-150-split-header" hidden="">
                <div class="c-header__container">
                    <h2 id="About-the-journal" class="c-header__heading c-header__heading--js-hide">About the journal</h2>
                    <ul class="c-header__list c-header__list--js-stack">
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/aims" data-track="click" data-track-action="aims &amp; scope" data-track-label="link">
                                    Aims &amp; Scope
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/journal-information" data-track="click" data-track-action="journal information" data-track-label="link">
                                    Journal Information
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/journal-impact" data-track="click" data-track-action="journal metrics" data-track-label="link">
                                    Journal Metrics
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editors" data-track="click" data-track-action="about the editors" data-track-label="link">
                                    About the Editors
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/research-cross-journal-editorial-team" data-track="click" data-track-action="research cross-journal editorial team" data-track-label="link">
                                    Research Cross-Journal Editorial Team
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/reviews-cross-journal-editorial-team" data-track="click" data-track-action="reviews cross-journal editorial team" data-track-label="link">
                                    Reviews Cross-Journal Editorial Team
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/statistics-advisory-panel" data-track="click" data-track-action="statistical advisory panel" data-track-label="link">
                                    Statistical Advisory Panel
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/our-publishing-models" data-track="click" data-track-action="our publishing models" data-track-label="link">
                                    Our publishing models
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editorial-values-statement" data-track="click" data-track-action="editorial values statement" data-track-label="link">
                                    Editorial Values Statement
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editorial-policies" data-track="click" data-track-action="editorial policies" data-track-label="link">
                                    Editorial Policies
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/content" data-track="click" data-track-action="content types" data-track-label="link">
                                    Content Types
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/web-feeds" data-track="click" data-track-action="web feeds" data-track-label="link">
                                    Web Feeds
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/contact" data-track="click" data-track-action="contact" data-track-label="link">
                                    Contact
                                </a>
                            </li>
                        
                    </ul>
                </div>
            </nav>
                                </li>
                                
                                    <li class="c-header__item c-header__item--dropdown-menu" data-test="publish-with-us-button">
                                        <a href="javascript:;" class="c-header__link c-header__link--dropdown-menu" data-header-expander="" data-test="menu-button--publish" data-track="click" data-track-action="open publish with us expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                            <span>Publish <span class="c-header__show-text">with us</span></span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                        </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="Publish-with-us-label" id="publish-with-us" data-test="publish-with-us" data-track-component="nature-150-split-header" hidden="">
                <div class="c-header__container">
                    <h2 id="Publish-with-us-label" class="c-header__heading c-header__heading--js-hide">Publish with us</h2>
                    <ul class="c-header__list c-header__list--js-stack">
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/submission-guidelines" data-track="click" data-track-action="submission guidelines" data-track-label="link">
                                    Submission Guidelines
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/for-reviewers" data-track="click" data-track-action="for reviewers" data-track-label="link">
                                    For Reviewers
                                </a>
                            </li>
                        
                        
                            <li class="c-header__item">
                                <a class="c-header__link" data-test="nature-author-services" data-track="nav_language_services" data-track-context="header publish with us dropdown menu" data-track-action="manuscript author services" data-track-label="link manuscript author services" href="https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&amp;utm_medium=Website_Nature&amp;utm_campaign=Platform+Experimentation+2022&amp;utm_id=PE2022">
                                    Language editing services
                                </a>
                            </li>
                        
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/open-access-funding" data-test="funding-eligibility-link" data-track="click_explore_funding" data-track-context="header publish with us" data-track-action="funding eligibility">Open access funding</a>
                            </li>
                        
                        
                            <li class="c-header__item c-header__item--keyline">
                                <a class="c-header__link" href="https://mts-nmed.nature.com/cgi-bin/main.plex" data-track="click_submit_manuscript" data-track-context="submit link in Nature header dropdown menu" data-track-action="submit manuscript" data-track-label="link (publish with us dropdown menu)" data-track-external="" data-gtm-criteo="submit-manuscript">Submit manuscript<svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m15 0c1.1045695 0 2 .8954305 2 2v5.5c0 .27614237-.2238576.5-.5.5s-.5-.22385763-.5-.5v-5.5c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-9v3c0 1.1045695-.8954305 2-2 2h-3v10c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h7.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-7.5c-1.1045695 0-2-.8954305-2-2v-10.17157288c0-.53043297.21071368-1.0391408.58578644-1.41421356l3.82842712-3.82842712c.37507276-.37507276.88378059-.58578644 1.41421356-.58578644zm-.5442863 8.18867991 3.3545404 3.35454039c.2508994.2508994.2538696.6596433.0035959.909917-.2429543.2429542-.6561449.2462671-.9065387-.0089489l-2.2609825-2.3045251.0010427 7.2231989c0 .3569916-.2898381.6371378-.6473715.6371378-.3470771 0-.6473715-.2852563-.6473715-.6371378l-.0010428-7.2231995-2.2611222 2.3046654c-.2531661.2580415-.6562868.2592444-.9065605.0089707-.24295423-.2429542-.24865597-.6576651.0036132-.9099343l3.3546673-3.35466731c.2509089-.25090888.6612706-.25227691.9135302-.00001728zm-.9557137-3.18867991c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm-8.5-3.587-3.587 3.587h2.587c.55228475 0 1-.44771525 1-1zm8.5 1.587c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill="#fff"></path></svg>
                                </a>
                            </li>
                        
                    </ul>
                </div>
            </nav>
                                    </li>
                                
                            
                            
                        </ul>
                        <ul class="c-header__menu c-header__menu--hide-lg-max">
                            
                                <li class="c-header__item" data-test="alert-link">
                                    <a class="c-header__link" href="https://journal-alerts.springernature.com/subscribe?journal_id=41591" rel="nofollow" data-track="nav_sign_up_for_alerts" data-track-action="Sign up for alerts" data-track-label="link (desktop site header)" data-track-external="">
                                        <span>Sign up for alerts</span><svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill="#222"></path></svg>
                                    </a>
                                </li>
                            
                            
                                <li class="c-header__item c-header__item--pipe">
                                    <a class="c-header__link" href="https://www.nature.com/nm.rss" data-track="click" data-track-action="rss feed" data-track-label="link">
                                            <span>RSS feed</span>
                                    </a>
                                </li>
                            
                        </ul>
                    </div>
                </div>
            </div>
        
    </header>


    
    
        <nav class="u-mb-16" aria-label="breadcrumbs">
            <div class="u-container">
                <ol class="c-breadcrumbs" itemscope="" itemtype="https://schema.org/BreadcrumbList">
                    <li class="c-breadcrumbs__item" id="breadcrumb0" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:nature"><span itemprop="name">nature</span></a><meta itemprop="position" content="1">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb1" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/nm" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:nature medicine"><span itemprop="name">nature medicine</span></a><meta itemprop="position" content="2">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb2" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/nm/articles?type=article" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:articles"><span itemprop="name">articles</span></a><meta itemprop="position" content="3">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb3" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem">
                                    <span itemprop="name">article</span><meta itemprop="position" content="4"></li>
                </ol>
            </div>
        </nav>
    



    

</div>


<div class="u-container u-mt-32 u-mb-32 u-clearfix" id="content" data-component="article-container" data-container-type="article">
    <main class="c-article-main-column u-float-left js-main-column" data-track-component="article body">
        
            
                <div class="c-context-bar u-hide" id="js-enable-context-bar" data-test="context-bar" data-context-bar="" aria-hidden="true">
                    <div class="c-context-bar__container u-container" data-track-context="sticky banner">
                        <div class="c-context-bar__title">
                            Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial
                        </div>
                        
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-022-02015-7.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                    </div>
                </div>
            
        
        <article lang="en">
            
                <div class="c-pdf-button__container u-mb-16 u-hide-at-lg js-context-bar-sticky-point-mobile">
                    <div class="c-pdf-container" data-track-context="article body">
                        
                            
                                
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-022-02015-7.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                            
                        
                    </div>
                </div>
            
            <div class="c-article-header">
                <header>
                    <ul class="c-article-identifiers" data-test="article-identifier">
                        
        <li class="c-article-identifiers__item" data-test="article-category">Article</li>
    
        <li class="c-article-identifiers__item">
            <a href="https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research" data-track="click" data-track-action="open access" data-track-label="link" class="u-color-open-access" data-test="open-access">Open access</a>
        </li>
    
    

                        <li class="c-article-identifiers__item">Published: <time datetime="2022-10-13">13 October 2022</time></li>
                    </ul>

                    <h1 class="c-article-title" data-test="article-title" data-article-title="">Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial</h1>
                    <ul class="c-article-author-list c-article-author-list--short js-no-scroll" data-test="authors-list" data-component-authors-activator="authors-list"><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Richard_D_-Carvajal-Aff1" data-author-popup="auth-Richard_D_-Carvajal-Aff1" data-author-search="Carvajal, Richard D." data-track-context="researcher popup with no profile" data-track-index="1_21">Richard D. Carvajal</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-3796-1118"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-3796-1118</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Marcus_O_-Butler-Aff2" data-author-popup="auth-Marcus_O_-Butler-Aff2" data-author-search="Butler, Marcus O." data-track-context="researcher popup with no profile" data-track-index="2_21">Marcus O. Butler</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-9840-7057"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-9840-7057</a></span><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Alexander_N_-Shoushtari-Aff3-Aff4" data-author-popup="auth-Alexander_N_-Shoushtari-Aff3-Aff4" data-author-search="Shoushtari, Alexander N." data-track-context="researcher popup with no profile" data-track-index="3_21">Alexander N. Shoushtari</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-8065-4412"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-8065-4412</a></span><sup class="u-js-hide"><a href="#Aff3" tabindex="-1">3</a>,<a href="#Aff4" tabindex="-1">4</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Jessica_C_-Hassel-Aff5" data-author-popup="auth-Jessica_C_-Hassel-Aff5" data-author-search="Hassel, Jessica C." data-track-context="researcher popup with no profile" data-track-index="4_21">Jessica C. Hassel</a><sup class="u-js-hide"><a href="#Aff5" tabindex="-1">5</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Alexandra-Ikeguchi-Aff6" data-author-popup="auth-Alexandra-Ikeguchi-Aff6" data-author-search="Ikeguchi, Alexandra" data-track-context="researcher popup with no profile" data-track-index="5_21">Alexandra Ikeguchi</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-4448-9755"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-4448-9755</a></span><sup class="u-js-hide"><a href="#Aff6" tabindex="-1">6</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Leonel-Hernandez_Aya-Aff7" data-author-popup="auth-Leonel-Hernandez_Aya-Aff7" data-author-search="Hernandez-Aya, Leonel" data-track-context="researcher popup with no profile" data-track-index="6_21">Leonel Hernandez-Aya</a><sup class="u-js-hide"><a href="#Aff7" tabindex="-1">7</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Paul-Nathan-Aff8" data-author-popup="auth-Paul-Nathan-Aff8" data-author-search="Nathan, Paul" data-track-context="researcher popup with no profile" data-track-index="7_21">Paul Nathan</a><sup class="u-js-hide"><a href="#Aff8" tabindex="-1">8</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Omid-Hamid-Aff9" data-author-popup="auth-Omid-Hamid-Aff9" data-author-search="Hamid, Omid" data-track-context="researcher popup with no profile" data-track-index="8_21">Omid Hamid</a><sup class="u-js-hide"><a href="#Aff9" tabindex="-1">9</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Josep_M_-Piulats-Aff10" data-author-popup="auth-Josep_M_-Piulats-Aff10" data-author-search="Piulats, Josep M." data-track-context="researcher popup with no profile" data-track-index="9_21">Josep M. Piulats</a><sup class="u-js-hide"><a href="#Aff10" tabindex="-1">10</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Matthew-Rioth-Aff11" data-author-popup="auth-Matthew-Rioth-Aff11" data-author-search="Rioth, Matthew" data-track-context="researcher popup with no profile" data-track-index="10_21">Matthew Rioth</a><sup class="u-js-hide"><a href="#Aff11" tabindex="-1">11</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Douglas_B_-Johnson-Aff12" data-author-popup="auth-Douglas_B_-Johnson-Aff12" data-author-search="Johnson, Douglas B." data-track-context="researcher popup with no profile" data-track-index="11_21">Douglas B. Johnson</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-6390-773X"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-6390-773X</a></span><sup class="u-js-hide"><a href="#Aff12" tabindex="-1">12</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Jason_J_-Luke-Aff13" data-author-popup="auth-Jason_J_-Luke-Aff13" data-author-search="Luke, Jason J." data-track-context="researcher popup with no profile" data-track-index="12_21">Jason J. Luke</a><sup class="u-js-hide"><a href="#Aff13" tabindex="-1">13</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Enrique-Espinosa-Aff14" data-author-popup="auth-Enrique-Espinosa-Aff14" data-author-search="Espinosa, Enrique" data-track-context="researcher popup with no profile" data-track-index="13_21">Enrique Espinosa</a><sup class="u-js-hide"><a href="#Aff14" tabindex="-1">14</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Serge-Leyvraz-Aff15" data-author-popup="auth-Serge-Leyvraz-Aff15" data-author-search="Leyvraz, Serge" data-track-context="researcher popup with no profile" data-track-index="14_21">Serge Leyvraz</a><sup class="u-js-hide"><a href="#Aff15" tabindex="-1">15</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Laura-Collins-Aff16" data-author-popup="auth-Laura-Collins-Aff16" data-author-search="Collins, Laura" data-track-context="researcher popup with no profile" data-track-index="15_21">Laura Collins</a><sup class="u-js-hide"><a href="#Aff16" tabindex="-1">16</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Howard_M_-Goodall-Aff16" data-author-popup="auth-Howard_M_-Goodall-Aff16" data-author-search="Goodall, Howard M." data-track-context="researcher popup with no profile" data-track-index="16_21">Howard M. Goodall</a><sup class="u-js-hide"><a href="#Aff16" tabindex="-1">16</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Koustubh-Ranade-Aff17" data-author-popup="auth-Koustubh-Ranade-Aff17" data-author-search="Ranade, Koustubh" data-track-context="researcher popup with no profile" data-track-index="17_21">Koustubh Ranade</a><sup class="u-js-hide"><a href="#Aff17" tabindex="-1">17</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Chris-Holland-Aff17" data-author-popup="auth-Chris-Holland-Aff17" data-author-search="Holland, Chris" data-track-context="researcher popup with no profile" data-track-index="18_21">Chris Holland</a><sup class="u-js-hide"><a href="#Aff17" tabindex="-1">17</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Shaad_E_-Abdullah-Aff17" data-author-popup="auth-Shaad_E_-Abdullah-Aff17" data-author-search="Abdullah, Shaad E." data-track-context="researcher popup with no profile" data-track-index="19_21">Shaad E. Abdullah</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-0776-7477"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-0776-7477</a></span><sup class="u-js-hide"><a href="#Aff17" tabindex="-1">17</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Joseph_J_-Sacco-Aff18-Aff19" data-author-popup="auth-Joseph_J_-Sacco-Aff18-Aff19" data-author-search="Sacco, Joseph J." data-track-context="researcher popup with no profile" data-track-index="20_21">Joseph J. Sacco</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-2591-9796"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-2591-9796</a></span><sup class="u-js-hide"><a href="#Aff18" tabindex="-1">18</a>,<a href="#Aff19" tabindex="-1">19</a></sup> &amp; </li><li class="c-article-author-list__show-more" aria-label="Show all 21 authors for this article" title="Show all 21 authors for this article">…</li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Takami-Sato-Aff20" data-author-popup="auth-Takami-Sato-Aff20" data-author-search="Sato, Takami" data-corresp-id="c1" data-track-context="researcher popup with no profile" data-track-index="21_21">Takami Sato<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-mail-medium"></use></svg></a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-2221-0415"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-2221-0415</a></span><sup class="u-js-hide"><a href="#Aff20" tabindex="-1">20</a></sup>&nbsp;</li></ul><button aria-expanded="false" class="c-article-author-list__button"><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-down-medium"></use></svg><span>Show authors</span></button>

                    

                    <p class="c-article-info-details" data-container-section="info">
                        
    <a data-test="journal-link" href="/nm" data-track="click" data-track-action="journal homepage" data-track-category="article body" data-track-label="link"><i data-test="journal-title">Nature Medicine</i></a>

                        <b data-test="journal-volume"><span class="u-visually-hidden">volume</span>&nbsp;28</b>,&nbsp;<span class="u-visually-hidden">pages </span>2364–2373 (<span data-test="article-publication-year">2022</span>)<a href="#citeas" class="c-article-info-details__cite-as u-hide-print" data-track="click" data-track-action="cite this article" data-track-label="link">Cite this article</a>
                    </p>
                    
        <div class="c-article-metrics-bar__wrapper u-clear-both">
            <ul class="c-article-metrics-bar u-list-reset">
                
                    <li class=" c-article-metrics-bar__item" data-test="access-count">
                        <p class="c-article-metrics-bar__count">18k <span class="c-article-metrics-bar__label">Accesses</span></p>
                    </li>
                
                
                    <li class="c-article-metrics-bar__item" data-test="citation-count">
                        <p class="c-article-metrics-bar__count">95 <span class="c-article-metrics-bar__label">Citations</span></p>
                    </li>
                
                
                    
                        <li class="c-article-metrics-bar__item" data-test="altmetric-score">
                            <p class="c-article-metrics-bar__count">408 <span class="c-article-metrics-bar__label">Altmetric</span></p>
                        </li>
                    
                
                <li class="c-article-metrics-bar__item">
                    <p class="c-article-metrics-bar__details"><a href="/articles/s41591-022-02015-7/metrics" data-track="click" data-track-action="view metrics" data-track-label="link" rel="nofollow">Metrics <span class="u-visually-hidden">details</span></a></p>
                </li>
            </ul>
        </div>
    
                    
                </header>

                
    

                
    
    

    
    

                
            </div>

        <div class="c-article-body">
            <section aria-labelledby="Abs1" data-title="Abstract" lang="en"><div class="c-article-section" id="Abs1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Abs1">Abstract</h2><div class="c-article-section__content" id="Abs1-content"><p>In patients with previously treated metastatic uveal melanoma, the historical 1 year overall survival rate is 37% with a median overall survival of 7.8 months. We conducted a multicenter, single-arm, open-label phase 2 study of tebentafusp, a soluble T cell receptor bispecific (gp100×CD3), in 127 patients with treatment-refractory metastatic uveal melanoma (NCT02570308). The primary endpoint was the estimation of objective response rate based on RECIST (Response Evaluation Criteria in Solid Tumours) v1.1. Secondary objectives included safety, overall survival, progression-free survival and disease control rate. All patients had at least one treatment-related adverse event, with rash (87%), pyrexia (80%) and pruritus (67%) being the most common. Toxicity was mostly mild to moderate in severity but was greatly reduced in incidence and intensity after the initial three doses. Despite a low overall response rate of 5% (95% CI: 2–10%), the 1 year overall survival rate was 62% (95% CI: 53–70%) with a median overall survival of 16.8 months (95% CI: 12.9–21.3), suggesting benefit beyond traditional radiographic-based response criteria. In an exploratory analysis, early on-treatment reduction in circulating tumour DNA was strongly associated with overall survival, even in patients with radiographic progression. Our findings indicate that tebentafusp has promising clinical activity with an acceptable safety profile in patients with previously treated metastatic uveal melanoma, and data suggesting ctDNA as an early indicator of clinical benefit from tebentafusp need confirmation in a randomized trial.</p></div></div></section>

            
                
            

            
                
                    
        
            <section aria-labelledby="inline-recommendations" data-title="Inline Recommendations" class="c-article-recommendations" data-track-component="inline-recommendations">
                <h3 class="c-article-recommendations-title" id="inline-recommendations">Similar content being viewed by others</h3>
                <div class="c-article-recommendations-list">
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41467-021-25332-w/MediaObjects/41467_2021_25332_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41467-021-25332-w?fromPaywallRec=false" data-track="select_recommendations_1" data-track-context="inline recommendations" data-track-action="click recommendations inline - 1" data-track-label="10.1038/s41467-021-25332-w">The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">27 August 2021</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41416-022-02133-6/MediaObjects/41416_2022_2133_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41416-022-02133-6?fromPaywallRec=false" data-track="select_recommendations_2" data-track-context="inline recommendations" data-track-action="click recommendations inline - 2" data-track-label="10.1038/s41416-022-02133-6">A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">09 January 2023</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41598-024-55675-5/MediaObjects/41598_2024_55675_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41598-024-55675-5?fromPaywallRec=false" data-track="select_recommendations_3" data-track-context="inline recommendations" data-track-action="click recommendations inline - 3" data-track-label="10.1038/s41598-024-55675-5">Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">03 April 2024</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                </div>
            </section>
        
            <script>
                window.dataLayer = window.dataLayer || [];
                window.dataLayer.push({
                    recommendations: {
                        recommender: 'semantic',
                        model: 'specter',
                        policy_id: 'NA',
                        timestamp: 1749524364,
                        embedded_user: 'null'
                    }
                });
            </script>
        
    
                
                
                <div class="main-content">
                    
                        <section data-title="Main"><div class="c-article-section" id="Sec1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec1">Main</h2><div class="c-article-section__content" id="Sec1-content"><p>Uveal melanoma is the most common primary eye tumour<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1" title="Milam, R. W. &amp; Daniels, A. B. Uveal melanoma. In Melanoma (ed. Riker, A.) pp. 273–312 (Springer, 2018). 
                  https://doi.org/10.1007/978-3-319-78310-9_16
                  
                " href="/articles/s41591-022-02015-7#ref-CR1" id="ref-link-section-d71731262e978">1</a></sup> but it remains a rare condition, affecting fewer than 10 individuals per million<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 2" title="Stang, A., Parkin, D. M., Ferlay, J. &amp; Jöckel, K. International uveal melanoma incidence trends in view of a decreasing proportion of morphological verification. Int. J. Cancer 114, 114–123 (2005)." href="/articles/s41591-022-02015-7#ref-CR2" id="ref-link-section-d71731262e982">2</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 3" title="Virgili, G. et al. Incidence of uveal melanoma in Europe. Ophthalmology 114, 2309–2315 (2007)." href="/articles/s41591-022-02015-7#ref-CR3" id="ref-link-section-d71731262e985">3</a></sup>. Up to half of the patients with uveal melanoma will develop metastatic disease<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Kujala, E., Makitie, T. &amp; Kivela, T. Very long-term prognosis of patients with malignant uveal melanoma. Invest. Ophthalmol. Vis. Sci. 44, 4651–4659 (2003)." href="#ref-CR4" id="ref-link-section-d71731262e989">4</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Singh, M., Durairaj, P. &amp; Yeung, J. Uveal melanoma: a review of the literature. Oncol. Ther. 6, 87–104 (2018)." href="#ref-CR5" id="ref-link-section-d71731262e989_1">5</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 6" title="Yang, J., Manson, D. K., Marr, B. P. &amp; Carvajal, R. D. Treatment of uveal melanoma: where are we now? Ther. Adv. Med. Oncol. 10, 1758834018757175 (2018)." href="/articles/s41591-022-02015-7#ref-CR6" id="ref-link-section-d71731262e992">6</a></sup>, with the liver as the predominant site of distant spread<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 7" title="Carvajal, R. D. et al. Metastatic disease from uveal melanoma: treatment options and future prospects. Br. J. Ophthalmol. 101, 38–44 (2017)." href="/articles/s41591-022-02015-7#ref-CR7" id="ref-link-section-d71731262e996">7</a></sup>. Nearly all cases of uveal melanoma harbor one of four initiating oncogenic driver mutations in <i>GNAQ</i>, <i>GNA11</i>, <i>PLCB4</i> or <i>CYSLTR2</i> in a mutually independent fashion, as well as a secondary oncogenic event affecting <i>EIFA1X</i>, <i>BAP1</i> or genes encoding for spliceosome components, most commonly <i>SF3B1</i> (refs. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Harbour, J. W. et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330, 1410–1413 (2010)." href="#ref-CR8" id="ref-link-section-d71731262e1023">8</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Karlsson, J. et al. Molecular profiling of driver events in metastatic uveal melanoma. Nat. Commun. 11, 1894 (2020)." href="#ref-CR9" id="ref-link-section-d71731262e1023_1">9</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 10" title="Martin, M. et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat. Genet. 45, 933–936 (2013)." href="/articles/s41591-022-02015-7#ref-CR10" id="ref-link-section-d71731262e1026">10</a></sup>). Uveal melanoma has one of the lowest mutational burdens of all malignancies, with approximately 0.5 mutations per megabase and a median of 32 coding mutations per tumour<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 11" title="Johnson, C. P. et al. Systematic genomic and translational efficiency studies of uveal melanoma. PLoS One 12, e0178189 (2017)." href="/articles/s41591-022-02015-7#ref-CR11" id="ref-link-section-d71731262e1030">11</a></sup>, and is characterized by low expression of programmed cell death ligand 1 (PD-L1)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="Javed, A. et al. PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. Immunotherapy 9, 1323–1330 (2017)." href="/articles/s41591-022-02015-7#ref-CR12" id="ref-link-section-d71731262e1034">12</a></sup>.</p><p>Tebentafusp, a first-in-class immune-mobilizing monoclonal T cell receptor (TCR) against cancer (ImmTAC), has been demonstrated in a phase 3 trial to improve overall survival in patients with previously untreated metastatic uveal melanoma when compared with investigator’s choice and represents the first therapy to demonstrate such a benefit in this disease<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Nathan, P. et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med. 385, 1196–1206 (2021)." href="/articles/s41591-022-02015-7#ref-CR13" id="ref-link-section-d71731262e1041">13</a></sup>. The overall survival at 1 year was 73% in the tebentafusp group and 59% in the control group, with a hazard ratio (HR) for death of 0.51 (95% CI: 0.37–0.71, <i>P</i> &lt; 0.001). These results are superior to those observed with targeted therapies such as selumetinib<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 14" title="Carvajal, R. D. et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA 311, 2397–2405 (2014)." href="/articles/s41591-022-02015-7#ref-CR14" id="ref-link-section-d71731262e1048">14</a></sup> and immune checkpoint blockade. Two single-arm studies of combined ipilimumab and nivolumab in untreated and a mixed population of untreated and previously treated patients with metastatic uveal melanoma reported 1 year overall survival rates of 52% and 56% (refs. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 15" title="Pelster, M. S. et al. Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study. J. Clin. Oncol. 39, 599–607 (2021)." href="/articles/s41591-022-02015-7#ref-CR15" id="ref-link-section-d71731262e1052">15</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 16" title="Piulats, J. M. et al. Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). J. Clin. Oncol. 39, 586–598 (2021)." href="/articles/s41591-022-02015-7#ref-CR16" id="ref-link-section-d71731262e1055">16</a></sup>), respectively, which are similar to those reported in recent meta-analyses<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Khoja, L. et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an International Rare Cancers Initiative (IRCI) ocular melanoma study. Ann. Oncol. 30, 1370–1380 (2019)." href="/articles/s41591-022-02015-7#ref-CR17" id="ref-link-section-d71731262e1059">17</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Rantala, E. S., Hernberg, M. &amp; Kivelä, T. T. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 29, 561–568 (2019)." href="/articles/s41591-022-02015-7#ref-CR18" id="ref-link-section-d71731262e1062">18</a></sup>.</p><p>Tebentafusp consists of a soluble affinity-enhanced TCR, specific for the gp100 peptide YLEPGPVTA–HLA-A*02:01 complexes presented on the surface of melanocytic cells, fused to an anti-CD3 single-chain variable fragment<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Bossi, G., Buisson, S., Oates, J., Jakobsen, B. K. &amp; Hassan, N. J. ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells. Cancer Immunol. Immunother. 63, 437–448 (2014)." href="#ref-CR19" id="ref-link-section-d71731262e1069">19</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Liddy, N. et al. Monoclonal TCR-redirected tumor cell killing. Nat. Med. 18, 980–987 (2012)." href="#ref-CR20" id="ref-link-section-d71731262e1069_1">20</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Middleton, M. R. et al. Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma. Clin. Cancer Res. 26, 5869–5878 (2020)." href="#ref-CR21" id="ref-link-section-d71731262e1069_2">21</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Boudousquie, C. et al. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells. Immunology 152, 425–438 (2017)." href="/articles/s41591-022-02015-7#ref-CR22" id="ref-link-section-d71731262e1072">22</a></sup>. Once bound to their target gp100–HLA complex, polyclonal T cells are recruited and activated through CD3 ligation to release cytokines and cytolytic mediators against target cells<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Bossi, G., Buisson, S., Oates, J., Jakobsen, B. K. &amp; Hassan, N. J. ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells. Cancer Immunol. Immunother. 63, 437–448 (2014)." href="#ref-CR19" id="ref-link-section-d71731262e1076">19</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Liddy, N. et al. Monoclonal TCR-redirected tumor cell killing. Nat. Med. 18, 980–987 (2012)." href="#ref-CR20" id="ref-link-section-d71731262e1076_1">20</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Middleton, M. R. et al. Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma. Clin. Cancer Res. 26, 5869–5878 (2020)." href="#ref-CR21" id="ref-link-section-d71731262e1076_2">21</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Boudousquie, C. et al. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells. Immunology 152, 425–438 (2017)." href="/articles/s41591-022-02015-7#ref-CR22" id="ref-link-section-d71731262e1079">22</a></sup>. In the first-in-human multicenter phase 1 study of tebentafusp, 3 of 15 (20%) evaluable patients with metastatic uveal melanoma achieved a partial response and 7 (47%) achieved stable disease, with an observed 1 year overall survival rate of 65% (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 21" title="Middleton, M. R. et al. Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma. Clin. Cancer Res. 26, 5869–5878 (2020)." href="/articles/s41591-022-02015-7#ref-CR21" id="ref-link-section-d71731262e1083">21</a></sup>). A dose–response relationship was observed, with tebentafusp doses at or exceeding the maximum tolerated dose being associated with a greater response<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Middleton, M. R. et al. Abstract CT106: a phase I/IIa study of IMCgp100: partial and complete durable responses with a novel first-in-class immunotherapy for advanced melanoma. Clin. Trials 75, CT106 (2015)." href="#ref-CR23" id="ref-link-section-d71731262e1087">23</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Middleton, M. R. et al. Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific T cell redirector with solid tumour activity: results from the FIH study in melanoma (Abstract 3016). J. Clin. Oncol. 34(15 Suppl.), 3016 (2016)." href="#ref-CR24" id="ref-link-section-d71731262e1087_1">24</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 25" title="Carvajal, R. et al. Safety, efficacy and biology of the gp100 TCR-based bispecific T cell redirector, IMCgp100 in advanced uveal melanoma in two Phase 1 trials (Poster 208). J. Immunother. Cancer 5(Suppl. 2), P208 (2017)." href="/articles/s41591-022-02015-7#ref-CR25" id="ref-link-section-d71731262e1090">25</a></sup>. The phase 1 dose escalation portion of this phase 1/2 study (IMCgp100-102) was therefore designed to identify a higher and potentially more effective recommended phase 2 dose. Using a step-up dosing regimen to mitigate acute toxicity, a recommended phase 2 dose that was 36% higher than the maximum tolerated dose identified in the first-in-human trial was achieved<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Carvajal, R. et al. Safety, efficacy and biology of the gp100 TCR-based bispecific T cell redirector, IMCgp100 in advanced uveal melanoma in two Phase 1 trials (Poster 208). J. Immunother. Cancer 5(Suppl. 2), P208 (2017)." href="#ref-CR25" id="ref-link-section-d71731262e1094">25</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Sato, T. et al. Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T-cell based toxicity and preliminary efficacy in advanced uveal melanoma (Abstract 9531). J. Clin. Oncol. 35(15 Suppl.), 9531 (2017)." href="#ref-CR26" id="ref-link-section-d71731262e1094_1">26</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 27" title="Carvajal, R. D. et al. Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma. J. Clin. Oncol. 40, 1939–1948 (2022)." href="/articles/s41591-022-02015-7#ref-CR27" id="ref-link-section-d71731262e1097">27</a></sup>. An early analysis of safety and efficacy in these heavily pre-treated patients (<i>n</i> = 19) demonstrated a promising 1 year overall survival rate of 73%, despite a modest overall response rate of 11% (refs. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 25" title="Carvajal, R. et al. Safety, efficacy and biology of the gp100 TCR-based bispecific T cell redirector, IMCgp100 in advanced uveal melanoma in two Phase 1 trials (Poster 208). J. Immunother. Cancer 5(Suppl. 2), P208 (2017)." href="/articles/s41591-022-02015-7#ref-CR25" id="ref-link-section-d71731262e1105">25</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 26" title="Sato, T. et al. Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T-cell based toxicity and preliminary efficacy in advanced uveal melanoma (Abstract 9531). J. Clin. Oncol. 35(15 Suppl.), 9531 (2017)." href="/articles/s41591-022-02015-7#ref-CR26" id="ref-link-section-d71731262e1108">26</a></sup>), suggesting a decoupling of overall response rate as a surrogate for overall survival. This lack of correlation between overall response rate and overall survival was also observed in the tebentafusp cohort of the phase 3 trial in which the overall response rate was limited to 9% despite a very significant survival benefit<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Nathan, P. et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med. 385, 1196–1206 (2021)." href="/articles/s41591-022-02015-7#ref-CR13" id="ref-link-section-d71731262e1112">13</a></sup>.</p><p>A similar but less pronounced disconnect between radiographic response and overall survival has been observed in other studies of immunotherapies<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="O’Day, S. et al. A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma (Abstract 4). J. Clin. Oncol. 28(18 Suppl.), 4 (2010)." href="/articles/s41591-022-02015-7#ref-CR28" id="ref-link-section-d71731262e1119">28</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 29" title="Hodi, F. S. et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J. Clin. Oncol. 34, 1510–1517 (2016)." href="/articles/s41591-022-02015-7#ref-CR29" id="ref-link-section-d71731262e1122">29</a></sup>, prompting efforts to identify novel and effective surrogates for treatment benefit. Recent evidence indicates that a reduction in circulating tumour DNA is associated with clinical response to treatment in many cancer settings<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Raja, R. et al. Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab. Clin. Cancer Res. 24, 6212–6222 (2018)." href="#ref-CR30" id="ref-link-section-d71731262e1126">30</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Goldberg, S. B. et al. Early assessment of lung cancer immunotherapy response via circulating tumor DNA. Clin. Cancer Res. 24, 1872–1880 (2018)." href="#ref-CR31" id="ref-link-section-d71731262e1126_1">31</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Zou, W. et al. ctDNA predicts overall survival in patients with NSCLC treated with PD-L1 blockade or with chemotherapy. JCO Precis. Oncol. 5, 827–838 (2021)." href="#ref-CR32" id="ref-link-section-d71731262e1126_2">32</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Vandekerkhove, G. et al. Plasma ctDNA is a tumor tissue surrogate and enables clinical–genomic stratification of metastatic bladder cancer. Nat. Commun. 12, 184 (2021)." href="#ref-CR33" id="ref-link-section-d71731262e1126_3">33</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 34" title="Lee, J. H. et al. Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies. JAMA Oncol. 4, 717–721 (2018)." href="/articles/s41591-022-02015-7#ref-CR34" id="ref-link-section-d71731262e1129">34</a></sup> and can predict benefit to immunotherapy<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 30" title="Raja, R. et al. Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab. Clin. Cancer Res. 24, 6212–6222 (2018)." href="/articles/s41591-022-02015-7#ref-CR30" id="ref-link-section-d71731262e1133">30</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 35" title="Bratman, S. V. et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat. Cancer 1, 873–881 (2020)." href="/articles/s41591-022-02015-7#ref-CR35" id="ref-link-section-d71731262e1136">35</a></sup>. This is of particular importance given that activation of the immune system can lead to different kinetics of response to therapy<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 36" title="Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012)." href="/articles/s41591-022-02015-7#ref-CR36" id="ref-link-section-d71731262e1140">36</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 37" title="Wolchok, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412–7420 (2009)." href="/articles/s41591-022-02015-7#ref-CR37" id="ref-link-section-d71731262e1143">37</a></sup>, and commonly used radiographic treatment response assessment criteria such as the Response Evaluation Criteria in Solid Tumours (RECIST)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 38" title="Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009)." href="/articles/s41591-022-02015-7#ref-CR38" id="ref-link-section-d71731262e1147">38</a></sup> may not account for response patterns associated with immune activation, limiting their applicability in such settings.</p><p>The objective of the phase 2 expansion of IMCgp100-102 was to characterize the antitumour activity of tebentafusp in patients with previously treated metastatic uveal melanoma, a patient population distinct to that enrolled in the randomized phase 3 study, and to explore the association of early ctDNA dynamics with clinical outcomes in this setting.</p></div></div></section><section data-title="Results"><div class="c-article-section" id="Sec2-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec2">Results</h2><div class="c-article-section__content" id="Sec2-content"><h3 class="c-article__sub-heading" id="Sec3">Study design</h3><p>This open-label, international, phase 1/2 study (<a href="https://clinicaltrials.gov/ct2/show/NCT02570308">NCT02570308</a>) included a phase 1 dose escalation as well as an expansion cohort and was subsequently expanded into a full phase 2 study. The results of the phase 1 dose escalation portion of this study have been recently reported<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 27" title="Carvajal, R. D. et al. Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma. J. Clin. Oncol. 40, 1939–1948 (2022)." href="/articles/s41591-022-02015-7#ref-CR27" id="ref-link-section-d71731262e1174">27</a></sup>. Patients in the phase 2 study received weekly intravenous (i.v.) tebentafusp, initially at 20 μg on day 1, 30 μg on day 8, 68 μg on day 15 and then 68 μg i.v. once weekly thereafter as the recommended phase 2 dose, with the length of a treatment cycle defined as 4 weeks (28 days). Following at least the first three infusions, patients were observed for a minimum of 16 hours for monitoring of vital signs and, if necessary, provision of supportive care. After this induction period and provided that no grade 2 or higher hypotension was noted, the observation period for tebentafusp could be reduced to 30–60 minutes. Patients with an initial assessment of progressive disease according to RECIST v1.1 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 38" title="Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009)." href="/articles/s41591-022-02015-7#ref-CR38" id="ref-link-section-d71731262e1178">38</a></sup>) could continue therapy beyond progressive disease provided that they did not have symptomatic progression requiring alternative therapy and the investigator believed that they were continuing to derive clinical benefit. After a patient was assessed as having RECIST progressive disease the treatment was continued until confirmation of immune-related progressive disease. This was defined as an additional ≥20% increase in tumour burden (that is, the sum of diameters of both target and new measurable lesions) as per the modified immune-related RECIST (irRECIST) criteria<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 39" title="Bohnsack, O., Hoos, A. &amp; Ludajic, K. Adaptation and modification of the immune related response criteria (IRRC): IrRECIST (Abstract e22121). J. Clin. Oncol. 32(15 Suppl.), e22121 (2014)." href="/articles/s41591-022-02015-7#ref-CR39" id="ref-link-section-d71731262e1182">39</a></sup>, which were used to evaluate the response to and duration of treatment beyond progression.</p><p>The primary objective of the phase 2 study was to estimate the overall response rate based on RECIST v1.1. Secondary endpoints included safety, overall survival, progression-free survival, disease control rate (defined as the proportion of patients with either an objective response (that is, partial or complete response) or a best overall response of stable disease recorded at least 24 weeks (±1 week) after the date of the first dose of study drug), time to response, duration of response (defined as the time from the date of the first documented objective response (that is, partial or complete response) until the date of documented disease progression or death by any cause in the absence of disease progression), and the rate and duration of minor response, defined as a 10–29% reduction in the sum of the longest diameters of target lesions (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-022-02015-7#Sec10">Methods</a>). Imaging-based endpoints were assessed by blinded, independent central review. For overall survival, patients who did not die were censored on the date on which they were last known to be alive. For progression-free survival and duration of response, patients who were known to be alive and without disease progression were censored at the date on which they were last known to be progression free. To assess potential predictors of efficacy of tebentafusp, changes in serum ctDNA levels were measured using a custom panel including mutations commonly found in uveal melanoma (GNAQ Q209L/P; GNA11 Q209L; SF3B1 K700E, R625L/H/C; PLCB4 D630N/Y/V; CYSLTR2 L129Q; and EIF1AX G15D) (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-022-02015-7#Sec10">Methods</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-02015-7#MOESM1">4</a>).</p><h3 class="c-article__sub-heading" id="Sec4">Patients and treatment</h3><p>Of the 148 HLA-A*02:01-positive patients screened, 127 patients met the eligibility criteria and were enrolled between January and December 2017 in 26 study centers in five countries (Canada, Germany, Spain, United Kingdom and United States) (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-02015-7#Fig4">1</a>). The median age was 61 years (range, 25–88 years) and 50% of patients were male (Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-022-02015-7#Tab1">1</a>). The majority of patients (96%) had hepatic involvement. A total of 53% of patients had either American Joint Committee on Cancer (AJCC) M1b or M1c disease and 58% of patients had a baseline lactate dehydrogenase (LDH) level above the upper limit of normal (ULN). The median time from initial diagnosis to the development of metastatic disease was 3 years (range, 0–28 years) and the median and mean time since primary diagnosis to enrollment was 4.4 and 6.3 years (range, 1–28 years), respectively. All patients had received at least one prior line of therapy in the metastatic setting, with 34% receiving ≥2 lines of prior systemic (±liver-directed) therapy. More than two-thirds of patients (<i>n</i> = 90) received prior immune checkpoint inhibition, of whom 68% had primary resistance to treatment with a prior best response of progressive disease, and 32% relapsed, with a prior best response of at least stable disease, following treatment. At the time of data cut-off the median duration of study follow-up was 19.5 months (95% CI: 16–22.2 months).</p><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-1"><figure><figcaption class="c-article-table__figcaption"><b id="Tab1" data-test="table-caption">Table 1 Demographics and baseline characteristics</b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/s41591-022-02015-7/tables/1" aria-label="Full size table 1"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>Analysis of tumour biopsies (<i>n</i> = 63) showed that 61 (97%) had likely loss of one copy of <i>BAP1</i> (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-022-02015-7#Sec10">Methods</a>), 23 (37%) had mutations in the gene encoding GNAQ, 26 (41%) in GNA11, three (5%) in CYSLTR2, one (2%) in PLCB4 and 11 (17%) in SF3B1. Mutations in <i>EIF1AX</i> were not detected in tumour biopsies.</p><p>All 127 patients (100%) received the study drug, of whom 21 (17%) remained on treatment at the time of data cut-off. The median duration of treatment was 5.5 months (range, 0–35 months). The primary reason for treatment discontinuation was disease progression (70%); six patients (5%) discontinued treatment due to an adverse event regardless of causality. At the data cut-off date, 53 patients (42%) remained in the study and 74 (58%) were reported to have ended the study. Death was the primary cause of study discontinuation (69/74; 93%). Nearly all of the deaths (67/69) were related to disease progression; the cause of death in two patients was listed as ‘other’, including cerebrovascular event in the setting of a fall in one, and clinical disease progression in the other. There were no deaths due to adverse events or caused by the study drug (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-02015-7#Fig4">1</a>).</p><h3 class="c-article__sub-heading" id="Sec5">Safety and adverse events</h3><p>All patients had at least one treatment-related adverse event (Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-022-02015-7#Tab2">2</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-02015-7#MOESM1">2</a>). The most frequently reported treatment-related adverse events of any grade could be classified as skin related, due to the targeting of gp100-positive melanocytes, or cytokine related, due to T cell activation, and included rash (87%), pyrexia (80%), pruritus (67%) and chills (64%). A total of 51 patients (40%) had a grade 3 event as their maximum grade, one-third of which were rash events (<i>n</i> = 20), and eight patients (6%) had a grade 4-related adverse event (hypotension and multiple organ dysfunction syndrome in one patient; lymphopenia; γ-glutamyltransferase increased; atrial fibrillation; amylase increased; hypophosphatemia; hypokalemia; and aspartate aminotransferase increased). A total of 25 patients (20%), 21 patients (17%) and four patients (3%) had treatment-related adverse events leading to hospitalization, dose interruptions and drug discontinuation, respectively. Following the 16 hour observation period after the first three doses, seven patients (6%) required an additional overnight stay due to a treatment-related adverse event. Treatment-related adverse events leading to discontinuation included atrial fibrillation and cytokine release syndrome, multiple organ dysfunction syndrome and cytokine release syndrome, left ventricular dysfunction, and dyspnea. There were no treatment-related deaths.</p><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-2"><figure><figcaption class="c-article-table__figcaption"><b id="Tab2" data-test="table-caption">Table 2 Most common treatment-related adverse events<sup>a</sup></b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/s41591-022-02015-7/tables/2" aria-label="Full size table 2"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>Consistent with the phase 1 studies, adverse events related to tebentafusp, including rash, generally occurred early in the course of treatment and reduced in incidence and severity with repeated dosing, with ~65% of patients having rash from weeks 1 to 3 and 23% in week 8 (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-02015-7#Fig1">1</a>). Patients with symptomatic rash were generally managed successfully with antihistamine and topical corticosteroid therapy, and no patient discontinued treatment due to rash.</p><p>Cytokine release syndrome is a common adverse event with T cell engaging therapies and 109 patients (86%) had cytokine release syndrome based on American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading criteria<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 40" title="Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625–638 (2019)." href="/articles/s41591-022-02015-7#ref-CR40" id="ref-link-section-d71731262e2746">40</a></sup>. Most patients had either grade 1 (33%) or grade 2 (49%) cytokine release syndrome as their maximum grade. Very few patients had grade 3 (3.1%) or 4 (0.8%) events. Two patients had cytokine release syndrome events leading to discontinuation, including a patient who had a serious adverse event of grade 3 cytokine release syndrome on cycle 1 day 1 (C1D1) with a concurrent serious adverse event of grade 4 atrial fibrillation. The patient was treated with i.v. fluids, paracetamol, i.v. methylprednisolone, and oxygen. The cytokine release syndrome resolved the next day and the study drug was discontinued due to the event of atrial fibrillation. The second patient had grade 4 cytokine release syndrome on C1D1 with concurrent adverse events of grade 1 pyrexia, grade 4 hypotension and grade 4 multiple organ dysfunction. The patient received i.v. fluids followed by i.v. steroids, tocilizumab and vasopressors and was intubated for respiratory support. The event of cytokine release syndrome resolved 2 days later, and the study drug was discontinued due to the event of multiple organ dysfunction.</p><p>The onset of cytokine release syndrome, based on an increase in body temperature, generally began within 8–10 hours following administration and, as with other treatment-related adverse events, most events occurred following the first three doses, with a marked reduction in the incidence and severity of cytokine release syndrome thereafter (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-02015-7#Fig1">1</a>). All five grade 3 and 4 episodes occurred following one of the initial two doses, during the step-up dosing regimen. Patients were generally treated with antipyretics (<i>n</i> = 96, 88%), i.v. fluids (<i>n</i> = 48, 44%) and/or systemic glucocorticoids (<i>n</i> = 28, 26%). Supplemental oxygen (<i>n</i> = 9, 8%), vasopressors (<i>n</i> = 2, 2%) and tocilizumab (<i>n</i> = 2, 2%) were less frequently used to manage more severe cases.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-1" data-title="Incidence and severity of treatment-related adverse events after the initial tebentafusp doses."><figure><figcaption><b id="Fig1" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 1: Incidence and severity of treatment-related adverse events after the initial tebentafusp doses.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-02015-7/figures/1" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig1_HTML.png?as=webp"><img aria-describedby="Fig1" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig1_HTML.png" alt="figure 1" loading="lazy" width="685" height="361"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-1-desc"><p>Percentage of treated patients with grade 1–2 grade 3–4 treatment-related adverse events after each dose of tebentafusp. A total of 127 patients received dose 1, 122 received dose 2, 122 received dose 3, 119 received dose 4 and 113 received dose 8. There were no treatment-related deaths. CRS, cytokine release syndrome.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-02015-7/figures/1" data-track-dest="link:Figure1 Full size image" aria-label="Full size image figure 1" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><h3 class="c-article__sub-heading" id="Sec6">Tumour response and progression-free survival</h3><p>The primary endpoint of overall response rate as per RECIST v1.1 by independent central review was 5% (95% CI: 2–10%) (Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-022-02015-7#Tab3">3</a>), with six patients achieving a partial response (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-02015-7#Fig5">2</a>). Of these six patients, three had ongoing responses for &gt;6 months, one had an ongoing response for &gt;12 months and one patient was censored at 5.3 months. The median duration of response was 8.7 months (95% CI: 5.6–24.5 months) and the median time to response was 4.6 months, with response times ranging from 1.6 to 20.5 months.</p><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-3"><figure><figcaption class="c-article-table__figcaption"><b id="Tab3" data-test="table-caption">Table 3 Best overall RECIST response rate</b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/s41591-022-02015-7/tables/3" aria-label="Full size table 3"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>Of the 127 patients, 57 (45%) achieved stable disease at ≥8 weeks. The disease control rate was 32% (<i>n</i> = 40; 95% CI: 24–40%) at ≥16 weeks and 23% (<i>n</i> = 29; 95% CI: 16–31%) at ≥24 weeks. Any tumour shrinkage of target lesions was observed in 44% (<i>n</i> = 51) of evaluable patients (<i>n</i> = 116), including 10 of 55 patients (18%) with a best RECIST response of progressive disease (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-02015-7#Fig6">3a</a>), consistent with radiographic pseudoprogression.</p><p>The median progression-free survival was 2.8 months (95% CI: 2–3.6 months). The estimated progression-free survival rates were 25% (95% CI: 18–33%) at 6 months and 11% (95% CI: 6–17%) at 12 months (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-02015-7#Fig7">4</a>). A total of 90 patients (71%) were treated beyond initial disease progression, with a median duration of treatment following confirmation of RECIST progressive disease of 2.9 months (range, 0–23.1 months; Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-02015-7#Fig8">5</a>). Of these patients, six (7%) achieved immune-related stable disease and 69 (77%) had confirmed immune-related progressive disease, per modified irRECIST as assessed by blinded, independent central review.</p><h3 class="c-article__sub-heading" id="Sec7">Overall survival</h3><p>With a median duration of study follow-up of 19.5 months (95% CI: 16–22.2 months), the median overall survival was 16.8 months (95% CI: 12.9–21.3 months) in this patient population with previously treated metastatic uveal melanoma. The estimated 1 year and 2 year overall survival rates were 62% (95% CI: 53–70%) (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-02015-7#Fig2">2</a>) and 37% (95% CI: 27–48%), respectively. Longer survival was associated with development of any tumour shrinkage, including partial response by RECIST criteria, with most patients (86%) with tebentafusp-induced tumour shrinkage alive at 12 months (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-02015-7#Fig6">3b</a>). Even among patients with tumour growth (≥20% increase from baseline) as best change on treatment, 43% (12/28) were alive at 12 months. In predefined subgroup analyses, the overall survival at 1 year was 51% in patients ≥65 years of age, 45% for patients with elevated LDH at baseline, and 75%, 60% and 25% in patients with largest target liver metastasis at baseline of ≤3 cm (M1a), &gt;3 cm to ≤8 cm (M1b) and &gt;8 cm (M1c), respectively. In patients who had previously relapsed (best overall response of complete response, partial response or stable disease on prior therapy) following immunological checkpoint inhibition, 1 year overall survival was 76% (95% CI: 56–88%) compared with 60% (95% CI: 46–71%) in patients who were refractory (best overall response of progressive disease on prior therapy) to prior checkpoint inhibition (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-02015-7#MOESM1">3</a>). This survival appears superior when compared with similar populations from meta-analyses (Extended Data Figs. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-02015-7#Fig9">6</a> and <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-02015-7#Fig10">7</a>) or with patients in the control arm of the randomized phase 3 study<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Nathan, P. et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med. 385, 1196–1206 (2021)." href="/articles/s41591-022-02015-7#ref-CR13" id="ref-link-section-d71731262e3023">13</a></sup> who received subsequent therapy (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-02015-7#Fig11">8</a>).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-2" data-title="Overall survival for tebentafusp-treated patients with metastatic uveal melanoma."><figure><figcaption><b id="Fig2" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 2: Overall survival for tebentafusp-treated patients with metastatic uveal melanoma.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-02015-7/figures/2" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig2_HTML.png?as=webp"><img aria-describedby="Fig2" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig2_HTML.png" alt="figure 2" loading="lazy" width="685" height="465"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-2-desc"><p>Kaplan–Meier plot of overall survival (<i>n</i> = 127). Events are deaths due to any cause. Patients not known to have died at the time of analysis are censored (+). The median overall survival was 16.8 months (95% CI: 12.9–21.3 months) with a 1 year overall survival rate of 62% (95% CI: 53–70%). The 1 year overall survival rate, median overall survival and corresponding two-sided, 95% confidence intervals were estimated using the Kaplan–Meier method.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-02015-7/figures/2" data-track-dest="link:Figure2 Full size image" aria-label="Full size image figure 2" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><h3 class="c-article__sub-heading" id="Sec8">Early ctDNA reduction correlates with overall survival</h3><p>On-treatment reductions in ctDNA levels have been previously shown to correlate with clinical outcome in studies involving checkpoint blockade<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 30" title="Raja, R. et al. Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab. Clin. Cancer Res. 24, 6212–6222 (2018)." href="/articles/s41591-022-02015-7#ref-CR30" id="ref-link-section-d71731262e3061">30</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 32" title="Zou, W. et al. ctDNA predicts overall survival in patients with NSCLC treated with PD-L1 blockade or with chemotherapy. JCO Precis. Oncol. 5, 827–838 (2021)." href="/articles/s41591-022-02015-7#ref-CR32" id="ref-link-section-d71731262e3064">32</a></sup>. Therefore, we evaluated ctDNA levels at baseline and at weeks 5, 9 and 25 after completion of one, two and six cycles of treatment, respectively. Of the 127 patients in the trial, 118 (93%) had evaluable serum samples, with most (109/118; 92%) found to have detectable ctDNA at any timepoint up to and including week 9 (baseline, week 5, week 9). A total of 99 of these 118 patients (84%) had detectable ctDNA at baseline and on treatment, of whom 94 had mutations detected in one or more uveal melanoma genes (<i>GNAQ</i>, <i>GNA11</i>, <i>SF3B1</i>, <i>PLCB4</i>, <i>CYSLTR2</i>) at a variant allelic frequency of &gt;0.3 at baseline and were included in the analyses (<a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-022-02015-7#Sec10">Methods</a>, Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-022-02015-7#Tab1">1</a> and Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-02015-7#MOESM1">4</a>). Given that patient data were limited at week 25, this timepoint was excluded from analysis. In the subset of patients (<i>n</i> = 45) with both baseline ctDNA data and mutational analysis from tumour biopsies, there was good concordance: 82% of the known uveal melanoma-specific mutations in ctDNA were also found in tumour biopsies; for mutations in <i>GNAQ/GNA11</i> the concordance was 85% (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-02015-7#MOESM1">5</a>), and 43 of 45 tumour samples (96%) had likely loss of one copy of <i>BAP1</i> (see <a data-track="click" data-track-label="link" data-track-action="section anchor" href="/articles/s41591-022-02015-7#Sec10">Methods</a>). However, the sensitivity of base calling in the sequencing of tumour biopsies was lower due to a lack of matched normal tissue. For patients with known uveal mutations detected in both tumour biopsies and ctDNA (<i>n</i> = 38), concordance was 97%. Only one patient had detectable <i>EIF1AX</i> mutations in ctDNA at week 5.</p><p>Mean tumour molecules per ml serum detected at baseline was strongly correlated with tumour burden as defined using the RECIST sum of longest diameters of the target lesions (Spearman’s <i>r</i> = 0.6, <i>P</i> = 6.4 × 10<sup>−10</sup>) and baseline LDH (Spearman’s <i>r</i> = 0.77, <i>P</i> = 6.76 × 10<sup>−19</sup>; Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-02015-7#Fig12">9a</a>,<a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-02015-7#Fig12">b</a>, respectively). Likewise, subgroups with larger tumours or serum alkaline phosphatase or LDH above ULN were more likely to have ctDNA levels above the median (Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-022-02015-7#Tab1">1</a>). No association of baseline ctDNA level with prior immunotherapy was detected (<i>P</i> = 0.42; Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-02015-7#Fig12">9c</a>), although a higher percentage of patients who received anti-programmed cell death 1 (anti-PD1) or anti-PD-L1 monotherapy had below-median levels of baseline ctDNA (<i>P</i> = 0.019, Fisher’s exact test; Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-022-02015-7#Tab1">1</a>). However, patient numbers are small, and such an association was not observed for anti-cytotoxic T lymphocyte antigen (anti-CTLA) monotherapy or combination anti-PD1 and anti-CTL4. There was also no association between baseline ctDNA level and cytokine release syndrome, but baseline ctDNA was marginally higher in patients who did not have rash in week 1 (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-02015-7#Fig12">9d,e</a>). Consistent with the association with measures of tumour burden (RECIST sum of longest diameters of the target lesions and LDH), baseline ctDNA levels were associated with overall survival. The subset of patients with below-median levels of ctDNA had longer overall survival compared with the subset with above-median levels of ctDNA at baseline (HR 0.23, 95% CI: 0.13–0.41, <i>P</i> = 2.05 × 10<sup>−7</sup>; Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-02015-7#Fig13">10a</a>). Notably, seven of the nine patients without detectable ctDNA at baseline were alive after 12 months and none of the nine patients had detectable ctDNA by week 9.</p><p>By weeks 5 and 9, 66% of patients (59/90) and 71% of patients (67/94), respectively, with baseline and on treatment measurements of mean tumour molecules per ml serum had any (&gt;0) ctDNA reduction (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-02015-7#MOESM1">6</a> and Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-02015-7#Fig3">3a</a>). A total of 29% of patients (27/94) had an increase in ctDNA by week 9, and there were no patients who did not have some change from baseline ctDNA levels (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-02015-7#Fig3">3a</a>). Twelve patients had complete ctDNA clearance (undetectable), of whom one had a partial response, seven had stable disease, three had progressive disease and one was non-evaluable by RECIST (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-02015-7#MOESM1">7</a>). For the remaining 82 patients without ctDNA clearance, three had a partial response, 34 had stable disease, 44 had progressive disease and one was non-evaluable by RECIST (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-02015-7#MOESM1">7</a>). The magnitude of ctDNA reduction by week 9 was strongly associated with improvement in overall survival (<i>R</i><sup>2</sup> = 0.9, <i>P</i> = 8.89 × 10<sup>−7</sup>): a 0.1 log reduction was associated with an HR of 0.8, while a 1 log reduction was associated with an HR of 0.4, a 2 log reduction was associated with an HR of 0.2, a 3 log reduction was associated with an HR of 0.2, and ctDNA clearance was associated with an HR of 0.1 (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-02015-7#Fig3">3b</a>). The 1 year overall survival rate in patients with ctDNA clearance (<i>n</i> = 12) was 100% compared with 52% in those with increased ctDNA (<i>n</i> = 27) (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-02015-7#Fig3">3c</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-02015-7#Fig13">10b</a>). Even in the subset with ≥1 log reduction in ctDNA but without clearance there was a trend for longer overall survival (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-02015-7#Fig13">10c</a>). Notably, of the 47 patients with a best radiographic response of progressive disease who were also evaluable for ctDNA, one-third (<i>n</i> = 16) had a ≥0.5 log reduction in ctDNA by week 9, including three with ctDNA clearance; 14 patients (30%) had &lt;0.5 log reduction and 17 (36%) had increased ctDNA (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-02015-7#MOESM1">7</a>). In these patients with progressive disease, ctDNA reduction of ≥0.5 log (including patients who cleared their ctDNA) was associated with improved overall survival, compared with patients with progressive disease with a &lt;0.5 log ctDNA reduction or ctDNA increase (HR 0.47, 95% CI: 0.22–1.01, <i>P</i> = 0.042; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-02015-7#Fig3">3d</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-022-02015-7#Fig13">10d</a>). Of the 16 patients with progressive disease with ≥0.5 log reduction of ctDNA by week 9, 12 developed new lesions.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-3" data-title="On-treatment ctDNA reduction correlated with survival benefit."><figure><figcaption><b id="Fig3" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 3: On-treatment ctDNA reduction correlated with survival benefit.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-022-02015-7/figures/3" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig3_HTML.png?as=webp"><img aria-describedby="Fig3" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig3_HTML.png" alt="figure 3" loading="lazy" width="685" height="506"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-3-desc"><p><b>a</b>, Waterfall plot showing log<sub>10</sub> change in ctDNA level by week 9 in all evaluable patients (<i>n</i> = 94). Percentages have been rounded to the nearest whole number. ﻿<b>b</b>, Correlation between ctDNA reduction in patients with metastatic uveal melanoma by week 9 with tebentafusp and the HR for death (<i>R</i><sup>2</sup> = 0.9, <i>P</i> = 8.89 × 10<sup>−7</sup> by linear model (two sided); <i>n</i> = 94). Hazard ratios were derived by comparing subsets of patients with ctDNA above or below the thresholds given on the <i>x</i> axis. <b>c</b>,<b>d</b>, Kaplan–Meier comparison of overall survival in patients with ctDNA clearance (<i>n</i> = 12) versus patients without clearance (<i>n</i> = 82) by 9 weeks (HR 0.08, 95% CI: 0.01–0.54, <i>P</i> = 4.22 × 10<sup>−5</sup>) (<b>c</b>) and patients with best overall response of progressive disease with a reduction in ctDNA by ≥0.5 log fold change (<i>n</i> = 16) versus &lt;0.5 log fold change (includes patients with increased ctDNA; <i>n</i> = 31) by week 9 (HR for death 0.47, 95% CI: 0.22–1.01, <i>P</i> = 0.042) (<b>d</b>). <b>b</b>–<b>d</b>, Hazard ratios and confidence intervals were generated using a Cox proportional hazard model. <i>P</i> values were generated using a two-sided Cox likelihood ratio test.</p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-022-02015-7/figures/3" data-track-dest="link:Figure3 Full size image" aria-label="Full size image figure 3" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div></div></div></section><section data-title="Discussion"><div class="c-article-section" id="Sec9-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec9">Discussion</h2><div class="c-article-section__content" id="Sec9-content"><p>Data from this study provide the longest follow-up of overall survival and safety of a soluble TCR therapeutic to date. The observed 1 year overall survival rate of 62% and median overall survival of 16.8 months compare very favorably with an analysis using data on a similar population of previously treated patients with metastatic uveal melanoma from a recent meta-analysis that resulted in a 1 year overall survival of 37% and a median overall survival of 7.8 months<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Rantala, E. S., Hernberg, M. &amp; Kivelä, T. T. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 29, 561–568 (2019)." href="/articles/s41591-022-02015-7#ref-CR18" id="ref-link-section-d71731262e3329">18</a></sup>. These data also support the recent approval of tebentafusp for HLA-A*02:01-positive adult patients with unresectable metastatic uveal melanoma regardless of prior treatment history in the United States, European Union and United Kingdom.</p><p>In this cohort of previously treated patients, tebentafusp had a predictable and manageable safety profile supported by a very low rate (3%) of treatment discontinuation due to treatment-related adverse events and no treatment-related deaths. As observed in the phase 1 study and the recent phase 3 study, most treatment-related adverse events recorded could be classified as either skin related or cytokine mediated, consistent with tebentafusp’s proposed mechanism of action. After each of the first three doses patients need to be monitored for at least 16 hours, to facilitate prompt intervention and management when the risk for cytokine release syndrome is highest. Following the first few doses, treatment-related adverse events tend to decrease in both frequency and severity, enabling the monitoring period to be shortened to 30–60 minutes.</p><p>RECIST v1.1 underestimated the degree of clinical benefit from tebentafusp. Although the primary endpoint of overall response rate was low at 5%, 44% of patients achieved some degree of tumour shrinkage. More than 70% of all of the patients were treated beyond initial radiographic progression, and nearly half of the patients with tumour growth (≥20%) as best response were alive at 12 months. This pattern of clinical benefit is similar to what was observed in the randomized phase 3 trial of tebentafusp versus investigator’s choice in previously untreated patients with metastatic uveal melanoma, in which tebentafusp-treated patients with a best response of progressive disease had a better overall survival than patients with a best response of progressive disease on the investigator’s choice control arm (HR 0.43)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Nathan, P. et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med. 385, 1196–1206 (2021)." href="/articles/s41591-022-02015-7#ref-CR13" id="ref-link-section-d71731262e3339">13</a></sup>. Together, these data highlight the need for new measures of clinical activity that correlate with overall survival for this new class of immuno-oncology therapy.</p><p>Higher levels of ctDNA at baseline have been shown to be correlated with tumour burden and poor prognosis, while on-treatment reductions in ctDNA are associated with improved outcomes, including prolonged progression-free survival and overall survival<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Raja, R. et al. Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab. Clin. Cancer Res. 24, 6212–6222 (2018)." href="#ref-CR30" id="ref-link-section-d71731262e3346">30</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Goldberg, S. B. et al. Early assessment of lung cancer immunotherapy response via circulating tumor DNA. Clin. Cancer Res. 24, 1872–1880 (2018)." href="#ref-CR31" id="ref-link-section-d71731262e3346_1">31</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Zou, W. et al. ctDNA predicts overall survival in patients with NSCLC treated with PD-L1 blockade or with chemotherapy. JCO Precis. Oncol. 5, 827–838 (2021)." href="#ref-CR32" id="ref-link-section-d71731262e3346_2">32</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 33" title="Vandekerkhove, G. et al. Plasma ctDNA is a tumor tissue surrogate and enables clinical–genomic stratification of metastatic bladder cancer. Nat. Commun. 12, 184 (2021)." href="/articles/s41591-022-02015-7#ref-CR33" id="ref-link-section-d71731262e3349">33</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 41" title="Zhang, Q. et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. 10, 1842–1853 (2020)." href="/articles/s41591-022-02015-7#ref-CR41" id="ref-link-section-d71731262e3352">41</a></sup>. In a recent analysis of samples from patients with 16 advanced stage tumour types treated with checkpoint inhibition (durvalumab ± tremelimumab), early on-treatment reductions in ctDNA were not only associated with improved survival but were also able to be used to differentiate responders from non-responders in patients who had radiologic stable disease at their first assessment<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 41" title="Zhang, Q. et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. 10, 1842–1853 (2020)." href="/articles/s41591-022-02015-7#ref-CR41" id="ref-link-section-d71731262e3356">41</a></sup>. Likewise, in this study we observed a significant linear relationship between the level of ctDNA reduction and overall survival. Baseline ctDNA levels correlated with tumour burden and, by week 9 on tebentafusp, more than two-thirds of patients had some degree of ctDNA reduction, with greater reduction being associated with longer survival. This association was true even for patients with a best radiographic response of progressive disease, three of whom had complete ctDNA clearance, which may reflect changes in tumour size on treatment due to immune activation and infiltration into the tumour rather than frank tumour growth, as proposed for other forms of immuno-oncology therapy<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 42" title="Chiou, V. L. &amp; Burotto, M. Pseudoprogression and immune-related response in solid tumors. J. Clin. Oncol. 33, 3541–3543 (2015)." href="/articles/s41591-022-02015-7#ref-CR42" id="ref-link-section-d71731262e3360">42</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 43" title="Giacomo, A. M. D. et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol. Immunother. 58, 1297–1306 (2009)." href="/articles/s41591-022-02015-7#ref-CR43" id="ref-link-section-d71731262e3363">43</a></sup>. Additionally, tumour-infiltrating lymphocytes, edema and tumour necrosis without clearance of debris could also result in the appearance of radiographic progression in the presence of ctDNA reduction or clearance.</p><p>In a study of 125 melanoma patients, Lee et al.<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 34" title="Lee, J. H. et al. Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies. JAMA Oncol. 4, 717–721 (2018)." href="/articles/s41591-022-02015-7#ref-CR34" id="ref-link-section-d71731262e3371">34</a></sup> demonstrated that ctDNA reduction had utility in identifying the nine patients with pseudoprogression and was associated with overall survival in that subset. In this study with a larger percentage of patients having long overall survival despite apparent radiographic progression, we used a quantitative approach to demonstrate that ctDNA reduction even without complete clearance can provide useful information regarding benefit from tebentafusp. These findings suggest that early reductions in ctDNA reflect tebentafusp-related activity in the tumour and may provide a more precise molecular predictor of clinical response to tebentafusp than traditional radiographic response criteria. Further studies are needed to assess how changes in ctDNA correlate with other pharmacodynamic changes including T cell infiltration into the tumour<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 44" title="Butler, M. O. et al. Abstract 517: Tebentafusp induces transient systemic inflammation and modifies the micro-environment to sensitize uveal melanoma tumors to cytotoxic CD8 cells. Cancer Res. 81(13 Suppl.), 517 (2021)." href="/articles/s41591-022-02015-7#ref-CR44" id="ref-link-section-d71731262e3375">44</a></sup>, and whether other potential surrogate endpoints, such as radiomic features of tumour lesions (particularly change in tumour heterogeneity)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 45" title="Beylergil, V. et al. Abstract 819: Radiomic markers associated with clinical benefit in advanced uveal melanoma patients with radiographic progression on tebentafusp. J. Immunother. Cancer 9(2 Suppl.), 819 (2021)." href="/articles/s41591-022-02015-7#ref-CR45" id="ref-link-section-d71731262e3379">45</a></sup>, can be identified that better capture these changes<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 46" title="Dercle, L. et al. Identification of non-small cell lung cancer sensitive to systemic cancer therapies using radiomics. Clin. Cancer Res. 26, 2151–2162 (2020)." href="/articles/s41591-022-02015-7#ref-CR46" id="ref-link-section-d71731262e3383">46</a></sup>.</p><p>Commonly used approaches for analyzing ctDNA include next-generation sequencing or digital droplet (dd) polymerase chain reaction (PCR)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 47" title="Keller, L., Belloum, Y., Wikman, H. &amp; Pantel, K. Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. Br. J. Cancer 124, 345–358 (2021)." href="/articles/s41591-022-02015-7#ref-CR47" id="ref-link-section-d71731262e3390">47</a></sup>. Both approaches have their strengths and limitations: ddPCR can be economical but needs to be focused on known mutations and can be challenging to optimize for certain mutations. Next-generation sequencing can enable discovery of new mutations but can be less cost-effective. Here, we used multiplex PCR followed by next-generation sequencing to enable discovery of new variants and for convenience, given that it fitted into other sequencing projects ongoing in the laboratory.</p><p>Our study was limited by the absence of a control arm. To interpret the clinical findings, we compared overall survival from this study with that of published studies of first-line ipilimumab plus nivolumab as well as the Rantala et al. and the Khoja et al. meta-analyses<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Piulats, J. M. et al. Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). J. Clin. Oncol. 39, 586–598 (2021)." href="#ref-CR16" id="ref-link-section-d71731262e3397">16</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Khoja, L. et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an International Rare Cancers Initiative (IRCI) ocular melanoma study. Ann. Oncol. 30, 1370–1380 (2019)." href="#ref-CR17" id="ref-link-section-d71731262e3397_1">17</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 18" title="Rantala, E. S., Hernberg, M. &amp; Kivelä, T. T. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 29, 561–568 (2019)." href="/articles/s41591-022-02015-7#ref-CR18" id="ref-link-section-d71731262e3400">18</a></sup>. We also performed a propensity score analysis that accounts for differences in baseline prognostic factors between patients in this study and patients randomized to the control arm of the phase 3 study (IMCgp100-202) who received subsequent therapy after progression<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 13" title="Nathan, P. et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N. Engl. J. Med. 385, 1196–1206 (2021)." href="/articles/s41591-022-02015-7#ref-CR13" id="ref-link-section-d71731262e3404">13</a></sup>. This latter dataset represents the most recent overall survival follow-up of a second line plus metastatic uveal melanoma population available in the public domain. In each case, the overall survival from previously treated metastatic uveal melanoma for patients who received tebentafusp in this study was found to be superior to the comparator.</p><p>The exploratory analysis of ctDNA levels was a retrospective hypothesis-generating analysis using samples collected from a single-arm phase 2 trial, thus limiting interpretation. These results need to be confirmed in a prospective randomized study before ctDNA dynamics on tebentafusp can be introduced to routine clinical practice to manage patient treatment.</p><p>In conclusion, tebentafusp demonstrates a promising survival benefit for patients with metastatic disease that has progressed on at least one line of prior therapy, with ctDNA as an early indicator of benefit. The addition of ctDNA analysis to assess the molecular response to treatment may provide a more sensitive means than standard imaging studies to identify those patients who will benefit most from tebentafusp treatment.</p></div></div></section><section data-title="Methods"><div class="c-article-section" id="Sec10-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec10">Methods</h2><div class="c-article-section__content" id="Sec10-content"><h3 class="c-article__sub-heading" id="Sec11">Study design and participants</h3><p>This open-label, international, phase 1/2 study (<a href="https://clinicaltrials.gov/ct2/show/NCT02570308">NCT02570308</a>) was composed of a phase 1 dose escalation and an initial expansion cohort that was subsequently expanded into a full phase 2 expansion study. The primary objective of the phase 1 portion of the study was to identify the maximum tolerated dose and determine the recommended phase 2 dose, the results of which are reported elsewhere<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 27" title="Carvajal, R. D. et al. Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma. J. Clin. Oncol. 40, 1939–1948 (2022)." href="/articles/s41591-022-02015-7#ref-CR27" id="ref-link-section-d71731262e3433">27</a></sup>. The primary objective of the phase 2 portion was to estimate the objective response rate based on RECIST v1.1 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 38" title="Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009)." href="/articles/s41591-022-02015-7#ref-CR38" id="ref-link-section-d71731262e3437">38</a></sup>) in patients treated at the recommended phase 2 dose of tebentafusp. Secondary objectives included assessment of the safety and antitumour efficacy of tebentafusp with the parameters of overall survival, progression-free survival, disease control rate (defined as the proportion of patients with either an objective response (that is, partial or complete response) or a best overall response of stable disease recorded at least 24 weeks (±1 week) after the date of first dose of study drug), time to response, duration of response (defined as the time from the date of first documented objective response (complete or partial response) until the date of documented disease progression or death by any cause in the absence of disease progression), and the rate and duration of minor response (defined as tumour response with a 10%–29% reduction in the sum of the longest diameters of the target lesions).</p><p>Patients with an initial assessment of progressive disease according to RECIST v1.1 could continue therapy beyond initial progressive disease, provided that they did not have symptomatic progression requiring alternative therapy and the investigator believed they were continuing to derive clinical benefit. The modified immune-related RECIST (irRECIST) criteria<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 39" title="Bohnsack, O., Hoos, A. &amp; Ludajic, K. Adaptation and modification of the immune related response criteria (IRRC): IrRECIST (Abstract e22121). J. Clin. Oncol. 32(15 Suppl.), e22121 (2014)." href="/articles/s41591-022-02015-7#ref-CR39" id="ref-link-section-d71731262e3444">39</a></sup> were used to evaluate response to treatment beyond progression. Tumour-based endpoints were assessed by a blinded, independent central review with investigator assessment data collected as a secondary evaluation. To assess potential predictors of the efficacy of tebentafusp, change in serum ctDNA level in response to treatment was also measured.</p><p>The trial was carried out in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice guidelines, and the study protocol was approved by the relevant ethics bodies at each participating site: Princess Margaret Cancer Centre, Toronto, Canada; Charite Universitaetsmedizin Berlin – Campus Benjamin Franklin, Berlin, Germany; Universitaetsklinikum Heidelberg, Heidelberg, Germany; Institut Catala d’Oncologia (ICO) l’Hospitalet, Hospital Duran i Reynals, Barcelona, Spain; Hospital Universitario Virgen Macarena, Seville, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain/Hospital Universitario La Paz, Madrid, Spain; Hospital General Universitario de Valencia, Valencia, Spain; The Clatterbridge Cancer Centre, Wirral, UK; Mount Vernon Cancer Centre, Northwood, UK; Columbia University Medical Center, New York, USA; Washington University School of Medicine, St Louis, USA; Thomas Jefferson University Hospital, Philadelphia, USA; Vanderbilt University Medical Center, Nashville, USA; Memorial Sloan Kettering Cancer Center, New York, USA; University of Colorado Cancer Center, Aurora, USA; The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, USA; H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, USA; University of California San Diego Moores Cancer Center, La Jolla, USA; California Pacific Medical Center, San Francisco, USA; Baylor Scott &amp; White Health, Dallas, USA; Dean A. McGee Eye Institute, University of Oklahoma, Oklahoma City, USA; Georgetown University – Lombardi Comprehensive Cancer Center, Washington, USA; University of Miami Hospital Clinics/Sylvester Comprehensive Cancer Center, USA; The University of Chicago Medical Center, Chicago, USA; Roswell Park Cancer Institute, Buffalo, USA; and Providence Portland Medical Center, Portland, USA. Patients provided written informed consent before being screened for enrollment. The eligibility criteria for study enrollment included being ≥18 years of age and having a histologically or cytologically confirmed diagnosis of metastatic uveal melanoma, a life expectancy of &gt;3 months as estimated by the investigator, a positive test for HLA-A*02:01 as assessed by central assay, measurable disease according to RECIST v1.1, having disease progression while on one or two prior lines of therapy (including chemotherapy, immunotherapy, or targeted therapy) in the metastatic or advanced setting, and an Eastern Cooperative Oncology Group (ECOG) performance score of ≤1. Patients were excluded from the study if they had symptomatic or untreated central nervous system metastases or central nervous system metastases that required doses of corticosteroids within 3 weeks prior to study day 1, a history of severe hypersensitivity reactions to other biologic drugs or monoclonal antibodies, out-of-range protocol-defined laboratory parameters, or clinically significant cardiac disease or impaired cardiac function.</p><h3 class="c-article__sub-heading" id="Sec12">Procedures</h3><p>Tebentafusp was given intravenously using a step-up weekly dosing regimen that was optimized during the phase 1 portion of the study<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 27" title="Carvajal, R. D. et al. Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma. J. Clin. Oncol. 40, 1939–1948 (2022)." href="/articles/s41591-022-02015-7#ref-CR27" id="ref-link-section-d71731262e3459">27</a></sup>. In this phase 2 portion of the study, all patients received 20 μg on cycle 1 day 1 (C1D1), 30 μg on cycle 1 day 8 (C1D8), and then the recommended phase 2 dose of 68 μg on cycle 1 day 15 (C1D15) and weekly thereafter in cycles of 4 weeks (28 days). Following at least the first three infusions, patients were observed for a minimum of 16 h for monitoring of vital signs and, if necessary, provision of supportive care. After this induction period and provided that no grade 2 or higher hypotension was noted, the observation period for tebentafusp could be reduced to 30–60 min. Treatment continued until confirmation of disease progression as per the modified irRECIST Criteria, intolerable toxicity, investigator decision, or patient withdrawal of consent. The modification to irRECIST was to redefine confirmed immune-related progressive disease as unequivocal progression of non-target lesions and/or new non-measurable disease or an additional 20% increase in tumour burden (that is, the sum of diameters of both the target and measurable new lesions) from the initial progressive disease assessment per RECIST v1.1 rather than from the nadir. An independent data monitoring committee was established to provide oversight of safety and efficacy considerations and to give advice and recommendations regarding steps to ensure both patient safety and the ethical integrity of the study. Radiologic assessments were performed every 8 weeks from C1D1 until C11D1 (40 weeks), then every 12 weeks until progressive disease as per RECIST v1.1, immune-related progressive disease as per the modified irRECIST for patients who continued treatment beyond progressive disease per RECIST v1.1, or discontinuation of study drug.</p><h3 class="c-article__sub-heading" id="Sec13">Outcomes</h3><p>Treatment efficacy was assessed using RECIST v1.1 and Kaplan–Meier survival analysis. Overall survival was measured from the start of treatment to the time of death. Patients were censored on the last date on which they were known to be alive. Adverse events were assessed by the investigator and graded as per the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.03, except for cytokine release syndrome, which was graded according to the 2019 ASTCT Consensus Grading for Cytokine Release Syndrome<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 40" title="Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625–638 (2019)." href="/articles/s41591-022-02015-7#ref-CR40" id="ref-link-section-d71731262e3471">40</a></sup>. Rash is a composite term for a list of skin toxicities of any grade (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-02015-7#MOESM1">1</a>).</p><h3 class="c-article__sub-heading" id="Sec14">Circulating tumour DNA analysis</h3><p>Serum samples collected at baseline and at weeks 5, 9 and 25 on treatment were used to assess the ctDNA level. The analysis focused on mutations up to and including the week 9 on-treatment timepoint given that patient data were sparse at the week 25 timepoint. A custom panel of mutations commonly found in uveal melanoma was designed to assess changes in ctDNA (Natera; Supplementary Data Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-02015-7#MOESM1">4</a>). Using a panel-based ctDNA approach as in this study, the assessment of BAP1 copy number loss and mutations is very challenging because they can be spread across the gene, without a hotspot. Moreover, genomic studies indicated that BAP1 alterations (copy number loss or mutations) are almost always present in the context of other uveal melanoma mutations, particularly GNAQ or GNA11 (refs. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 48" title="Robertson, A. G. et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell 32, 204–220 (2017)." href="/articles/s41591-022-02015-7#ref-CR48" id="ref-link-section-d71731262e3489">48</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 49" title="Shain, A. H. et al. The genetic evolution of metastatic uveal melanoma. Nat. Genet. 51, 1123–1130 (2019)." href="/articles/s41591-022-02015-7#ref-CR49" id="ref-link-section-d71731262e3492">49</a></sup>), which are well-covered by the ctDNA panel used here. For this reason, BAP1 was not included in this ctDNA panel. ctDNA was amplified using multiplex PCR and analyzed with next-generation sequencing (performed by Natera Inc). Variants with allele frequencies ≤0.3% at baseline were excluded from the analysis<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 30" title="Raja, R. et al. Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab. Clin. Cancer Res. 24, 6212–6222 (2018)." href="/articles/s41591-022-02015-7#ref-CR30" id="ref-link-section-d71731262e3496">30</a></sup>.</p><h3 class="c-article__sub-heading" id="Sec15">Tumour mutation analysis</h3><p>All of the tumour biopsies were from sites of metastasis, with the majority of samples coming from liver metastases. Tumour biopsies were analyzed for mutations in GNAQ, GNA11, PLCB4, CYSLTR2, SF3B1 and EIF1AX. DNA libraries were generated from tumour biopsy samples, which were snap frozen, using the Illumina ExomeSeq all exon v6 kit. Paired end fragments of 100 bp in length were sequenced (50 million reads per sample) using the Illumina NovaSeq system. The resulting reads were aligned using BWA-MEM (Burrows–Wheeler aligner – maximal exact match) v0.7.15. Reads were mapped to the GRCh38 primary assembly provided by Ensembl. Duplicate reads were flagged using the MarkDuplicate function of Picard to prevent variant call errors. Somatic variants were called using MuTect2 (GATK Somatic SNVs and INDELs 4.1.6.0).</p><p>The BAP1 copy number was estimated using CNVkit v0.9.3 in tumour-only mode with purity correction estimates on BAM files generated from the BWA-MEM alignment step (as detailed above). Separate reference files were used for male and female samples. Copy number loss was defined using a −0.2log<sub>2</sub> copy ratio cut-off as used in other analyses of metastatic uveal melanoma samples<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 9" title="Karlsson, J. et al. Molecular profiling of driver events in metastatic uveal melanoma. Nat. Commun. 11, 1894 (2020)." href="/articles/s41591-022-02015-7#ref-CR9" id="ref-link-section-d71731262e3514">9</a></sup>. Samples that had a negative log<sub>2</sub> copy ratio that was greater than −0.2 were called ‘likely loss’ due to the inherent limitations of metastatic sample collection and the absence of a paired normal tissue.</p><h3 class="c-article__sub-heading" id="Sec16">Statistical analysis</h3><p>Approximately 150 patients were to be enrolled, including a minimum of 120 patients for RECIST v1.1 evaluation. With 120 patients and an observed objective response rate of 10% or more, the precision around the estimation of objective response rate was assessed to be 5.3–16.8% using 95% confidence intervals. The primary analysis of the study was conducted after ≥120 evaluable patients had been enrolled and followed for ≥12 months from the start of treatment.</p><p>Data were analyzed and reported based on all patient data up to the data cut-off date of 20 March 2020, by which time all patients had at least 1 year of follow-up from the start of treatment. Confidence intervals for objective response rate and related endpoints were calculated using exact methods. Time-to-event endpoints such as overall survival were analyzed graphically using Kaplan–Meier methods and the median and 95% confidence intervals were calculated using the method of Brookmeyer and Crowley. All analyses of efficacy were performed using PROC FREQ, PROC LIFETEST and PROC PHREG in SAS v9.4 or R 4.1.0 for ctDNA analyses.</p><p>The analysis set presented here includes all patients who received at least one full or partial dose of tebentafusp (<i>n</i> = 127). All safety analyses were performed using the safety analysis set, which also includes all patients who received at least one full or partial dose of tebentafusp (<i>n</i> = 127).</p><p>Subgroup analyses of best overall response, overall survival and progression-free survival were conducted for a number of covariates relating to line of therapy, prior therapy, best response to prior therapy, prior immuno-oncology checkpoint inhibitors and prior immunotherapy.</p><p>Exploratory analyses that compare overall survival results from this study with external overall survival data from the literature used separate Cox proportional hazards models to derive hazard ratios and 95% confidence intervals for each comparison of tebentafusp to the external dataset. An exploratory overall survival analysis compared patients in this study with patients from the control arm of a randomized study in front-line metastatic uveal melanoma who had progressive disease and received subsequent systemic therapy in a second-line setting according to a statistical analysis plan developed before the analysis took place. Given that patient-level data were available for that analysis, a propensity score model and inverse probability of treatment weights were applied to the Kaplan–Meier estimates. The weighting strategy used was the average treatment effect of the treated<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 50" title="Imbens, G. W. Nonparametric estimation of average treatment effects under exogeneity: a review. Rev. Econ. Stat. 86, 4–29 (2004)." href="/articles/s41591-022-02015-7#ref-CR50" id="ref-link-section-d71731262e3547">50</a></sup>, whereby tebentafusp patients from this study received a weight of 1.0 and the patients who received other systemic therapies received a weight of <i>p</i><sub><i>i</i></sub>/(1−<i>p</i><sub><i>i</i></sub>), where <i>p</i><sub><i>i</i></sub> represents the probability of receiving tebentafusp according to the propensity score model for the <i>i</i>-th patient. The hazard ratio comparing tebentafusp to the systemic therapy group was derived from a weighted Cox proportional hazards model and the 95% confidence interval was derived using robust sandwich estimation from the weighted Cox model.</p><p>For analysis of ctDNA, survival analysis was carried out using the R package survminer v0.4.9, and the Cox likelihood ratio test was used to assess differences between the survival curves. Univariate Cox proportional hazards methods (R package survival v3.2-11) were used to model the prognostic importance of potential predictors of survival. The correlation between hazard ratio and log reduction in ctDNA was assessed using linear regression (R stats package 4.1).</p><p>The Spearman test for correlation, Fisher exact test and the Wilcoxon rank sum test were used to assess associations between baseline ctDNA levels and clinically derived patient groupings (tests were two sided and were carried out using R stats package 4.1).</p><h3 class="c-article__sub-heading" id="Sec17">Reporting summary</h3><p>Further information on research design is available in the <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-02015-7#MOESM2">Nature Research Reporting Summary</a> linked to this article.</p></div></div></section>
                    
                </div>
            

            <div class="u-mt-32">
                <section data-title="Data availability"><div class="c-article-section" id="data-availability-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="data-availability">Data availability</h2><div class="c-article-section__content" id="data-availability-content">
              
              <p>Redacted versions of the IMCgp100-102 study protocol and statistical analysis plan are available at ClinicalTrials.gov (<a href="https://clinicaltrials.gov/ct2/show/NCT02570308">NCT02570308</a>). Upon publication, access to pre-existing summary outputs (tables or figures) of trial level data may be granted to qualified academic researchers in the field upon request and approval by the study management committee and subject to appropriate data sharing and transfer agreements. Requesters should submit a proposal including purpose, data format (for example, sas files), hypothesis and specific rationale to info@immunocore.com. To protect the privacy and confidentiality of the patients in this study, sequencing data supporting the ctDNA and tumour mutational analyses have not been made publicly available in a repository. A source data file containing sequencing data from tumour biopsies for the uveal melanoma associated genes is provided as Supplementary information to this manuscript (Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-022-02015-7#MOESM3">8</a>). Access to de-identified gene limited datasets may be granted to qualified academic researchers 24 months after publication upon request as outlined above for clinical data.</p>
            </div></div></section><div id="MagazineFulltextArticleBodySuffix"><section aria-labelledby="Bib1" data-title="References"><div class="c-article-section" id="Bib1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Bib1">References</h2><div class="c-article-section__content" id="Bib1-content"><div data-container-section="references"><ol class="c-article-references" data-track-component="outbound reference" data-track-context="references section"><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="1."><p class="c-article-references__text" id="ref-CR1">Milam, R. W. &amp; Daniels, A. B. Uveal melanoma. In <i>Melanoma</i> (ed. Riker, A.) pp. 273–312 (Springer, 2018). <a href="https://doi.org/10.1007/978-3-319-78310-9_16" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="10.1007/978-3-319-78310-9_16">https://doi.org/10.1007/978-3-319-78310-9_16</a></p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="2."><p class="c-article-references__text" id="ref-CR2">Stang, A., Parkin, D. M., Ferlay, J. &amp; Jöckel, K. International uveal melanoma incidence trends in view of a decreasing proportion of morphological verification. <i>Int. J. Cancer</i> <b>114</b>, 114–123 (2005).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1002/ijc.20690" data-track-item_id="10.1002/ijc.20690" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1002%2Fijc.20690" aria-label="Article reference 2" data-doi="10.1002/ijc.20690">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD2MXhtFCnsL0%3D" aria-label="CAS reference 2">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15523698" aria-label="PubMed reference 2">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 2" href="http://scholar.google.com/scholar_lookup?&amp;title=International%20uveal%20melanoma%20incidence%20trends%20in%20view%20of%20a%20decreasing%20proportion%20of%20morphological%20verification&amp;journal=Int.%20J.%20Cancer&amp;doi=10.1002%2Fijc.20690&amp;volume=114&amp;pages=114-123&amp;publication_year=2005&amp;author=Stang%2CA&amp;author=Parkin%2CDM&amp;author=Ferlay%2CJ&amp;author=J%C3%B6ckel%2CK">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="3."><p class="c-article-references__text" id="ref-CR3">Virgili, G. et al. Incidence of uveal melanoma in Europe. <i>Ophthalmology</i> <b>114</b>, 2309–2315 (2007).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.ophtha.2007.01.032" data-track-item_id="10.1016/j.ophtha.2007.01.032" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ophtha.2007.01.032" aria-label="Article reference 3" data-doi="10.1016/j.ophtha.2007.01.032">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17498805" aria-label="PubMed reference 3">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 3" href="http://scholar.google.com/scholar_lookup?&amp;title=Incidence%20of%20uveal%20melanoma%20in%20Europe&amp;journal=Ophthalmology&amp;doi=10.1016%2Fj.ophtha.2007.01.032&amp;volume=114&amp;pages=2309-2315&amp;publication_year=2007&amp;author=Virgili%2CG">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="4."><p class="c-article-references__text" id="ref-CR4">Kujala, E., Makitie, T. &amp; Kivela, T. Very long-term prognosis of patients with malignant uveal melanoma. <i>Invest. Ophthalmol. Vis. Sci.</i> <b>44</b>, 4651–4659 (2003).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1167/iovs.03-0538" data-track-item_id="10.1167/iovs.03-0538" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1167%2Fiovs.03-0538" aria-label="Article reference 4" data-doi="10.1167/iovs.03-0538">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=14578381" aria-label="PubMed reference 4">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 4" href="http://scholar.google.com/scholar_lookup?&amp;title=Very%20long-term%20prognosis%20of%20patients%20with%20malignant%20uveal%20melanoma&amp;journal=Invest.%20Ophthalmol.%20Vis.%20Sci.&amp;doi=10.1167%2Fiovs.03-0538&amp;volume=44&amp;pages=4651-4659&amp;publication_year=2003&amp;author=Kujala%2CE&amp;author=Makitie%2CT&amp;author=Kivela%2CT">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="5."><p class="c-article-references__text" id="ref-CR5">Singh, M., Durairaj, P. &amp; Yeung, J. Uveal melanoma: a review of the literature. <i>Oncol. Ther.</i> <b>6</b>, 87–104 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1007/s40487-018-0056-8" data-track-item_id="10.1007/s40487-018-0056-8" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1007/s40487-018-0056-8" aria-label="Article reference 5" data-doi="10.1007/s40487-018-0056-8">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32700136" aria-label="PubMed reference 5">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359963" aria-label="PubMed Central reference 5">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 5" href="http://scholar.google.com/scholar_lookup?&amp;title=Uveal%20melanoma%3A%20a%20review%20of%20the%20literature&amp;journal=Oncol.%20Ther.&amp;doi=10.1007%2Fs40487-018-0056-8&amp;volume=6&amp;pages=87-104&amp;publication_year=2018&amp;author=Singh%2CM&amp;author=Durairaj%2CP&amp;author=Yeung%2CJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="6."><p class="c-article-references__text" id="ref-CR6">Yang, J., Manson, D. K., Marr, B. P. &amp; Carvajal, R. D. Treatment of uveal melanoma: where are we now? <i>Ther. Adv. Med. Oncol.</i> <b>10</b>, 1758834018757175 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1177/1758834018757175" data-track-item_id="10.1177/1758834018757175" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1177%2F1758834018757175" aria-label="Article reference 6" data-doi="10.1177/1758834018757175">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29497459" aria-label="PubMed reference 6">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824910" aria-label="PubMed Central reference 6">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 6" href="http://scholar.google.com/scholar_lookup?&amp;title=Treatment%20of%20uveal%20melanoma%3A%20where%20are%20we%20now%3F&amp;journal=Ther.%20Adv.%20Med.%20Oncol.&amp;doi=10.1177%2F1758834018757175&amp;volume=10&amp;publication_year=2018&amp;author=Yang%2CJ&amp;author=Manson%2CDK&amp;author=Marr%2CBP&amp;author=Carvajal%2CRD">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="7."><p class="c-article-references__text" id="ref-CR7">Carvajal, R. D. et al. Metastatic disease from uveal melanoma: treatment options and future prospects. <i>Br. J. Ophthalmol.</i> <b>101</b>, 38–44 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1136/bjophthalmol-2016-309034" data-track-item_id="10.1136/bjophthalmol-2016-309034" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1136%2Fbjophthalmol-2016-309034" aria-label="Article reference 7" data-doi="10.1136/bjophthalmol-2016-309034">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27574175" aria-label="PubMed reference 7">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 7" href="http://scholar.google.com/scholar_lookup?&amp;title=Metastatic%20disease%20from%20uveal%20melanoma%3A%20treatment%20options%20and%20future%20prospects&amp;journal=Br.%20J.%20Ophthalmol.&amp;doi=10.1136%2Fbjophthalmol-2016-309034&amp;volume=101&amp;pages=38-44&amp;publication_year=2017&amp;author=Carvajal%2CRD">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="8."><p class="c-article-references__text" id="ref-CR8">Harbour, J. W. et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. <i>Science</i> <b>330</b>, 1410–1413 (2010).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1126/science.1194472" data-track-item_id="10.1126/science.1194472" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1126%2Fscience.1194472" aria-label="Article reference 8" data-doi="10.1126/science.1194472">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3cXhsVyrsbbI" aria-label="CAS reference 8">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21051595" aria-label="PubMed reference 8">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3087380" aria-label="PubMed Central reference 8">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 8" href="http://scholar.google.com/scholar_lookup?&amp;title=Frequent%20mutation%20of%20BAP1%20in%20metastasizing%20uveal%20melanomas&amp;journal=Science&amp;doi=10.1126%2Fscience.1194472&amp;volume=330&amp;pages=1410-1413&amp;publication_year=2010&amp;author=Harbour%2CJW">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="9."><p class="c-article-references__text" id="ref-CR9">Karlsson, J. et al. Molecular profiling of driver events in metastatic uveal melanoma. <i>Nat. Commun.</i> <b>11</b>, 1894 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41467-020-15606-0" data-track-item_id="10.1038/s41467-020-15606-0" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41467-020-15606-0" aria-label="Article reference 9" data-doi="10.1038/s41467-020-15606-0">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXnsFSksbw%3D" aria-label="CAS reference 9">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32313009" aria-label="PubMed reference 9">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171146" aria-label="PubMed Central reference 9">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 9" href="http://scholar.google.com/scholar_lookup?&amp;title=Molecular%20profiling%20of%20driver%20events%20in%20metastatic%20uveal%20melanoma&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fs41467-020-15606-0&amp;volume=11&amp;publication_year=2020&amp;author=Karlsson%2CJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="10."><p class="c-article-references__text" id="ref-CR10">Martin, M. et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. <i>Nat. Genet.</i> <b>45</b>, 933–936 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/ng.2674" data-track-item_id="10.1038/ng.2674" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fng.2674" aria-label="Article reference 10" data-doi="10.1038/ng.2674">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3sXpvVyrt7c%3D" aria-label="CAS reference 10">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23793026" aria-label="PubMed reference 10">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307600" aria-label="PubMed Central reference 10">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 10" href="http://scholar.google.com/scholar_lookup?&amp;title=Exome%20sequencing%20identifies%20recurrent%20somatic%20mutations%20in%20EIF1AX%20and%20SF3B1%20in%20uveal%20melanoma%20with%20disomy%203&amp;journal=Nat.%20Genet.&amp;doi=10.1038%2Fng.2674&amp;volume=45&amp;pages=933-936&amp;publication_year=2013&amp;author=Martin%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="11."><p class="c-article-references__text" id="ref-CR11">Johnson, C. P. et al. Systematic genomic and translational efficiency studies of uveal melanoma. <i>PLoS One</i> <b>12</b>, e0178189 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1371/journal.pone.0178189" data-track-item_id="10.1371/journal.pone.0178189" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1371%2Fjournal.pone.0178189" aria-label="Article reference 11" data-doi="10.1371/journal.pone.0178189">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28594900" aria-label="PubMed reference 11">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464544" aria-label="PubMed Central reference 11">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 11" href="http://scholar.google.com/scholar_lookup?&amp;title=Systematic%20genomic%20and%20translational%20efficiency%20studies%20of%20uveal%20melanoma&amp;journal=PLoS%20One&amp;doi=10.1371%2Fjournal.pone.0178189&amp;volume=12&amp;publication_year=2017&amp;author=Johnson%2CCP">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="12."><p class="c-article-references__text" id="ref-CR12">Javed, A. et al. PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. <i>Immunotherapy</i> <b>9</b>, 1323–1330 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.2217/imt-2017-0066" data-track-item_id="10.2217/imt-2017-0066" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.2217%2Fimt-2017-0066" aria-label="Article reference 12" data-doi="10.2217/imt-2017-0066">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhvVOit7nL" aria-label="CAS reference 12">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29185395" aria-label="PubMed reference 12">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 12" href="http://scholar.google.com/scholar_lookup?&amp;title=PD-L1%20expression%20in%20tumor%20metastasis%20is%20different%20between%20uveal%20melanoma%20and%20cutaneous%20melanoma&amp;journal=Immunotherapy&amp;doi=10.2217%2Fimt-2017-0066&amp;volume=9&amp;pages=1323-1330&amp;publication_year=2017&amp;author=Javed%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="13."><p class="c-article-references__text" id="ref-CR13">Nathan, P. et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. <i>N. Engl. J. Med.</i> <b>385</b>, 1196–1206 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa2103485" data-track-item_id="10.1056/NEJMoa2103485" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa2103485" aria-label="Article reference 13" data-doi="10.1056/NEJMoa2103485">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXitV2ksbbE" aria-label="CAS reference 13">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34551229" aria-label="PubMed reference 13">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 13" href="http://scholar.google.com/scholar_lookup?&amp;title=Overall%20survival%20benefit%20with%20tebentafusp%20in%20metastatic%20uveal%20melanoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa2103485&amp;volume=385&amp;pages=1196-1206&amp;publication_year=2021&amp;author=Nathan%2CP">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="14."><p class="c-article-references__text" id="ref-CR14">Carvajal, R. D. et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. <i>JAMA</i> <b>311</b>, 2397–2405 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1001/jama.2014.6096" data-track-item_id="10.1001/jama.2014.6096" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1001%2Fjama.2014.6096" aria-label="Article reference 14" data-doi="10.1001/jama.2014.6096">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24938562" aria-label="PubMed reference 14">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4249701" aria-label="PubMed Central reference 14">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 14" href="http://scholar.google.com/scholar_lookup?&amp;title=Effect%20of%20selumetinib%20vs%20chemotherapy%20on%20progression-free%20survival%20in%20uveal%20melanoma%3A%20a%20randomized%20clinical%20trial&amp;journal=JAMA&amp;doi=10.1001%2Fjama.2014.6096&amp;volume=311&amp;pages=2397-2405&amp;publication_year=2014&amp;author=Carvajal%2CRD">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="15."><p class="c-article-references__text" id="ref-CR15">Pelster, M. S. et al. Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study. <i>J. Clin. Oncol.</i> <b>39</b>, 599–607 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/JCO.20.00605" data-track-item_id="10.1200/JCO.20.00605" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.20.00605" aria-label="Article reference 15" data-doi="10.1200/JCO.20.00605">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XhslKlsLw%3D" aria-label="CAS reference 15">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33125309" aria-label="PubMed reference 15">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 15" href="http://scholar.google.com/scholar_lookup?&amp;title=Nivolumab%20and%20ipilimumab%20in%20metastatic%20uveal%20melanoma%3A%20results%20from%20a%20single-arm%20phase%20II%20study&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.20.00605&amp;volume=39&amp;pages=599-607&amp;publication_year=2021&amp;author=Pelster%2CMS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="16."><p class="c-article-references__text" id="ref-CR16">Piulats, J. M. et al. Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). <i>J. Clin. Oncol.</i> <b>39</b>, 586–598 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/JCO.20.00550" data-track-item_id="10.1200/JCO.20.00550" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.20.00550" aria-label="Article reference 16" data-doi="10.1200/JCO.20.00550">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XhslKlsL8%3D" aria-label="CAS reference 16">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33417511" aria-label="PubMed reference 16">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 16" href="http://scholar.google.com/scholar_lookup?&amp;title=Nivolumab%20plus%20ipilimumab%20for%20treatment-na%C3%AFve%20metastatic%20uveal%20melanoma%3A%20an%20open-label%2C%20multicenter%2C%20phase%20II%20trial%20by%20the%20Spanish%20Multidisciplinary%20Melanoma%20Group%20%28GEM-1402%29&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.20.00550&amp;volume=39&amp;pages=586-598&amp;publication_year=2021&amp;author=Piulats%2CJM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="17."><p class="c-article-references__text" id="ref-CR17">Khoja, L. et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an International Rare Cancers Initiative (IRCI) ocular melanoma study. <i>Ann. Oncol.</i> <b>30</b>, 1370–1380 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/annonc/mdz176" data-track-item_id="10.1093/annonc/mdz176" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fannonc%2Fmdz176" aria-label="Article reference 17" data-doi="10.1093/annonc/mdz176">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:STN:280:DC%2BB3M3hvVOgug%3D%3D" aria-label="CAS reference 17">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31150059" aria-label="PubMed reference 17">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 17" href="http://scholar.google.com/scholar_lookup?&amp;title=Meta-analysis%20in%20metastatic%20uveal%20melanoma%20to%20determine%20progression%20free%20and%20overall%20survival%20benchmarks%3A%20an%20International%20Rare%20Cancers%20Initiative%20%28IRCI%29%20ocular%20melanoma%20study&amp;journal=Ann.%20Oncol.&amp;doi=10.1093%2Fannonc%2Fmdz176&amp;volume=30&amp;pages=1370-1380&amp;publication_year=2019&amp;author=Khoja%2CL">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="18."><p class="c-article-references__text" id="ref-CR18">Rantala, E. S., Hernberg, M. &amp; Kivelä, T. T. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. <i>Melanoma Res.</i> <b>29</b>, 561–568 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1097/CMR.0000000000000575" data-track-item_id="10.1097/CMR.0000000000000575" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1097%2FCMR.0000000000000575" aria-label="Article reference 18" data-doi="10.1097/CMR.0000000000000575">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30664106" aria-label="PubMed reference 18">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887637" aria-label="PubMed Central reference 18">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 18" href="http://scholar.google.com/scholar_lookup?&amp;title=Overall%20survival%20after%20treatment%20for%20metastatic%20uveal%20melanoma%3A%20a%20systematic%20review%20and%20meta-analysis&amp;journal=Melanoma%20Res.&amp;doi=10.1097%2FCMR.0000000000000575&amp;volume=29&amp;pages=561-568&amp;publication_year=2019&amp;author=Rantala%2CES&amp;author=Hernberg%2CM&amp;author=Kivel%C3%A4%2CTT">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="19."><p class="c-article-references__text" id="ref-CR19">Bossi, G., Buisson, S., Oates, J., Jakobsen, B. K. &amp; Hassan, N. J. ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells. <i>Cancer Immunol. Immunother.</i> <b>63</b>, 437–448 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1007/s00262-014-1525-z" data-track-item_id="10.1007/s00262-014-1525-z" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1007/s00262-014-1525-z" aria-label="Article reference 19" data-doi="10.1007/s00262-014-1525-z">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2cXis1Siurg%3D" aria-label="CAS reference 19">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24531387" aria-label="PubMed reference 19">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 19" href="http://scholar.google.com/scholar_lookup?&amp;title=ImmTAC-redirected%20tumour%20cell%20killing%20induces%20and%20potentiates%20antigen%20cross-presentation%20by%20dendritic%20cells&amp;journal=Cancer%20Immunol.%20Immunother.&amp;doi=10.1007%2Fs00262-014-1525-z&amp;volume=63&amp;pages=437-448&amp;publication_year=2014&amp;author=Bossi%2CG&amp;author=Buisson%2CS&amp;author=Oates%2CJ&amp;author=Jakobsen%2CBK&amp;author=Hassan%2CNJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="20."><p class="c-article-references__text" id="ref-CR20">Liddy, N. et al. Monoclonal TCR-redirected tumor cell killing. <i>Nat. Med.</i> <b>18</b>, 980–987 (2012).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nm.2764" data-track-item_id="10.1038/nm.2764" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnm.2764" aria-label="Article reference 20" data-doi="10.1038/nm.2764">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC38XmsFyjtrg%3D" aria-label="CAS reference 20">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22561687" aria-label="PubMed reference 20">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 20" href="http://scholar.google.com/scholar_lookup?&amp;title=Monoclonal%20TCR-redirected%20tumor%20cell%20killing&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fnm.2764&amp;volume=18&amp;pages=980-987&amp;publication_year=2012&amp;author=Liddy%2CN">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="21."><p class="c-article-references__text" id="ref-CR21">Middleton, M. R. et al. Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma. <i>Clin. Cancer Res.</i> <b>26</b>, 5869–5878 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-20-1247" data-track-item_id="10.1158/1078-0432.CCR-20-1247" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-20-1247" aria-label="Article reference 21" data-doi="10.1158/1078-0432.CCR-20-1247">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXis1equrjF" aria-label="CAS reference 21">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32816891" aria-label="PubMed reference 21">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210997" aria-label="PubMed Central reference 21">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 21" href="http://scholar.google.com/scholar_lookup?&amp;title=Tebentafusp%2C%20a%20TCR%2Fanti-CD3%20bispecific%20fusion%20protein%20targeting%20gp100%2C%20potently%20activated%20antitumor%20immune%20responses%20in%20patients%20with%20metastatic%20melanoma&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-20-1247&amp;volume=26&amp;pages=5869-5878&amp;publication_year=2020&amp;author=Middleton%2CMR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="22."><p class="c-article-references__text" id="ref-CR22">Boudousquie, C. et al. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8<sup>+</sup> and CD4<sup>+</sup> T cells. <i>Immunology</i> <b>152</b>, 425–438 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1111/imm.12779" data-track-item_id="10.1111/imm.12779" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1111%2Fimm.12779" aria-label="Article reference 22" data-doi="10.1111/imm.12779">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXht1GiurvI" aria-label="CAS reference 22">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28640942" aria-label="PubMed reference 22">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629433" aria-label="PubMed Central reference 22">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 22" href="http://scholar.google.com/scholar_lookup?&amp;title=Polyfunctional%20response%20by%20ImmTAC%20%28IMCgp100%29%20redirected%20CD8%2B%20and%20CD4%2B%20T%20cells&amp;journal=Immunology&amp;doi=10.1111%2Fimm.12779&amp;volume=152&amp;pages=425-438&amp;publication_year=2017&amp;author=Boudousquie%2CC">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="23."><p class="c-article-references__text" id="ref-CR23">Middleton, M. R. et al. Abstract CT106: a phase I/IIa study of IMCgp100: partial and complete durable responses with a novel first-in-class immunotherapy for advanced melanoma. <i>Clin. Trials</i> <b>75</b>, CT106 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 23" href="http://scholar.google.com/scholar_lookup?&amp;title=Abstract%20CT106%3A%20a%20phase%20I%2FIIa%20study%20of%20IMCgp100%3A%20partial%20and%20complete%20durable%20responses%20with%20a%20novel%20first-in-class%20immunotherapy%20for%20advanced%20melanoma&amp;journal=Clin.%20Trials&amp;volume=75&amp;publication_year=2015&amp;author=Middleton%2CMR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="24."><p class="c-article-references__text" id="ref-CR24">Middleton, M. R. et al. Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific T cell redirector with solid tumour activity: results from the FIH study in melanoma (Abstract 3016). <i>J. Clin. Oncol.</i> <b>34</b>(15 Suppl.), 3016 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/JCO.2016.34.15_suppl.3016" data-track-item_id="10.1200/JCO.2016.34.15_suppl.3016" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2016.34.15_suppl.3016" aria-label="Article reference 24" data-doi="10.1200/JCO.2016.34.15_suppl.3016">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 24" href="http://scholar.google.com/scholar_lookup?&amp;title=Safety%2C%20pharmacokinetics%20and%20efficacy%20of%20IMCgp100%2C%20a%20first-in-class%20soluble%20TCR-antiCD3%20bispecific%20T%20cell%20redirector%20with%20solid%20tumour%20activity%3A%20results%20from%20the%20FIH%20study%20in%20melanoma%20%28Abstract%203016%29&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2016.34.15_suppl.3016&amp;volume=34&amp;issue=15%20Suppl.&amp;publication_year=2016&amp;author=Middleton%2CMR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="25."><p class="c-article-references__text" id="ref-CR25">Carvajal, R. et al. Safety, efficacy and biology of the gp100 TCR-based bispecific T cell redirector, IMCgp100 in advanced uveal melanoma in two Phase 1 trials (Poster 208). <i>J. Immunother. Cancer</i> <b>5</b>(Suppl. 2), P208 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 25" href="http://scholar.google.com/scholar_lookup?&amp;title=Safety%2C%20efficacy%20and%20biology%20of%20the%20gp100%20TCR-based%20bispecific%20T%20cell%20redirector%2C%20IMCgp100%20in%20advanced%20uveal%20melanoma%20in%20two%20Phase%201%20trials%20%28Poster%20208%29&amp;journal=J.%20Immunother.%20Cancer&amp;volume=5&amp;issue=Suppl.%202&amp;publication_year=2017&amp;author=Carvajal%2CR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="26."><p class="c-article-references__text" id="ref-CR26">Sato, T. et al. Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T-cell based toxicity and preliminary efficacy in advanced uveal melanoma (Abstract 9531). <i>J. Clin. Oncol.</i> <b>35</b>(15 Suppl.), 9531 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/JCO.2017.35.15_suppl.9531" data-track-item_id="10.1200/JCO.2017.35.15_suppl.9531" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2017.35.15_suppl.9531" aria-label="Article reference 26" data-doi="10.1200/JCO.2017.35.15_suppl.9531">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 26" href="http://scholar.google.com/scholar_lookup?&amp;title=Intra-patient%20escalation%20dosing%20strategy%20with%20IMCgp100%20results%20in%20mitigation%20of%20T-cell%20based%20toxicity%20and%20preliminary%20efficacy%20in%20advanced%20uveal%20melanoma%20%28Abstract%209531%29&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2017.35.15_suppl.9531&amp;volume=35&amp;issue=15%20Suppl.&amp;publication_year=2017&amp;author=Sato%2CT">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="27."><p class="c-article-references__text" id="ref-CR27">Carvajal, R. D. et al. Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma. <i>J. Clin. Oncol.</i> <b>40</b>, 1939–1948 (2022).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/JCO.21.01805" data-track-item_id="10.1200/JCO.21.01805" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.21.01805" aria-label="Article reference 27" data-doi="10.1200/JCO.21.01805">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XhsVOmtb%2FJ" aria-label="CAS reference 27">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35254876" aria-label="PubMed reference 27">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177239" aria-label="PubMed Central reference 27">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 27" href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%20I%20study%20of%20safety%2C%20tolerability%2C%20and%20efficacy%20of%20tebentafusp%20using%20a%20step-up%20dosing%20regimen%20and%20expansion%20in%20patients%20with%20metastatic%20uveal%20melanoma&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.21.01805&amp;volume=40&amp;pages=1939-1948&amp;publication_year=2022&amp;author=Carvajal%2CRD">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="28."><p class="c-article-references__text" id="ref-CR28">O’Day, S. et al. A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma (Abstract 4). <i>J. Clin. Oncol.</i> <b>28</b>(18 Suppl.), 4 (2010).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/jco.2010.28.18_suppl.4" data-track-item_id="10.1200/jco.2010.28.18_suppl.4" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2Fjco.2010.28.18_suppl.4" aria-label="Article reference 28" data-doi="10.1200/jco.2010.28.18_suppl.4">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 28" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20phase%20III%2C%20randomized%2C%20double-blind%2C%20multicenter%20study%20comparing%20monotherapy%20with%20ipilimumab%20or%20gp100%20peptide%20vaccine%20and%20the%20combination%20in%20patients%20with%20previously%20treated%2C%20unresectable%20stage%20III%20or%20IV%20melanoma%20%28Abstract%204%29&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2Fjco.2010.28.18_suppl.4&amp;volume=28&amp;issue=18%20Suppl.&amp;publication_year=2010&amp;author=O%E2%80%99Day%2CS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="29."><p class="c-article-references__text" id="ref-CR29">Hodi, F. S. et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. <i>J. Clin. Oncol.</i> <b>34</b>, 1510–1517 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/JCO.2015.64.0391" data-track-item_id="10.1200/JCO.2015.64.0391" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2015.64.0391" aria-label="Article reference 29" data-doi="10.1200/JCO.2015.64.0391">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXisFWjtr8%3D" aria-label="CAS reference 29">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26951310" aria-label="PubMed reference 29">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070547" aria-label="PubMed Central reference 29">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 29" href="http://scholar.google.com/scholar_lookup?&amp;title=Evaluation%20of%20immune-related%20response%20criteria%20and%20RECIST%20v1.1%20in%20patients%20with%20advanced%20melanoma%20treated%20with%20pembrolizumab&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2015.64.0391&amp;volume=34&amp;pages=1510-1517&amp;publication_year=2016&amp;author=Hodi%2CFS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="30."><p class="c-article-references__text" id="ref-CR30">Raja, R. et al. Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab. <i>Clin. Cancer Res.</i> <b>24</b>, 6212–6222 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-18-0386" data-track-item_id="10.1158/1078-0432.CCR-18-0386" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-18-0386" aria-label="Article reference 30" data-doi="10.1158/1078-0432.CCR-18-0386">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXht1ait7rN" aria-label="CAS reference 30">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30093454" aria-label="PubMed reference 30">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 30" href="http://scholar.google.com/scholar_lookup?&amp;title=Early%20reduction%20in%20ctDNA%20predicts%20survival%20in%20patients%20with%20lung%20and%20bladder%20cancer%20treated%20with%20durvalumab&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-18-0386&amp;volume=24&amp;pages=6212-6222&amp;publication_year=2018&amp;author=Raja%2CR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="31."><p class="c-article-references__text" id="ref-CR31">Goldberg, S. B. et al. Early assessment of lung cancer immunotherapy response via circulating tumor DNA. <i>Clin. Cancer Res.</i> <b>24</b>, 1872–1880 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-17-1341" data-track-item_id="10.1158/1078-0432.CCR-17-1341" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-17-1341" aria-label="Article reference 31" data-doi="10.1158/1078-0432.CCR-17-1341">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXnslKmu7Y%3D" aria-label="CAS reference 31">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29330207" aria-label="PubMed reference 31">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5899677" aria-label="PubMed Central reference 31">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 31" href="http://scholar.google.com/scholar_lookup?&amp;title=Early%20assessment%20of%20lung%20cancer%20immunotherapy%20response%20via%20circulating%20tumor%20DNA&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-17-1341&amp;volume=24&amp;pages=1872-1880&amp;publication_year=2018&amp;author=Goldberg%2CSB">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="32."><p class="c-article-references__text" id="ref-CR32">Zou, W. et al. ctDNA predicts overall survival in patients with NSCLC treated with PD-L1 blockade or with chemotherapy. <i>JCO Precis. Oncol.</i> <b>5</b>, 827–838 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/PO.21.00057" data-track-item_id="10.1200/PO.21.00057" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2FPO.21.00057" aria-label="Article reference 32" data-doi="10.1200/PO.21.00057">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34994614" aria-label="PubMed reference 32">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 32" href="http://scholar.google.com/scholar_lookup?&amp;title=ctDNA%20predicts%20overall%20survival%20in%20patients%20with%20NSCLC%20treated%20with%20PD-L1%20blockade%20or%20with%20chemotherapy&amp;journal=JCO%20Precis.%20Oncol.&amp;doi=10.1200%2FPO.21.00057&amp;volume=5&amp;pages=827-838&amp;publication_year=2021&amp;author=Zou%2CW">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="33."><p class="c-article-references__text" id="ref-CR33">Vandekerkhove, G. et al. Plasma ctDNA is a tumor tissue surrogate and enables clinical–genomic stratification of metastatic bladder cancer. <i>Nat. Commun.</i> <b>12</b>, 184 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41467-020-20493-6" data-track-item_id="10.1038/s41467-020-20493-6" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41467-020-20493-6" aria-label="Article reference 33" data-doi="10.1038/s41467-020-20493-6">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXht1Smu7c%3D" aria-label="CAS reference 33">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33420073" aria-label="PubMed reference 33">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794518" aria-label="PubMed Central reference 33">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 33" href="http://scholar.google.com/scholar_lookup?&amp;title=Plasma%20ctDNA%20is%20a%20tumor%20tissue%20surrogate%20and%20enables%20clinical%E2%80%93genomic%20stratification%20of%20metastatic%20bladder%20cancer&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fs41467-020-20493-6&amp;volume=12&amp;publication_year=2021&amp;author=Vandekerkhove%2CG">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="34."><p class="c-article-references__text" id="ref-CR34">Lee, J. H. et al. Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies. <i>JAMA Oncol.</i> <b>4</b>, 717–721 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1001/jamaoncol.2017.5332" data-track-item_id="10.1001/jamaoncol.2017.5332" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1001%2Fjamaoncol.2017.5332" aria-label="Article reference 34" data-doi="10.1001/jamaoncol.2017.5332">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29423503" aria-label="PubMed reference 34">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5885201" aria-label="PubMed Central reference 34">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 34" href="http://scholar.google.com/scholar_lookup?&amp;title=Association%20between%20circulating%20tumor%20DNA%20and%20pseudoprogression%20in%20patients%20with%20metastatic%20melanoma%20treated%20with%20anti-programmed%20cell%20death%201%20antibodies&amp;journal=JAMA%20Oncol.&amp;doi=10.1001%2Fjamaoncol.2017.5332&amp;volume=4&amp;pages=717-721&amp;publication_year=2018&amp;author=Lee%2CJH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="35."><p class="c-article-references__text" id="ref-CR35">Bratman, S. V. et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. <i>Nat. Cancer</i> <b>1</b>, 873–881 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s43018-020-0096-5" data-track-item_id="10.1038/s43018-020-0096-5" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs43018-020-0096-5" aria-label="Article reference 35" data-doi="10.1038/s43018-020-0096-5">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB38XjsFeisLg%3D" aria-label="CAS reference 35">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35121950" aria-label="PubMed reference 35">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 35" href="http://scholar.google.com/scholar_lookup?&amp;title=Personalized%20circulating%20tumor%20DNA%20analysis%20as%20a%20predictive%20biomarker%20in%20solid%20tumor%20patients%20treated%20with%20pembrolizumab&amp;journal=Nat.%20Cancer&amp;doi=10.1038%2Fs43018-020-0096-5&amp;volume=1&amp;pages=873-881&amp;publication_year=2020&amp;author=Bratman%2CSV">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="36."><p class="c-article-references__text" id="ref-CR36">Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. <i>Nat. Rev. Cancer</i> <b>12</b>, 252–264 (2012).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nrc3239" data-track-item_id="10.1038/nrc3239" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnrc3239" aria-label="Article reference 36" data-doi="10.1038/nrc3239">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC38XksVegtrw%3D" aria-label="CAS reference 36">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22437870" aria-label="PubMed reference 36">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856023" aria-label="PubMed Central reference 36">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 36" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20blockade%20of%20immune%20checkpoints%20in%20cancer%20immunotherapy&amp;journal=Nat.%20Rev.%20Cancer&amp;doi=10.1038%2Fnrc3239&amp;volume=12&amp;pages=252-264&amp;publication_year=2012&amp;author=Pardoll%2CDM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="37."><p class="c-article-references__text" id="ref-CR37">Wolchok, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. <i>Clin. Cancer Res.</i> <b>15</b>, 7412–7420 (2009).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-09-1624" data-track-item_id="10.1158/1078-0432.CCR-09-1624" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-09-1624" aria-label="Article reference 37" data-doi="10.1158/1078-0432.CCR-09-1624">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD1MXhsFSnu7vN" aria-label="CAS reference 37">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19934295" aria-label="PubMed reference 37">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 37" href="http://scholar.google.com/scholar_lookup?&amp;title=Guidelines%20for%20the%20evaluation%20of%20immune%20therapy%20activity%20in%20solid%20tumors%3A%20immune-related%20response%20criteria&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-09-1624&amp;volume=15&amp;pages=7412-7420&amp;publication_year=2009&amp;author=Wolchok%2CJD">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="38."><p class="c-article-references__text" id="ref-CR38">Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). <i>Eur. J. Cancer</i> <b>45</b>, 228–247 (2009).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.ejca.2008.10.026" data-track-item_id="10.1016/j.ejca.2008.10.026" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ejca.2008.10.026" aria-label="Article reference 38" data-doi="10.1016/j.ejca.2008.10.026">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:STN:280:DC%2BD1M%2Fgs12rug%3D%3D" aria-label="CAS reference 38">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19097774" aria-label="PubMed reference 38">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 38" href="http://scholar.google.com/scholar_lookup?&amp;title=New%20response%20evaluation%20criteria%20in%20solid%20tumours%3A%20revised%20RECIST%20guideline%20%28version%201.1%29&amp;journal=Eur.%20J.%20Cancer&amp;doi=10.1016%2Fj.ejca.2008.10.026&amp;volume=45&amp;pages=228-247&amp;publication_year=2009&amp;author=Eisenhauer%2CEA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="39."><p class="c-article-references__text" id="ref-CR39">Bohnsack, O., Hoos, A. &amp; Ludajic, K. Adaptation and modification of the immune related response criteria (IRRC): IrRECIST (Abstract e22121). <i>J. Clin. Oncol.</i> <b>32</b>(15 Suppl.), e22121 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/jco.2014.32.15_suppl.e22121" data-track-item_id="10.1200/jco.2014.32.15_suppl.e22121" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2Fjco.2014.32.15_suppl.e22121" aria-label="Article reference 39" data-doi="10.1200/jco.2014.32.15_suppl.e22121">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 39" href="http://scholar.google.com/scholar_lookup?&amp;title=Adaptation%20and%20modification%20of%20the%20immune%20related%20response%20criteria%20%28IRRC%29%3A%20IrRECIST%20%28Abstract%20e22121%29&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2Fjco.2014.32.15_suppl.e22121&amp;volume=32&amp;issue=15%20Suppl.&amp;publication_year=2014&amp;author=Bohnsack%2CO&amp;author=Hoos%2CA&amp;author=Ludajic%2CK">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="40."><p class="c-article-references__text" id="ref-CR40">Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. <i>Biol. Blood Marrow Transplant.</i> <b>25</b>, 625–638 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.bbmt.2018.12.758" data-track-item_id="10.1016/j.bbmt.2018.12.758" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.bbmt.2018.12.758" aria-label="Article reference 40" data-doi="10.1016/j.bbmt.2018.12.758">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXhs1aksbw%3D" aria-label="CAS reference 40">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30592986" aria-label="PubMed reference 40">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 40" href="http://scholar.google.com/scholar_lookup?&amp;title=ASTCT%20consensus%20grading%20for%20cytokine%20release%20syndrome%20and%20neurologic%20toxicity%20associated%20with%20immune%20effector%20cells&amp;journal=Biol.%20Blood%20Marrow%20Transplant.&amp;doi=10.1016%2Fj.bbmt.2018.12.758&amp;volume=25&amp;pages=625-638&amp;publication_year=2019&amp;author=Lee%2CDW">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="41."><p class="c-article-references__text" id="ref-CR41">Zhang, Q. et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. <i>Cancer Discov.</i> <b>10</b>, 1842–1853 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2159-8290.CD-20-0047" data-track-item_id="10.1158/2159-8290.CD-20-0047" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2159-8290.CD-20-0047" aria-label="Article reference 41" data-doi="10.1158/2159-8290.CD-20-0047">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXktFWisL0%3D" aria-label="CAS reference 41">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32816849" aria-label="PubMed reference 41">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358981" aria-label="PubMed Central reference 41">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 41" href="http://scholar.google.com/scholar_lookup?&amp;title=Prognostic%20and%20predictive%20impact%20of%20circulating%20tumor%20DNA%20in%20patients%20with%20advanced%20cancers%20treated%20with%20immune%20checkpoint%20blockade&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-20-0047&amp;volume=10&amp;pages=1842-1853&amp;publication_year=2020&amp;author=Zhang%2CQ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="42."><p class="c-article-references__text" id="ref-CR42">Chiou, V. L. &amp; Burotto, M. Pseudoprogression and immune-related response in solid tumors. <i>J. Clin. Oncol.</i> <b>33</b>, 3541–3543 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/JCO.2015.61.6870" data-track-item_id="10.1200/JCO.2015.61.6870" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2015.61.6870" aria-label="Article reference 42" data-doi="10.1200/JCO.2015.61.6870">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XhtVakt7%2FL" aria-label="CAS reference 42">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26261262" aria-label="PubMed reference 42">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622096" aria-label="PubMed Central reference 42">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 42" href="http://scholar.google.com/scholar_lookup?&amp;title=Pseudoprogression%20and%20immune-related%20response%20in%20solid%20tumors&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2015.61.6870&amp;volume=33&amp;pages=3541-3543&amp;publication_year=2015&amp;author=Chiou%2CVL&amp;author=Burotto%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="43."><p class="c-article-references__text" id="ref-CR43">Giacomo, A. M. D. et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. <i>Cancer Immunol. Immunother.</i> <b>58</b>, 1297–1306 (2009).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1007/s00262-008-0642-y" data-track-item_id="10.1007/s00262-008-0642-y" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1007/s00262-008-0642-y" aria-label="Article reference 43" data-doi="10.1007/s00262-008-0642-y">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19139884" aria-label="PubMed reference 43">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 43" href="http://scholar.google.com/scholar_lookup?&amp;title=Therapeutic%20efficacy%20of%20ipilimumab%2C%20an%20anti-CTLA-4%20monoclonal%20antibody%2C%20in%20patients%20with%20metastatic%20melanoma%20unresponsive%20to%20prior%20systemic%20treatments%3A%20clinical%20and%20immunological%20evidence%20from%20three%20patient%20cases&amp;journal=Cancer%20Immunol.%20Immunother.&amp;doi=10.1007%2Fs00262-008-0642-y&amp;volume=58&amp;pages=1297-1306&amp;publication_year=2009&amp;author=Giacomo%2CAMD">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="44."><p class="c-article-references__text" id="ref-CR44">Butler, M. O. et al. Abstract 517: Tebentafusp induces transient systemic inflammation and modifies the micro-environment to sensitize uveal melanoma tumors to cytotoxic CD8 cells. <i>Cancer Res.</i> <b>81</b>(13 Suppl.), 517 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/1538-7445.AM2021-517" data-track-item_id="10.1158/1538-7445.AM2021-517" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F1538-7445.AM2021-517" aria-label="Article reference 44" data-doi="10.1158/1538-7445.AM2021-517">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 44" href="http://scholar.google.com/scholar_lookup?&amp;title=Abstract%20517%3A%20Tebentafusp%20induces%20transient%20systemic%20inflammation%20and%20modifies%20the%20micro-environment%20to%20sensitize%20uveal%20melanoma%20tumors%20to%20cytotoxic%20CD8%20cells&amp;journal=Cancer%20Res.&amp;doi=10.1158%2F1538-7445.AM2021-517&amp;volume=81&amp;issue=13%20Suppl.&amp;publication_year=2021&amp;author=Butler%2CMO">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="45."><p class="c-article-references__text" id="ref-CR45">Beylergil, V. et al. Abstract 819: Radiomic markers associated with clinical benefit in advanced uveal melanoma patients with radiographic progression on tebentafusp. <i>J. Immunother. Cancer</i> <b>9</b>(2 Suppl.), 819 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 45" href="http://scholar.google.com/scholar_lookup?&amp;title=Abstract%20819%3A%20Radiomic%20markers%20associated%20with%20clinical%20benefit%20in%20advanced%20uveal%20melanoma%20patients%20with%20radiographic%20progression%20on%20tebentafusp&amp;journal=J.%20Immunother.%20Cancer&amp;volume=9&amp;issue=2%20Suppl.&amp;publication_year=2021&amp;author=Beylergil%2CV">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="46."><p class="c-article-references__text" id="ref-CR46">Dercle, L. et al. Identification of non-small cell lung cancer sensitive to systemic cancer therapies using radiomics. <i>Clin. Cancer Res.</i> <b>26</b>, 2151–2162 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-19-2942" data-track-item_id="10.1158/1078-0432.CCR-19-2942" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-19-2942" aria-label="Article reference 46" data-doi="10.1158/1078-0432.CCR-19-2942">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXitVyktb%2FI" aria-label="CAS reference 46">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32198149" aria-label="PubMed reference 46">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239371" aria-label="PubMed Central reference 46">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 46" href="http://scholar.google.com/scholar_lookup?&amp;title=Identification%20of%20non-small%20cell%20lung%20cancer%20sensitive%20to%20systemic%20cancer%20therapies%20using%20radiomics&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-19-2942&amp;volume=26&amp;pages=2151-2162&amp;publication_year=2020&amp;author=Dercle%2CL">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="47."><p class="c-article-references__text" id="ref-CR47">Keller, L., Belloum, Y., Wikman, H. &amp; Pantel, K. Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. <i>Br. J. Cancer</i> <b>124</b>, 345–358 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41416-020-01047-5" data-track-item_id="10.1038/s41416-020-01047-5" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41416-020-01047-5" aria-label="Article reference 47" data-doi="10.1038/s41416-020-01047-5">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32968207" aria-label="PubMed reference 47">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 47" href="http://scholar.google.com/scholar_lookup?&amp;title=Clinical%20relevance%20of%20blood-based%20ctDNA%20analysis%3A%20mutation%20detection%20and%20beyond&amp;journal=Br.%20J.%20Cancer&amp;doi=10.1038%2Fs41416-020-01047-5&amp;volume=124&amp;pages=345-358&amp;publication_year=2021&amp;author=Keller%2CL&amp;author=Belloum%2CY&amp;author=Wikman%2CH&amp;author=Pantel%2CK">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="48."><p class="c-article-references__text" id="ref-CR48">Robertson, A. G. et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. <i>Cancer Cell</i> <b>32</b>, 204–220 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.ccell.2017.07.003" data-track-item_id="10.1016/j.ccell.2017.07.003" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ccell.2017.07.003" aria-label="Article reference 48" data-doi="10.1016/j.ccell.2017.07.003">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhtlClsbnJ" aria-label="CAS reference 48">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28810145" aria-label="PubMed reference 48">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5619925" aria-label="PubMed Central reference 48">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 48" href="http://scholar.google.com/scholar_lookup?&amp;title=Integrative%20analysis%20identifies%20four%20molecular%20and%20clinical%20subsets%20in%20uveal%20melanoma&amp;journal=Cancer%20Cell&amp;doi=10.1016%2Fj.ccell.2017.07.003&amp;volume=32&amp;pages=204-220&amp;publication_year=2017&amp;author=Robertson%2CAG">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="49."><p class="c-article-references__text" id="ref-CR49">Shain, A. H. et al. The genetic evolution of metastatic uveal melanoma. <i>Nat. Genet.</i> <b>51</b>, 1123–1130 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41588-019-0440-9" data-track-item_id="10.1038/s41588-019-0440-9" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41588-019-0440-9" aria-label="Article reference 49" data-doi="10.1038/s41588-019-0440-9">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXht1yktL7F" aria-label="CAS reference 49">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31253977" aria-label="PubMed reference 49">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6632071" aria-label="PubMed Central reference 49">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 49" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20genetic%20evolution%20of%20metastatic%20uveal%20melanoma&amp;journal=Nat.%20Genet.&amp;doi=10.1038%2Fs41588-019-0440-9&amp;volume=51&amp;pages=1123-1130&amp;publication_year=2019&amp;author=Shain%2CAH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="50."><p class="c-article-references__text" id="ref-CR50">Imbens, G. W. Nonparametric estimation of average treatment effects under exogeneity: a review. <i>Rev. Econ. Stat.</i> <b>86</b>, 4–29 (2004).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1162/003465304323023651" data-track-item_id="10.1162/003465304323023651" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1162%2F003465304323023651" aria-label="Article reference 50" data-doi="10.1162/003465304323023651">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 50" href="http://scholar.google.com/scholar_lookup?&amp;title=Nonparametric%20estimation%20of%20average%20treatment%20effects%20under%20exogeneity%3A%20a%20review&amp;journal=Rev.%20Econ.%20Stat.&amp;doi=10.1162%2F003465304323023651&amp;volume=86&amp;pages=4-29&amp;publication_year=2004&amp;author=Imbens%2CGW">
                    Google Scholar</a>&nbsp;
                </p></li></ol><p class="c-article-references__download u-hide-print"><a data-track="click" data-track-action="download citation references" data-track-label="link" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41591-022-02015-7?format=refman&amp;flavour=references">Download references<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p></div></div></div></section></div><section data-title="Acknowledgements"><div class="c-article-section" id="Ack1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Ack1">Acknowledgements</h2><div class="c-article-section__content" id="Ack1-content"><p>The authors thank the patients and their families and caregivers for participating in the study, as well as the study teams at the participating sites for their support of this trial and the following employees of Immunocore: R. Edukulla for statistical analysis support, M.L. McCully for assistance with the preparation of the manuscript, and D. Berman and M. Dar for critical review of the manuscript. A.N.S. was partly supported by Memorial Sloan Kettering Cancer Center’s National Cancer Institute Cancer Center Core Grant P30CA008748. This study was funded by Immunocore Ltd.</p></div></div></section><section aria-labelledby="author-information" data-title="Author information"><div class="c-article-section" id="author-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="author-information">Author information</h2><div class="c-article-section__content" id="author-information-content"><h3 class="c-article__sub-heading" id="affiliations">Authors and Affiliations</h3><ol class="c-article-author-affiliation__list"><li id="Aff1"><p class="c-article-author-affiliation__address">Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA</p><p class="c-article-author-affiliation__authors-list">Richard D. Carvajal</p></li><li id="Aff2"><p class="c-article-author-affiliation__address">Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada</p><p class="c-article-author-affiliation__authors-list">Marcus O. Butler</p></li><li id="Aff3"><p class="c-article-author-affiliation__address">Memorial Sloan Kettering Cancer Center, New York, NY, USA</p><p class="c-article-author-affiliation__authors-list">Alexander N. Shoushtari</p></li><li id="Aff4"><p class="c-article-author-affiliation__address">Weill Cornell Medical College, New York, NY, USA</p><p class="c-article-author-affiliation__authors-list">Alexander N. Shoushtari</p></li><li id="Aff5"><p class="c-article-author-affiliation__address">University Hospital Heidelberg, Heidelberg, Germany</p><p class="c-article-author-affiliation__authors-list">Jessica C. Hassel</p></li><li id="Aff6"><p class="c-article-author-affiliation__address">Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, USA</p><p class="c-article-author-affiliation__authors-list">Alexandra Ikeguchi</p></li><li id="Aff7"><p class="c-article-author-affiliation__address">Washington University School of Medicine, Saint Louis, MO, USA</p><p class="c-article-author-affiliation__authors-list">Leonel Hernandez-Aya</p></li><li id="Aff8"><p class="c-article-author-affiliation__address">Mount Vernon Cancer Centre – East and North Herts NHS Trust, Northwood, Middlesex, UK</p><p class="c-article-author-affiliation__authors-list">Paul Nathan</p></li><li id="Aff9"><p class="c-article-author-affiliation__address">The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, CA, USA</p><p class="c-article-author-affiliation__authors-list">Omid Hamid</p></li><li id="Aff10"><p class="c-article-author-affiliation__address">Institut Català d’Oncologia l’Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, Barcelona, Spain</p><p class="c-article-author-affiliation__authors-list">Josep M. Piulats</p></li><li id="Aff11"><p class="c-article-author-affiliation__address">UC Cancer Center, University of Colorado, Aurora, CO, USA</p><p class="c-article-author-affiliation__authors-list">Matthew Rioth</p></li><li id="Aff12"><p class="c-article-author-affiliation__address">Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA</p><p class="c-article-author-affiliation__authors-list">Douglas B. Johnson</p></li><li id="Aff13"><p class="c-article-author-affiliation__address">UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA</p><p class="c-article-author-affiliation__authors-list">Jason J. Luke</p></li><li id="Aff14"><p class="c-article-author-affiliation__address">Hospital Universitario La Paz – CIBERONC, Madrid, Spain</p><p class="c-article-author-affiliation__authors-list">Enrique Espinosa</p></li><li id="Aff15"><p class="c-article-author-affiliation__address">Charité Comprehensive Cancer Center, Charité – Universitätsmedizin Berlin, Berlin, Germany</p><p class="c-article-author-affiliation__authors-list">Serge Leyvraz</p></li><li id="Aff16"><p class="c-article-author-affiliation__address">Immunocore, Abingdon-on-Thames, UK</p><p class="c-article-author-affiliation__authors-list">Laura Collins&nbsp;&amp;&nbsp;Howard M. Goodall</p></li><li id="Aff17"><p class="c-article-author-affiliation__address">Immunocore, Rockville, MD, USA</p><p class="c-article-author-affiliation__authors-list">Koustubh Ranade,&nbsp;Chris Holland&nbsp;&amp;&nbsp;Shaad E. Abdullah</p></li><li id="Aff18"><p class="c-article-author-affiliation__address">Clatterbridge Cancer Center – NHS Foundation Trust, Wirral, UK</p><p class="c-article-author-affiliation__authors-list">Joseph J. Sacco</p></li><li id="Aff19"><p class="c-article-author-affiliation__address">University of Liverpool, Liverpool, UK</p><p class="c-article-author-affiliation__authors-list">Joseph J. Sacco</p></li><li id="Aff20"><p class="c-article-author-affiliation__address">Sidney Kimmel Cancer Center, Jefferson University, Philadelphia, PA, USA</p><p class="c-article-author-affiliation__authors-list">Takami Sato</p></li></ol><div class="u-js-hide u-hide-print" data-test="author-info"><span class="c-article__sub-heading">Authors</span><ol class="c-article-authors-search u-list-reset"><li id="auth-Richard_D_-Carvajal-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Richard D. Carvajal</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Richard%20D.%20Carvajal" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Richard%20D.%20Carvajal" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Richard%20D.%20Carvajal%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Marcus_O_-Butler-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Marcus O. Butler</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Marcus%20O.%20Butler" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Marcus%20O.%20Butler" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Marcus%20O.%20Butler%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Alexander_N_-Shoushtari-Aff3-Aff4"><span class="c-article-authors-search__title u-h3 js-search-name">Alexander N. Shoushtari</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Alexander%20N.%20Shoushtari" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Alexander%20N.%20Shoushtari" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Alexander%20N.%20Shoushtari%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Jessica_C_-Hassel-Aff5"><span class="c-article-authors-search__title u-h3 js-search-name">Jessica C. Hassel</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Jessica%20C.%20Hassel" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Jessica%20C.%20Hassel" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Jessica%20C.%20Hassel%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Alexandra-Ikeguchi-Aff6"><span class="c-article-authors-search__title u-h3 js-search-name">Alexandra Ikeguchi</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Alexandra%20Ikeguchi" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Alexandra%20Ikeguchi" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Alexandra%20Ikeguchi%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Leonel-Hernandez_Aya-Aff7"><span class="c-article-authors-search__title u-h3 js-search-name">Leonel Hernandez-Aya</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Leonel%20Hernandez-Aya" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Leonel%20Hernandez-Aya" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Leonel%20Hernandez-Aya%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Paul-Nathan-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">Paul Nathan</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Paul%20Nathan" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Paul%20Nathan" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Paul%20Nathan%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Omid-Hamid-Aff9"><span class="c-article-authors-search__title u-h3 js-search-name">Omid Hamid</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Omid%20Hamid" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Omid%20Hamid" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Omid%20Hamid%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Josep_M_-Piulats-Aff10"><span class="c-article-authors-search__title u-h3 js-search-name">Josep M. Piulats</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Josep%20M.%20Piulats" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Josep%20M.%20Piulats" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Josep%20M.%20Piulats%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Matthew-Rioth-Aff11"><span class="c-article-authors-search__title u-h3 js-search-name">Matthew Rioth</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Matthew%20Rioth" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Matthew%20Rioth" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Matthew%20Rioth%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Douglas_B_-Johnson-Aff12"><span class="c-article-authors-search__title u-h3 js-search-name">Douglas B. Johnson</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Douglas%20B.%20Johnson" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Douglas%20B.%20Johnson" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Douglas%20B.%20Johnson%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Jason_J_-Luke-Aff13"><span class="c-article-authors-search__title u-h3 js-search-name">Jason J. Luke</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Jason%20J.%20Luke" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Jason%20J.%20Luke" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Jason%20J.%20Luke%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Enrique-Espinosa-Aff14"><span class="c-article-authors-search__title u-h3 js-search-name">Enrique Espinosa</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Enrique%20Espinosa" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Enrique%20Espinosa" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Enrique%20Espinosa%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Serge-Leyvraz-Aff15"><span class="c-article-authors-search__title u-h3 js-search-name">Serge Leyvraz</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Serge%20Leyvraz" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Serge%20Leyvraz" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Serge%20Leyvraz%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Laura-Collins-Aff16"><span class="c-article-authors-search__title u-h3 js-search-name">Laura Collins</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Laura%20Collins" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Laura%20Collins" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Laura%20Collins%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Howard_M_-Goodall-Aff16"><span class="c-article-authors-search__title u-h3 js-search-name">Howard M. Goodall</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Howard%20M.%20Goodall" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Howard%20M.%20Goodall" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Howard%20M.%20Goodall%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Koustubh-Ranade-Aff17"><span class="c-article-authors-search__title u-h3 js-search-name">Koustubh Ranade</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Koustubh%20Ranade" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Koustubh%20Ranade" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Koustubh%20Ranade%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Chris-Holland-Aff17"><span class="c-article-authors-search__title u-h3 js-search-name">Chris Holland</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Chris%20Holland" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Chris%20Holland" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Chris%20Holland%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Shaad_E_-Abdullah-Aff17"><span class="c-article-authors-search__title u-h3 js-search-name">Shaad E. Abdullah</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Shaad%20E.%20Abdullah" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Shaad%20E.%20Abdullah" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Shaad%20E.%20Abdullah%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Joseph_J_-Sacco-Aff18-Aff19"><span class="c-article-authors-search__title u-h3 js-search-name">Joseph J. Sacco</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Joseph%20J.%20Sacco" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Joseph%20J.%20Sacco" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Joseph%20J.%20Sacco%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Takami-Sato-Aff20"><span class="c-article-authors-search__title u-h3 js-search-name">Takami Sato</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Takami%20Sato" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Takami%20Sato" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Takami%20Sato%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li></ol></div><h3 class="c-article__sub-heading" id="contributions">Contributions</h3><p>The study was designed in a collaboration between Immunocore (study sponsor) and the authors. R.D.C., P.N., K.R., C.H., S.E.A., J.J.S. and T.S. contributed to the conception, design and planning of the study. All authors contributed in the conduct of the study and the analysis and interpretation of data. R.D.C., M.O.B., A.N.S., J.C.H., A.I., L.H.-A., P.N., O.H., J.M.P., M.R., D.B.J., J.J.L., E.E., S.L., J.J.S. and T.S. enrolled and treated patients and gathered data. R.D.C., L.C., H.M.G., K.R., C.H., S.E.A., J.J.S. and T.S. analyzed and interpreted data. R.D.C., L.C., K.R., C.H., S.E.A., J.J.S. and T.S. drafted the manuscript. All authors critically reviewed iterations of the manuscript and approved the final draft for submission.</p><h3 class="c-article__sub-heading" id="corresponding-author">Corresponding author</h3><p id="corresponding-author-list">Correspondence to
                <a id="corresp-c1" href="mailto:takami.sato@jefferson.edu">Takami Sato</a>.</p></div></div></section><section data-title="Ethics declarations"><div class="c-article-section" id="ethics-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="ethics">Ethics declarations</h2><div class="c-article-section__content" id="ethics-content">
              
                <h3 class="c-article__sub-heading" id="FPar4">Competing interests</h3>
                <p>R.D.C. discloses consulting: Alkermes, BMS, Castle Biosciences, Delcath, Eisai, Hengrui, Ideaya, Immunocore, InxMed, Iovance, Merck, Novartis, Oncosec, Pierre Fabre, PureTech Health, Regeneron, Sanofi Genzyme, Sorrento Therapeutics, Trisalus; clinical/scientific advisory boards: Aura Biosciences, Chimeron, Rgenix. M.O.B. discloses advisory/consulting: Merck, BMS, Novartis, Sanofi, Pfizer, Adaptimmune, GSK, Immunocore, EMD Serono, Sun Pharma, Medison, Instil Bio, IOVANCE; research funding to self: Merck, Takara Bio; research funding to institution: Merck, BMS, Novartis, Sanofi, Adaptimmune, Immunocore, Regeneron, Lilly, Amgen, OncoSeq; Speaker: BMS, Merck, Pfizer, Novartis, Sanofi. A.N.S. discloses honoraria advisory board/personal fees: BMS, Castle Biosciences, Immunocore, Novartis; licensing/royalties: UpToDate; research funding to institution: BMS, Checkmate Pharmaceuticals, Foghorn Therapeutics, GSK, Immunocore, Novartis, Pfizer, Polaris, Targovax, Xcovery. J.C.H. discloses advisory boards (self): GSK, MSD, Pierre Fabre, Sun Pharma; advisory boards (institution): BMS, Immunocore, Novartis, Nektar, Philogen; contracted research: 4SC, BioNTech, BMS, Genentech/Roche, Idera, Immunocore, Iovance, Nektar, Novartis, Philogen, Pierre Fabre, Regeneron, Sanofi; honoraria: BMS, MSD, Novartis, Pierre Fabre, Roche, Sanofi, Sun Pharma; research funding to institution: BMS, Sun Pharma. A.I. discloses research funding to institution: Checkmate Pharmaceuticals, Dynavax, GSK/Sarah Cannon, Immunocore, Merck, Neon Therapeutics/Sarah Cannon. L.H.-A. discloses advisory/consulting: BMS, Castle Bioscience; research funding to institution: BMS, AstraZeneca, Merck, Amgen, Roche, Regeneron, Novartis, Immunocore, Merck-EMD, Corvus, Polynoma, Genentech, Foghorn. P.N. discloses advisory/consulting: BMS, Immunocore, Ipsen, Incyte, MSD, Merck, Novartis, Pfizer, 4SC; speaker’s bureau: BMS, Merck, Novartis, Pfizer; research funding to institution: Immunocore, Novartis. O.H. discloses contracted research (institute): Aduro, Akeso, Amgen, Bioatla, BMS, Genentech, GSK, Idera, Immunocore, Incyte, Merck, NextCure, Novartis, Pfizer, Sanofi/Regeneron, SeaGen, Zelluna; speaker’s bureau: BMS, Novartis, Pfizer, Sanofi/Regeneron; consulting/advisory board: Aduro, Akeso, Amgen, Beigene, Bioatla, BMS, Genentech, GSK, Idera, Immunocore, Incyte, Janssen, Merck, NextCure, Novartis, Pfizer, Sanofi/Regeneron, SeaGen, Tempus, Zelluna. J.M.P. discloses research funding: BeiGene, BMS, Immunocore, Mirati, MSD. M.R. discloses consulting: Health Advances. D.B.J. discloses consultancy: BMS, Catalyst, Iovance, Janssen, Mallinckrodt, Merck, Mosaic, Novartis, Oncosec, Pfizer, Targovax, Teiko; non-remunerated activities: Melanoma Guideline Committee (NCCN), Scientific Selection Committee (ASCO), Immunotherapy Toxicity Guidelines (SITC); research funding to self: BMS, Incyte; research funding to institution: Array Biopharma, Genentech, Immunocore, Nektar. J.J.L. discloses consulting: Abbvie, Bayer, BMS, Castle, Checkmate, Codiak, Crown, Day One, Duke St, EMD Serono, Endeavor, Flame, Genentech, Gilead, Glenmark, HotSpot, Kadmon, Janssen, Ikena, Immunocore, Incyte, IO Biotech, Macrogenics, Merck, Nektar, Novartis, Partner, Pfizer, Regeneron, Roivant, Servier, STINGthera, Synlogic, Synthekine; scientific advisory board (no stock): 7 Hills, Bright Peak, Exo, Fstar, Inzen, RefleXion, Xilio; scientific advisory board (stock): Actym, Alphamab Oncology, Arch Oncology, Kanaph, Mavu, NeoTx, Onc.AI, OncoNano, Pyxis, STipe, Tempest; Data and Safety Monitoring Board: Abbvie, Immutep, Evaxion; research funding to institution: Abbvie, Astellas, AstraZeneca, BMS, Corvus, Day One, EMD Serono, Fstar, Genmab, Ikena, Immatics, Incyte, Kadmon, KAHR, Macrogenics. Merck, Moderna, Nektar, NextCure, Numab, Palleon, Pfizer, Replimmune, Rubius, Servier, Scholar Rock, Synlogic, Takeda, Trishula, Tizona, Xencor; patents (provisional): serial no. 15/612,657 (Cancer Immunotherapy), PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof). E.E. discloses consulting: BMS, MSD, Novartis, Pierre Fabre; non-remunerated activities: Vice-President (Grupo Espanol Melanoma); speaker bureau: BMS, MSD, Novartis, Pierre Fabre. S.L. discloses consulting: Bayer, Immunocore; expenses: Bayer. L.C., H.M.G., K.R., C.H. and S.E.A. are employees and have stocks/shares or stock options in Immunocore, which could benefit from commercialization of these results. J.J.S. discloses advisory/consulting: Immunocore, BMS, MSD, Delcath, Amgen; speaker’s bureau: BMS, MSD, Pierre Fabre; research funding to institution: Immunocore, BMS, MSD, Amgen, AstraZeneca, Replimune. T.S. discloses advisory/consulting: Immunocore, Castle Biosciences; research funding to institution: Immunocore, Verastem.</p>
              
            </div></div></section><section data-title="Peer review"><div class="c-article-section" id="peer-review-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="peer-review">Peer review</h2><div class="c-article-section__content" id="peer-review-content">
              
              
                <h3 class="c-article__sub-heading" id="FPar3">Peer review information</h3>
                <p><i>Nature Medicine</i> thanks Martine Jager, Matteo Carlino, Harriet Kluger and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: Joao Monteiro, in collaboration with the <i>Nature Medicine</i> team.</p>
              
            </div></div></section><section data-title="Additional information"><div class="c-article-section" id="additional-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="additional-information">Additional information</h2><div class="c-article-section__content" id="additional-information-content"><p><b>Publisher’s note</b> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div></div></section><section data-title="Extended data"><div class="c-article-section" id="Sec19-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec19">Extended data</h2><div class="c-article-section__content" id="Sec19-content"><div data-test="supplementary-info"><div id="figshareContainer" class="c-article-figshare-container" data-test="figshare-container"></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig4"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 1 consort flowchart for a singl" href="/articles/s41591-022-02015-7/figures/4" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig4_ESM.jpg">Extended Data Fig. 1 CONSORT flowchart for a single-arm, open-label, phase 2 clinical trial with tebentafusp in patients with metastatic uveal melanoma.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>All patients who received at least 1 full or partial dose of study drug are in the Safety Set. All patients assigned to treatment who received at least 1 full or partial dose of study drug are in the Full Analysis Set (FAS). <sup>a</sup>One patient was classified as ‘Other – clinical disease progression’ rather than ‘Disease progression’ in error under reason for treatment discontinuation.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig5"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 2 tumour size change from basel" href="/articles/s41591-022-02015-7/figures/5" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig5_ESM.jpg">Extended Data Fig. 2 Tumour size change from baseline over time for patients with best overall response of partial response.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Spider plots showing change in tumour size over time for individual patients with a best overall response of partial response (PR) (n = 6). BOR = best overall response.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig6"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 3 clinical activity of tebentaf" href="/articles/s41591-022-02015-7/figures/6" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig6_ESM.jpg">Extended Data Fig. 3 Clinical activity of tebentafusp.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>(a)</b> Waterfall plot showing the best change in tumour size (n = 116). 44% of patients had tumour reduction at any time. Tumour size was measured as the sum of longest diameters or short axis of the target lesions according to RECIST v1.1 by Independent Central Review. Best percent change in target lesion size was the maximum percent reduction from baseline or the minimum percent increase from baseline (in the absence of a reduction), up until disease progression or starting subsequent alternative cancer therapy. Complete response, partial response or minor response required confirmation at least 4 weeks later. Reference lines at 20%, -10%, and -30% mark target lesion response criteria for disease progression (PD), minor response (MR), and partial response (PR), respectively. SD, stable disease. <b>(b)</b> Overall survival in months is plotted for each patient (n = 116). 61.2% of patients survived more than 12 months. + denotes censored. (A-B) Only patients with at least one evaluable post-baseline target lesion scan were included. Eleven patients overall were not included due to non-measurable disease at baseline or no evaluable post-baseline target lesion scans. Evaluable post-baseline scans must be on or prior to disease progression or starting subsequent alternative cancer therapy to be considered.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig7"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 4 progression-free survival." href="/articles/s41591-022-02015-7/figures/7" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig7_ESM.jpg">Extended Data Fig. 4 Progression-Free Survival.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Kaplan–Meier estimate of progression-free survival for patients treated with tebentafusp. Tick marks represent patients who were known to be alive and without disease progression as assessed per Response Evaluation Criteria in Solid Tumours, version 1.1, by blinded, independent, central radiologic review. The median progression-free survival was 2.76 months (95% CI: 2-3.7) and was estimated by the Kaplan–Meier method.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig8"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 5 swimlane plot of overall surv" href="/articles/s41591-022-02015-7/figures/8" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig8_ESM.jpg">Extended Data Fig. 5 Swimlane plot of overall survival and treatment beyond progression.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Swimlane plot showing overall survival, duration of treatment till progression and duration of treatment beyond initial progression (N = 127). The median duration of treatment beyond progression was 2.9 months (range: 0-23.1 months; n = 90).</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig9"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 6 subgroup analysis of os in th" href="/articles/s41591-022-02015-7/figures/9" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig9_ESM.jpg">Extended Data Fig. 6 Subgroup analysis of OS in the six major prognostic categories from this current study compared to a recent meta-analysis.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Digitized overlay of Kaplan–Meier estimates of overall survival for patients treated with tebentafusp in this study compared to curves from patients with the same negative baseline prognostic factor from a meta-analysis<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 17" title="Khoja, L. et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an International Rare Cancers Initiative (IRCI) ocular melanoma study. Ann. Oncol. 30, 1370–1380 (2019)." href="/articles/s41591-022-02015-7#ref-CR17" id="ref-link-section-d71731262e3850">17</a></sup> for ALP ≥ ULN, LDH ≥ ULN, ECOG &gt; 0, Age ≥ 65, largest liver lesion ≥ 3 cm and male sex.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig10"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 7 tebentafusp os in 2 l + popul" href="/articles/s41591-022-02015-7/figures/10" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig10_ESM.jpg">Extended Data Fig. 7 Tebentafusp OS in 2 L + population compared to meta-analysis and combination checkpoint inhibitors.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Digitized overlay of Kaplan–Meier estimates of overall survival for patients treated with tebentafusp in this study compared to 2 L + and 1 L populations from a meta-analysis (Rantala et al. 2019)18 and 1 L patients treated with combination ipilimumab and nivolumab in a single-arm phase 2 study (Piulats et al. 2021)16. Hazard ratios and 95% CIs calculated from a univariate Cox proportional hazards model. 1 L = first line, 2 L + = second line plus, IC = investigator’s choice, ipi = ipilimumab, nivo = nivolumab, OS = overall survival.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig11"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 8 iptw-adjusted kaplan–meier es" href="/articles/s41591-022-02015-7/figures/11" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig11_ESM.jpg">Extended Data Fig. 8 IPTW-Adjusted Kaplan–Meier Estimates of OS by Treatment Group.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Adjusted product-limit survival estimates with number of subjects at risk comparing OS from start of treatment of tebentafusp from this study (Study 102) (blue, n = 123) and Study 202 subsequent systemic therapy (red, n = 120). Using Propensity Scoring methods (IPTW), control patients in the IMCgp100-202 phase 3 study who received standard of care 2 L therapies were weighted so that, overall, they are similar with respect to their baseline prognostic factors to the tebentafusp-treated patients from this study (102). The primary analysis involving 2 L + patients from Study 102 compared to control patients in Study 202 who received any systemic therapy as their 2 L treatment resulted in an HR (95% CI) of 0.40 (0.29, 0.55). The hazard ratio was derived from a weighted Cox proportional hazards model and the 95% confidence interval was derived using robust sandwich estimation from the weighted Cox model. IPTW = inverse probability of treatment weights.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig12"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 9 baseline ctdna level correlat" href="/articles/s41591-022-02015-7/figures/12" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig12_ESM.jpg">Extended Data Fig. 9 Baseline ctDNA level correlated with tumour burden.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>(a-b)</b> Correlation between level of ctDNA at baseline and (a) tumour size at baseline (n = 94; R = 0.6, p = 6e-10) and (b) LDH level at baseline (n = 91; R = 0.77, p = 6.76e-19). P-value and rho determined using two-sided Spearman rank correlation test. Tumour size was measured as the sum of longest diameters (mm) of the target lesions at first scan according to RECIST v1.1 by Independent Central Review. (c-e) Level of ctDNA at baseline was plotted for <b>(c)</b> patients who received prior IO therapy (n = 59) versus patients who did not (n = 35) (p = 0.42), <b>(d)</b> patients who experienced Rash in Week 1 (n = 60) versus patients who did not (n = 34) (0.043) and <b>(e)</b> patients who experienced CRS (n = 82) versus patients who did not (n = 9) (p = 0.28). Pairwise comparison between groups were conducted using two-sided Wilcoxon signed-rank test. The median is represented by the middle line while the upper and lower borders of the box identify the 75th and 25th percentiles, respectively. The whiskers correspond the minimum and maximal values that is within 1.5 times the interquartile range.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig13"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 10 baseline and on-treatment ct" href="/articles/s41591-022-02015-7/figures/13" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig13_ESM.jpg">Extended Data Fig. 10 Baseline and on-treatment ctDNA level correlated with overall survival.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>(a)</b> Kaplan–Meier analysis of OS for patients with &gt; median ctDNA levels at baseline versus patients with &lt; median ctDNA levels at baseline (HR 0.23; 95% CI 0.13-0.41, p = 2.05e-7). <b>(b)</b> Kaplan–Meier analysis of OS landmarked to week 9 in patients with ctDNA clearance (n = 12) versus patients without clearance (n = 78) by 9 weeks (HR 0.08; 95% CI 0.01-0.56, p = 6.31e-5) and <b>(c)</b> Kaplan–Meier analysis of OS in patients with ctDNA clearance (n = 12) versus patients with ≥1 log ctDNA reduction (p = 0.001) and patients with increased ctDNA by 9 weeks (HR 0.74; 95% CI 0.32-1.71, p = 0.476). <b>(d)</b> Kaplan–Meier analysis of OS landmarked to week 9 in patients with best overall response of progressive disease with a reduction in ctDNA by ≥ 0.5 log fold change (n = 16) versus &lt; 0.5 log fold change (n = 27) by week 9. Hazard ratio for death 0.51 (95% CI 0.23-1.13), p = 0.087. (a-d) Hazard ratio and confidence intervals were generated from Cox proportional hazard model. P values were generated from two-sided Cox likelihood ratio test.</p></div></div></div></div></div></section><section data-title="Supplementary information"><div class="c-article-section" id="Sec20-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec20">Supplementary information</h2><div class="c-article-section__content" id="Sec20-content"><div data-test="supplementary-info"><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM1"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="supplementary information" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_MOESM1_ESM.pdf" data-supp-info-image="">Supplementary Information</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Supplementary Tables 1–7</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM2"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="reporting summary" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_MOESM2_ESM.pdf" data-supp-info-image="">Reporting Summary</a></h3></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM3"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="supplementary table 8" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_MOESM3_ESM.xlsx" data-supp-info-image="">Supplementary Table 8</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Anonymized gene sequencing mutation data of patients for the five uveal associated genes</p></div></div></div></div></div></section><section data-title="Rights and permissions"><div class="c-article-section" id="rightslink-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="rightslink">Rights and permissions</h2><div class="c-article-section__content" id="rightslink-content">
                <p><b>Open Access</b>  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <a href="http://creativecommons.org/licenses/by/4.0/" rel="license">http://creativecommons.org/licenses/by/4.0/</a>.</p>
              <p class="c-article-rights"><a data-track="click" data-track-action="view rights and permissions" data-track-label="link" href="https://s100.copyright.com/AppDispatchServlet?title=Clinical%20and%20molecular%20response%20to%20tebentafusp%20in%20previously%20treated%20patients%20with%20metastatic%20uveal%20melanoma%3A%20a%20phase%202%20trial&amp;author=Richard%20D.%20Carvajal%20et%20al&amp;contentID=10.1038%2Fs41591-022-02015-7&amp;copyright=The%20Author%28s%29%2C%20under%20exclusive%20licence%20to%20Springer%20Nature%20America%2C%20Inc.&amp;publication=1078-8956&amp;publicationDate=2022-10-13&amp;publisherName=SpringerNature&amp;orderBeanReset=true&amp;oa=CC%20BY">Reprints and permissions</a></p></div></div></section><section aria-labelledby="article-info" data-title="About this article"><div class="c-article-section" id="article-info-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="article-info">About this article</h2><div class="c-article-section__content" id="article-info-content"><div class="c-bibliographic-information"><div class="u-hide-print c-bibliographic-information__column c-bibliographic-information__column--border"><a data-crossmark="10.1038/s41591-022-02015-7" target="_blank" rel="noopener" href="https://crossmark.crossref.org/dialog/?doi=10.1038/s41591-022-02015-7" data-track="click" data-track-action="Click Crossmark" data-track-label="link" data-test="crossmark"><img loading="lazy" width="57" height="81" alt="Check for updates. Verify currency and authenticity via CrossMark" src="data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>"></a></div><div class="c-bibliographic-information__column"><h3 class="c-article__sub-heading" id="citeas">Cite this article</h3><p class="c-bibliographic-information__citation">Carvajal, R.D., Butler, M.O., Shoushtari, A.N. <i>et al.</i> Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial.
                    <i>Nat Med</i> <b>28</b>, 2364–2373 (2022). https://doi.org/10.1038/s41591-022-02015-7</p><p class="c-bibliographic-information__download-citation u-hide-print"><a data-test="citation-link" data-track="click" data-track-action="download article citation" data-track-label="link" data-track-external="" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41591-022-02015-7?format=refman&amp;flavour=citation">Download citation<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p><ul class="c-bibliographic-information__list" data-test="publication-history"><li class="c-bibliographic-information__list-item"><p>Received<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2022-04-04">04 April 2022</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Accepted<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2022-08-16">16 August 2022</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Published<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2022-10-13">13 October 2022</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Issue Date<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2022-11">November 2022</time></span></p></li><li class="c-bibliographic-information__list-item c-bibliographic-information__list-item--full-width"><p><abbr title="Digital Object Identifier">DOI</abbr><span class="u-hide">: </span><span class="c-bibliographic-information__value">https://doi.org/10.1038/s41591-022-02015-7</span></p></li></ul><div data-component="share-box"><div class="c-article-share-box u-display-block"><h3 class="c-article__sub-heading">Share this article</h3><p class="c-article-share-box__description">Anyone you share the following link with will be able to read this content:</p><button class="js-get-share-url c-article-share-box__button" type="button" id="get-share-url" data-track="click" data-track-label="button" data-track-external="" data-track-action="get shareable link">Get shareable link</button><div class="js-no-share-url-container u-display-none" hidden=""><p class="js-c-article-share-box__no-sharelink-info c-article-share-box__no-sharelink-info">Sorry, a shareable link is not currently available for this article.</p></div><div class="js-share-url-container u-display-none" hidden=""><p class="js-share-url c-article-share-box__only-read-input" id="share-url" data-track="click" data-track-label="button" data-track-action="select share url"></p><button class="js-copy-share-url c-article-share-box__button--link-like" type="button" id="copy-share-url" data-track="click" data-track-label="button" data-track-action="copy share url" data-track-external="">Copy to clipboard</button></div><p class="js-c-article-share-box__additional-info c-article-share-box__additional-info">
                            Provided by the Springer Nature SharedIt content-sharing initiative
                        </p></div></div><div data-component="article-info-list">
        <h3 class="c-article__sub-heading">Subjects</h3>
        <ul class="c-article-subject-list">
            <li class="c-article-subject-list__subject"><a href="/subjects/drug-development" data-track="click" data-track-action="view subject" data-track-label="link">Drug development</a></li><li class="c-article-subject-list__subject"><a href="/subjects/translational-research" data-track="click" data-track-action="view subject" data-track-label="link">Translational research</a></li>
        </ul>
    </div></div></div></div></div></section>
            </div>

            
        <section>
            <div class="c-article-section js-article-section" id="further-reading-section" data-test="further-reading-section">
                <h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="further-reading">This article is cited by</h2>
                <div class="c-article-section__content js-collapsible-section" id="further-reading-content">
                    <ul class="c-article-further-reading__list" id="further-reading-list">
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Digital PCR-based genetic profiling from vitreous fluid as liquid biopsy for primary uveal melanoma: a proof-of-concept study" href="https://doi.org/10.1186/s13046-025-03374-y">
                                        Digital PCR-based genetic profiling from vitreous fluid as liquid biopsy for primary uveal melanoma: a proof-of-concept study
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>R. J. Nell</li><li>M. Versluis</li><li>P. A. van der Velden</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Journal of Experimental &amp; Clinical Cancer Research</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer" href="https://doi.org/10.1038/s41467-025-57470-w">
                                        Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Esra Güç</li><li>Agatha Treveil</li><li>Adel Benlahrech</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Nature Communications</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology" href="https://doi.org/10.1038/s41698-025-00876-y">
                                        Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Alexandra Bartolomucci</li><li>Monyse Nobrega</li><li>Julia V. Burnier</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>npj Precision Oncology</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice" href="https://doi.org/10.1038/s41467-024-46558-4">
                                        HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Jianting Long</li><li>Xihe Chen</li><li>Yanyan Han</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Nature Communications</i> (2024)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma" href="https://doi.org/10.1038/s41416-024-02866-6">
                                        Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Chandrani Chattopadhyay</li><li>Janos Roszik</li><li>Elizabeth A. Grimm</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>British Journal of Cancer</i> (2024)</p>
                            </li>
                        
                    </ul>
                </div>
            </div>
        </section>
    

        </div>
</article>
</main>

<aside class="c-article-extras u-hide-print" aria-label="Article navigation" data-component-reading-companion="" data-container-type="reading-companion" data-track-component="reading companion">
    <div class="js-context-bar-sticky-point-desktop" data-track-context="reading companion">
        

        
            
                
                    
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-022-02015-7.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                
            
        
    </div>

    
        
    

    
    

    <div class="c-reading-companion">
        <div class="c-reading-companion__sticky" data-component="reading-companion-sticky" data-test="reading-companion-sticky" style="top: 40px;">
            <ul class="c-reading-companion__tabs" role="tablist"><li role="presentation"><button data-tab-target="sections" role="tab" id="tab-sections" aria-controls="tabpanel-sections" aria-selected="true" class="c-reading-companion__tab c-reading-companion__tab--active" data-track="click" data-track-action="sections tab" data-track-label="tab">Sections</button></li><li role="presentation"><button data-tab-target="figures" role="tab" id="tab-figures" aria-controls="tabpanel-figures" aria-selected="false" tabindex="-1" class="c-reading-companion__tab" data-track="click" data-track-action="figures tab" data-track-label="tab">Figures</button></li><li role="presentation"><button data-tab-target="references" role="tab" id="tab-references" aria-controls="tabpanel-references" aria-selected="false" tabindex="-1" class="c-reading-companion__tab" data-track="click" data-track-action="references tab" data-track-label="tab">References</button></li></ul><div class="c-reading-companion__panel c-reading-companion__sections c-reading-companion__panel--active" id="tabpanel-sections" aria-labelledby="tab-sections" role="tabpanel"><div class="c-reading-companion__scroll-pane" style="max-height: none;"><ul class="c-reading-companion__sections-list"><li id="rc-sec-Abs1" class="c-reading-companion__section-item"><a href="#Abs1" data-track="click" data-track-action="section anchor" data-track-label="link:Abstract">Abstract</a></li><li id="rc-sec-Sec1" class="c-reading-companion__section-item"><a href="#Sec1" data-track="click" data-track-action="section anchor" data-track-label="link:Main">Main</a></li><li id="rc-sec-Sec2" class="c-reading-companion__section-item"><a href="#Sec2" data-track="click" data-track-action="section anchor" data-track-label="link:Results">Results</a></li><li id="rc-sec-Sec9" class="c-reading-companion__section-item"><a href="#Sec9" data-track="click" data-track-action="section anchor" data-track-label="link:Discussion">Discussion</a></li><li id="rc-sec-Sec10" class="c-reading-companion__section-item"><a href="#Sec10" data-track="click" data-track-action="section anchor" data-track-label="link:Methods">Methods</a></li><li id="rc-sec-data-availability" class="c-reading-companion__section-item"><a href="#data-availability" data-track="click" data-track-action="section anchor" data-track-label="link:Data availability">Data availability</a></li><li id="rc-sec-Bib1" class="c-reading-companion__section-item"><a href="#Bib1" data-track="click" data-track-action="section anchor" data-track-label="link:References">References</a></li><li id="rc-sec-Ack1" class="c-reading-companion__section-item"><a href="#Ack1" data-track="click" data-track-action="section anchor" data-track-label="link:Acknowledgements">Acknowledgements</a></li><li id="rc-sec-author-information" class="c-reading-companion__section-item"><a href="#author-information" data-track="click" data-track-action="section anchor" data-track-label="link:Author information">Author information</a></li><li id="rc-sec-ethics" class="c-reading-companion__section-item"><a href="#ethics" data-track="click" data-track-action="section anchor" data-track-label="link:Ethics declarations">Ethics declarations</a></li><li id="rc-sec-peer-review" class="c-reading-companion__section-item"><a href="#peer-review" data-track="click" data-track-action="section anchor" data-track-label="link:Peer review">Peer review</a></li><li id="rc-sec-additional-information" class="c-reading-companion__section-item"><a href="#additional-information" data-track="click" data-track-action="section anchor" data-track-label="link:Additional information">Additional information</a></li><li id="rc-sec-Sec19" class="c-reading-companion__section-item"><a href="#Sec19" data-track="click" data-track-action="section anchor" data-track-label="link:Extended data">Extended data</a></li><li id="rc-sec-Sec20" class="c-reading-companion__section-item"><a href="#Sec20" data-track="click" data-track-action="section anchor" data-track-label="link:Supplementary information">Supplementary information</a></li><li id="rc-sec-rightslink" class="c-reading-companion__section-item"><a href="#rightslink" data-track="click" data-track-action="section anchor" data-track-label="link:Rights and permissions">Rights and permissions</a></li><li id="rc-sec-article-info" class="c-reading-companion__section-item"><a href="#article-info" data-track="click" data-track-action="section anchor" data-track-label="link:About this article">About this article</a></li><li id="rc-sec-further-reading" class="c-reading-companion__section-item"><a href="#further-reading" data-track="click" data-track-action="section anchor" data-track-label="link:This article is cited by">This article is cited by</a></li></ul></div>
                <div class="u-lazy-ad-wrapper u-mt-16 u-show" data-component-mpu="" style="display: none !important;">
                    <div class="c-ad c-ad--300x250">
                        <div class="c-ad__inner">
                            <p class="c-ad__label">Advertisement</p>
                            
    <div id="div-gpt-ad-right-2" class="div-gpt-ad advert medium-rectangle js-ad text-center hide-print grade-c-hide" data-ad-type="right" data-test="right-ad" data-pa11y-ignore="" data-gpt="" data-gpt-unitpath="/285/medicine.nature.com/article" data-gpt-sizes="300x250" data-gpt-targeting="type=article;pos=right;artid=s41591-022-02015-7;doi=10.1038/s41591-022-02015-7;subjmeta=153,308,575,692;kwrd=Drug+development,Translational+research">
        <noscript>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/medicine.nature.com/article&amp;sz=300x250&amp;c=-2126765865&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41591-022-02015-7%26doi%3D10.1038/s41591-022-02015-7%26subjmeta%3D153,308,575,692%26kwrd%3DDrug+development,Translational+research">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/medicine.nature.com/article&amp;sz=300x250&amp;c=-2126765865&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41591-022-02015-7%26doi%3D10.1038/s41591-022-02015-7%26subjmeta%3D153,308,575,692%26kwrd%3DDrug+development,Translational+research"
                     alt="Advertisement"
                     width="300"
                     height="250"></a>
        </noscript>
    </div>

                        </div>
                    </div>
                </div>
            </div>
            <div class="c-reading-companion__panel c-reading-companion__figures c-reading-companion__panel--full-width" id="tabpanel-figures" aria-labelledby="tab-figures" role="tabpanel"><div class="c-reading-companion__scroll-pane"><ul class="c-reading-companion__figures-list"><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig1">Fig. 1: Incidence and severity of treatment-related adverse events after the initial tebentafusp doses.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig1_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig1_HTML.png" alt="figure 1" aria-describedby="rc-Fig1"></picture><p class="c-reading-companion__figure-links"><a href="#Fig1" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-02015-7/figures/1" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig2">Fig. 2: Overall survival for tebentafusp-treated patients with metastatic uveal melanoma.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig2_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig2_HTML.png" alt="figure 2" aria-describedby="rc-Fig2"></picture><p class="c-reading-companion__figure-links"><a href="#Fig2" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-02015-7/figures/2" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig3">Fig. 3: On-treatment ctDNA reduction correlated with survival benefit.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig3_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig3_HTML.png" alt="figure 3" aria-describedby="rc-Fig3"></picture><p class="c-reading-companion__figure-links"><a href="#Fig3" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-02015-7/figures/3" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig4">Extended Data Fig. 1 CONSORT flowchart for a single-arm, open-label, phase 2 clinical trial with tebentafusp in patients with metastatic uveal melanoma.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig4_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig4_ESM.jpg" alt="extended data figure 4" aria-describedby="rc-Fig4"></picture><p class="c-reading-companion__figure-links"><a href="#Fig4" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-02015-7/figures/4" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig5">Extended Data Fig. 2 Tumour size change from baseline over time for patients with best overall response of partial response.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig5_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig5_ESM.jpg" alt="extended data figure 5" aria-describedby="rc-Fig5"></picture><p class="c-reading-companion__figure-links"><a href="#Fig5" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-02015-7/figures/5" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig6">Extended Data Fig. 3 Clinical activity of tebentafusp.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig6_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig6_ESM.jpg" alt="extended data figure 6" aria-describedby="rc-Fig6"></picture><p class="c-reading-companion__figure-links"><a href="#Fig6" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-02015-7/figures/6" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig7">Extended Data Fig. 4 Progression-Free Survival.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig7_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig7_ESM.jpg" alt="extended data figure 7" aria-describedby="rc-Fig7"></picture><p class="c-reading-companion__figure-links"><a href="#Fig7" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-02015-7/figures/7" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig8">Extended Data Fig. 5 Swimlane plot of overall survival and treatment beyond progression.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig8_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig8_ESM.jpg" alt="extended data figure 8" aria-describedby="rc-Fig8"></picture><p class="c-reading-companion__figure-links"><a href="#Fig8" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-02015-7/figures/8" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig9">Extended Data Fig. 6 Subgroup analysis of OS in the six major prognostic categories from this current study compared to a recent meta-analysis.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig9_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig9_ESM.jpg" alt="extended data figure 9" aria-describedby="rc-Fig9"></picture><p class="c-reading-companion__figure-links"><a href="#Fig9" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-02015-7/figures/9" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig10">Extended Data Fig. 7 Tebentafusp OS in 2 L + population compared to meta-analysis and combination checkpoint inhibitors.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig10_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig10_ESM.jpg" alt="extended data figure 10" aria-describedby="rc-Fig10"></picture><p class="c-reading-companion__figure-links"><a href="#Fig10" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-02015-7/figures/10" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig11">Extended Data Fig. 8 IPTW-Adjusted Kaplan–Meier Estimates of OS by Treatment Group.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig11_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig11_ESM.jpg" alt="extended data figure 11" aria-describedby="rc-Fig11"></picture><p class="c-reading-companion__figure-links"><a href="#Fig11" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-02015-7/figures/11" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig12">Extended Data Fig. 9 Baseline ctDNA level correlated with tumour burden.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig12_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig12_ESM.jpg" alt="extended data figure 12" aria-describedby="rc-Fig12"></picture><p class="c-reading-companion__figure-links"><a href="#Fig12" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-02015-7/figures/12" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig13">Extended Data Fig. 10 Baseline and on-treatment ctDNA level correlated with overall survival.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig13_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-022-02015-7/MediaObjects/41591_2022_2015_Fig13_ESM.jpg" alt="extended data figure 13" aria-describedby="rc-Fig13"></picture><p class="c-reading-companion__figure-links"><a href="#Fig13" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-022-02015-7/figures/13" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li></ul></div></div>
            <div class="c-reading-companion__panel c-reading-companion__references c-reading-companion__panel--full-width" id="tabpanel-references" aria-labelledby="tab-references" role="tabpanel"><div class="c-reading-companion__scroll-pane"><ol class="c-reading-companion__references-list c-reading-companion__references-list--numeric" data-track-context="article references sidebar"><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR1">Milam, R. W. &amp; Daniels, A. B. Uveal melanoma. In <i>Melanoma</i> (ed. Riker, A.) pp. 273–312 (Springer, 2018). <a href="https://doi.org/10.1007/978-3-319-78310-9_16" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="10.1007/978-3-319-78310-9_16">https://doi.org/10.1007/978-3-319-78310-9_16</a></p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR2">Stang, A., Parkin, D. M., Ferlay, J. &amp; Jöckel, K. International uveal melanoma incidence trends in view of a decreasing proportion of morphological verification. <i>Int. J. Cancer</i> <b>114</b>, 114–123 (2005).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1002%2Fijc.20690" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1002/ijc.20690" data-track-item_id="10.1002/ijc.20690">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2MXhtFCnsL0%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15523698" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=International%20uveal%20melanoma%20incidence%20trends%20in%20view%20of%20a%20decreasing%20proportion%20of%20morphological%20verification&amp;journal=Int.%20J.%20Cancer&amp;doi=10.1002%2Fijc.20690&amp;volume=114&amp;pages=114-123&amp;publication_year=2005&amp;author=Stang%2CA&amp;author=Parkin%2CDM&amp;author=Ferlay%2CJ&amp;author=J%C3%B6ckel%2CK" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR3">Virgili, G. et al. Incidence of uveal melanoma in Europe. <i>Ophthalmology</i> <b>114</b>, 2309–2315 (2007).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.ophtha.2007.01.032" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.ophtha.2007.01.032" data-track-item_id="10.1016/j.ophtha.2007.01.032">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17498805" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Incidence%20of%20uveal%20melanoma%20in%20Europe&amp;journal=Ophthalmology&amp;doi=10.1016%2Fj.ophtha.2007.01.032&amp;volume=114&amp;pages=2309-2315&amp;publication_year=2007&amp;author=Virgili%2CG" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR4">Kujala, E., Makitie, T. &amp; Kivela, T. Very long-term prognosis of patients with malignant uveal melanoma. <i>Invest. Ophthalmol. Vis. Sci.</i> <b>44</b>, 4651–4659 (2003).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1167%2Fiovs.03-0538" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1167/iovs.03-0538" data-track-item_id="10.1167/iovs.03-0538">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=14578381" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Very%20long-term%20prognosis%20of%20patients%20with%20malignant%20uveal%20melanoma&amp;journal=Invest.%20Ophthalmol.%20Vis.%20Sci.&amp;doi=10.1167%2Fiovs.03-0538&amp;volume=44&amp;pages=4651-4659&amp;publication_year=2003&amp;author=Kujala%2CE&amp;author=Makitie%2CT&amp;author=Kivela%2CT" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR5">Singh, M., Durairaj, P. &amp; Yeung, J. Uveal melanoma: a review of the literature. <i>Oncol. Ther.</i> <b>6</b>, 87–104 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1007/s40487-018-0056-8" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1007/s40487-018-0056-8" data-track-item_id="10.1007/s40487-018-0056-8">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32700136" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7359963" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Uveal%20melanoma%3A%20a%20review%20of%20the%20literature&amp;journal=Oncol.%20Ther.&amp;doi=10.1007%2Fs40487-018-0056-8&amp;volume=6&amp;pages=87-104&amp;publication_year=2018&amp;author=Singh%2CM&amp;author=Durairaj%2CP&amp;author=Yeung%2CJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR6">Yang, J., Manson, D. K., Marr, B. P. &amp; Carvajal, R. D. Treatment of uveal melanoma: where are we now? <i>Ther. Adv. Med. Oncol.</i> <b>10</b>, 1758834018757175 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1177%2F1758834018757175" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1177/1758834018757175" data-track-item_id="10.1177/1758834018757175">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29497459" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824910" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Treatment%20of%20uveal%20melanoma%3A%20where%20are%20we%20now%3F&amp;journal=Ther.%20Adv.%20Med.%20Oncol.&amp;doi=10.1177%2F1758834018757175&amp;volume=10&amp;publication_year=2018&amp;author=Yang%2CJ&amp;author=Manson%2CDK&amp;author=Marr%2CBP&amp;author=Carvajal%2CRD" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR7">Carvajal, R. D. et al. Metastatic disease from uveal melanoma: treatment options and future prospects. <i>Br. J. Ophthalmol.</i> <b>101</b>, 38–44 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1136%2Fbjophthalmol-2016-309034" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1136/bjophthalmol-2016-309034" data-track-item_id="10.1136/bjophthalmol-2016-309034">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27574175" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Metastatic%20disease%20from%20uveal%20melanoma%3A%20treatment%20options%20and%20future%20prospects&amp;journal=Br.%20J.%20Ophthalmol.&amp;doi=10.1136%2Fbjophthalmol-2016-309034&amp;volume=101&amp;pages=38-44&amp;publication_year=2017&amp;author=Carvajal%2CRD" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR8">Harbour, J. W. et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. <i>Science</i> <b>330</b>, 1410–1413 (2010).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1126%2Fscience.1194472" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1126/science.1194472" data-track-item_id="10.1126/science.1194472">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3cXhsVyrsbbI" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21051595" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3087380" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Frequent%20mutation%20of%20BAP1%20in%20metastasizing%20uveal%20melanomas&amp;journal=Science&amp;doi=10.1126%2Fscience.1194472&amp;volume=330&amp;pages=1410-1413&amp;publication_year=2010&amp;author=Harbour%2CJW" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR9">Karlsson, J. et al. Molecular profiling of driver events in metastatic uveal melanoma. <i>Nat. Commun.</i> <b>11</b>, 1894 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41467-020-15606-0" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41467-020-15606-0" data-track-item_id="10.1038/s41467-020-15606-0">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXnsFSksbw%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32313009" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171146" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Molecular%20profiling%20of%20driver%20events%20in%20metastatic%20uveal%20melanoma&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fs41467-020-15606-0&amp;volume=11&amp;publication_year=2020&amp;author=Karlsson%2CJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR10">Martin, M. et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. <i>Nat. Genet.</i> <b>45</b>, 933–936 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fng.2674" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/ng.2674" data-track-item_id="10.1038/ng.2674">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXpvVyrt7c%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23793026" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307600" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Exome%20sequencing%20identifies%20recurrent%20somatic%20mutations%20in%20EIF1AX%20and%20SF3B1%20in%20uveal%20melanoma%20with%20disomy%203&amp;journal=Nat.%20Genet.&amp;doi=10.1038%2Fng.2674&amp;volume=45&amp;pages=933-936&amp;publication_year=2013&amp;author=Martin%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR11">Johnson, C. P. et al. Systematic genomic and translational efficiency studies of uveal melanoma. <i>PLoS One</i> <b>12</b>, e0178189 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1371%2Fjournal.pone.0178189" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1371/journal.pone.0178189" data-track-item_id="10.1371/journal.pone.0178189">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28594900" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5464544" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Systematic%20genomic%20and%20translational%20efficiency%20studies%20of%20uveal%20melanoma&amp;journal=PLoS%20One&amp;doi=10.1371%2Fjournal.pone.0178189&amp;volume=12&amp;publication_year=2017&amp;author=Johnson%2CCP" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR12">Javed, A. et al. PD-L1 expression in tumor metastasis is different between uveal melanoma and cutaneous melanoma. <i>Immunotherapy</i> <b>9</b>, 1323–1330 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.2217%2Fimt-2017-0066" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.2217/imt-2017-0066" data-track-item_id="10.2217/imt-2017-0066">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhvVOit7nL" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29185395" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=PD-L1%20expression%20in%20tumor%20metastasis%20is%20different%20between%20uveal%20melanoma%20and%20cutaneous%20melanoma&amp;journal=Immunotherapy&amp;doi=10.2217%2Fimt-2017-0066&amp;volume=9&amp;pages=1323-1330&amp;publication_year=2017&amp;author=Javed%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR13">Nathan, P. et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. <i>N. Engl. J. Med.</i> <b>385</b>, 1196–1206 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa2103485" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa2103485" data-track-item_id="10.1056/NEJMoa2103485">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXitV2ksbbE" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34551229" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Overall%20survival%20benefit%20with%20tebentafusp%20in%20metastatic%20uveal%20melanoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa2103485&amp;volume=385&amp;pages=1196-1206&amp;publication_year=2021&amp;author=Nathan%2CP" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR14">Carvajal, R. D. et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. <i>JAMA</i> <b>311</b>, 2397–2405 (2014).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1001%2Fjama.2014.6096" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1001/jama.2014.6096" data-track-item_id="10.1001/jama.2014.6096">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24938562" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4249701" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Effect%20of%20selumetinib%20vs%20chemotherapy%20on%20progression-free%20survival%20in%20uveal%20melanoma%3A%20a%20randomized%20clinical%20trial&amp;journal=JAMA&amp;doi=10.1001%2Fjama.2014.6096&amp;volume=311&amp;pages=2397-2405&amp;publication_year=2014&amp;author=Carvajal%2CRD" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR15">Pelster, M. S. et al. Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study. <i>J. Clin. Oncol.</i> <b>39</b>, 599–607 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2FJCO.20.00605" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/JCO.20.00605" data-track-item_id="10.1200/JCO.20.00605">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XhslKlsLw%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33125309" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Nivolumab%20and%20ipilimumab%20in%20metastatic%20uveal%20melanoma%3A%20results%20from%20a%20single-arm%20phase%20II%20study&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.20.00605&amp;volume=39&amp;pages=599-607&amp;publication_year=2021&amp;author=Pelster%2CMS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR16">Piulats, J. M. et al. Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). <i>J. Clin. Oncol.</i> <b>39</b>, 586–598 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2FJCO.20.00550" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/JCO.20.00550" data-track-item_id="10.1200/JCO.20.00550">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XhslKlsL8%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33417511" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Nivolumab%20plus%20ipilimumab%20for%20treatment-na%C3%AFve%20metastatic%20uveal%20melanoma%3A%20an%20open-label%2C%20multicenter%2C%20phase%20II%20trial%20by%20the%20Spanish%20Multidisciplinary%20Melanoma%20Group%20%28GEM-1402%29&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.20.00550&amp;volume=39&amp;pages=586-598&amp;publication_year=2021&amp;author=Piulats%2CJM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR17">Khoja, L. et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an International Rare Cancers Initiative (IRCI) ocular melanoma study. <i>Ann. Oncol.</i> <b>30</b>, 1370–1380 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fannonc%2Fmdz176" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/annonc/mdz176" data-track-item_id="10.1093/annonc/mdz176">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BB3M3hvVOgug%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31150059" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Meta-analysis%20in%20metastatic%20uveal%20melanoma%20to%20determine%20progression%20free%20and%20overall%20survival%20benchmarks%3A%20an%20International%20Rare%20Cancers%20Initiative%20%28IRCI%29%20ocular%20melanoma%20study&amp;journal=Ann.%20Oncol.&amp;doi=10.1093%2Fannonc%2Fmdz176&amp;volume=30&amp;pages=1370-1380&amp;publication_year=2019&amp;author=Khoja%2CL" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR18">Rantala, E. S., Hernberg, M. &amp; Kivelä, T. T. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. <i>Melanoma Res.</i> <b>29</b>, 561–568 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1097%2FCMR.0000000000000575" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1097/CMR.0000000000000575" data-track-item_id="10.1097/CMR.0000000000000575">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30664106" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887637" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Overall%20survival%20after%20treatment%20for%20metastatic%20uveal%20melanoma%3A%20a%20systematic%20review%20and%20meta-analysis&amp;journal=Melanoma%20Res.&amp;doi=10.1097%2FCMR.0000000000000575&amp;volume=29&amp;pages=561-568&amp;publication_year=2019&amp;author=Rantala%2CES&amp;author=Hernberg%2CM&amp;author=Kivel%C3%A4%2CTT" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR19">Bossi, G., Buisson, S., Oates, J., Jakobsen, B. K. &amp; Hassan, N. J. ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells. <i>Cancer Immunol. Immunother.</i> <b>63</b>, 437–448 (2014).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1007/s00262-014-1525-z" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1007/s00262-014-1525-z" data-track-item_id="10.1007/s00262-014-1525-z">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXis1Siurg%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24531387" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=ImmTAC-redirected%20tumour%20cell%20killing%20induces%20and%20potentiates%20antigen%20cross-presentation%20by%20dendritic%20cells&amp;journal=Cancer%20Immunol.%20Immunother.&amp;doi=10.1007%2Fs00262-014-1525-z&amp;volume=63&amp;pages=437-448&amp;publication_year=2014&amp;author=Bossi%2CG&amp;author=Buisson%2CS&amp;author=Oates%2CJ&amp;author=Jakobsen%2CBK&amp;author=Hassan%2CNJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR20">Liddy, N. et al. Monoclonal TCR-redirected tumor cell killing. <i>Nat. Med.</i> <b>18</b>, 980–987 (2012).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnm.2764" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nm.2764" data-track-item_id="10.1038/nm.2764">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XmsFyjtrg%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22561687" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Monoclonal%20TCR-redirected%20tumor%20cell%20killing&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fnm.2764&amp;volume=18&amp;pages=980-987&amp;publication_year=2012&amp;author=Liddy%2CN" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR21">Middleton, M. R. et al. Tebentafusp, a TCR/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma. <i>Clin. Cancer Res.</i> <b>26</b>, 5869–5878 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F1078-0432.CCR-20-1247" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/1078-0432.CCR-20-1247" data-track-item_id="10.1158/1078-0432.CCR-20-1247">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXis1equrjF" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32816891" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210997" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Tebentafusp%2C%20a%20TCR%2Fanti-CD3%20bispecific%20fusion%20protein%20targeting%20gp100%2C%20potently%20activated%20antitumor%20immune%20responses%20in%20patients%20with%20metastatic%20melanoma&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-20-1247&amp;volume=26&amp;pages=5869-5878&amp;publication_year=2020&amp;author=Middleton%2CMR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR22">Boudousquie, C. et al. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8<sup>+</sup> and CD4<sup>+</sup> T cells. <i>Immunology</i> <b>152</b>, 425–438 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1111%2Fimm.12779" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1111/imm.12779" data-track-item_id="10.1111/imm.12779">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXht1GiurvI" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28640942" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629433" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Polyfunctional%20response%20by%20ImmTAC%20%28IMCgp100%29%20redirected%20CD8%2B%20and%20CD4%2B%20T%20cells&amp;journal=Immunology&amp;doi=10.1111%2Fimm.12779&amp;volume=152&amp;pages=425-438&amp;publication_year=2017&amp;author=Boudousquie%2CC" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR23">Middleton, M. R. et al. Abstract CT106: a phase I/IIa study of IMCgp100: partial and complete durable responses with a novel first-in-class immunotherapy for advanced melanoma. <i>Clin. Trials</i> <b>75</b>, CT106 (2015).</p><p class="c-reading-companion__reference-links"><a href="http://scholar.google.com/scholar_lookup?&amp;title=Abstract%20CT106%3A%20a%20phase%20I%2FIIa%20study%20of%20IMCgp100%3A%20partial%20and%20complete%20durable%20responses%20with%20a%20novel%20first-in-class%20immunotherapy%20for%20advanced%20melanoma&amp;journal=Clin.%20Trials&amp;volume=75&amp;publication_year=2015&amp;author=Middleton%2CMR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR24">Middleton, M. R. et al. Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific T cell redirector with solid tumour activity: results from the FIH study in melanoma (Abstract 3016). <i>J. Clin. Oncol.</i> <b>34</b>(15 Suppl.), 3016 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2FJCO.2016.34.15_suppl.3016" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/JCO.2016.34.15_suppl.3016" data-track-item_id="10.1200/JCO.2016.34.15_suppl.3016">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Safety%2C%20pharmacokinetics%20and%20efficacy%20of%20IMCgp100%2C%20a%20first-in-class%20soluble%20TCR-antiCD3%20bispecific%20T%20cell%20redirector%20with%20solid%20tumour%20activity%3A%20results%20from%20the%20FIH%20study%20in%20melanoma%20%28Abstract%203016%29&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2016.34.15_suppl.3016&amp;volume=34&amp;issue=15%20Suppl.&amp;publication_year=2016&amp;author=Middleton%2CMR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR25">Carvajal, R. et al. Safety, efficacy and biology of the gp100 TCR-based bispecific T cell redirector, IMCgp100 in advanced uveal melanoma in two Phase 1 trials (Poster 208). <i>J. Immunother. Cancer</i> <b>5</b>(Suppl. 2), P208 (2017).</p><p class="c-reading-companion__reference-links"><a href="http://scholar.google.com/scholar_lookup?&amp;title=Safety%2C%20efficacy%20and%20biology%20of%20the%20gp100%20TCR-based%20bispecific%20T%20cell%20redirector%2C%20IMCgp100%20in%20advanced%20uveal%20melanoma%20in%20two%20Phase%201%20trials%20%28Poster%20208%29&amp;journal=J.%20Immunother.%20Cancer&amp;volume=5&amp;issue=Suppl.%202&amp;publication_year=2017&amp;author=Carvajal%2CR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR26">Sato, T. et al. Intra-patient escalation dosing strategy with IMCgp100 results in mitigation of T-cell based toxicity and preliminary efficacy in advanced uveal melanoma (Abstract 9531). <i>J. Clin. Oncol.</i> <b>35</b>(15 Suppl.), 9531 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2FJCO.2017.35.15_suppl.9531" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/JCO.2017.35.15_suppl.9531" data-track-item_id="10.1200/JCO.2017.35.15_suppl.9531">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Intra-patient%20escalation%20dosing%20strategy%20with%20IMCgp100%20results%20in%20mitigation%20of%20T-cell%20based%20toxicity%20and%20preliminary%20efficacy%20in%20advanced%20uveal%20melanoma%20%28Abstract%209531%29&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2017.35.15_suppl.9531&amp;volume=35&amp;issue=15%20Suppl.&amp;publication_year=2017&amp;author=Sato%2CT" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR27">Carvajal, R. D. et al. Phase I study of safety, tolerability, and efficacy of tebentafusp using a step-up dosing regimen and expansion in patients with metastatic uveal melanoma. <i>J. Clin. Oncol.</i> <b>40</b>, 1939–1948 (2022).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2FJCO.21.01805" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/JCO.21.01805" data-track-item_id="10.1200/JCO.21.01805">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XhsVOmtb%2FJ" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35254876" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177239" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%20I%20study%20of%20safety%2C%20tolerability%2C%20and%20efficacy%20of%20tebentafusp%20using%20a%20step-up%20dosing%20regimen%20and%20expansion%20in%20patients%20with%20metastatic%20uveal%20melanoma&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.21.01805&amp;volume=40&amp;pages=1939-1948&amp;publication_year=2022&amp;author=Carvajal%2CRD" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR28">O’Day, S. et al. A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma (Abstract 4). <i>J. Clin. Oncol.</i> <b>28</b>(18 Suppl.), 4 (2010).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2Fjco.2010.28.18_suppl.4" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/jco.2010.28.18_suppl.4" data-track-item_id="10.1200/jco.2010.28.18_suppl.4">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=A%20phase%20III%2C%20randomized%2C%20double-blind%2C%20multicenter%20study%20comparing%20monotherapy%20with%20ipilimumab%20or%20gp100%20peptide%20vaccine%20and%20the%20combination%20in%20patients%20with%20previously%20treated%2C%20unresectable%20stage%20III%20or%20IV%20melanoma%20%28Abstract%204%29&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2Fjco.2010.28.18_suppl.4&amp;volume=28&amp;issue=18%20Suppl.&amp;publication_year=2010&amp;author=O%E2%80%99Day%2CS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR29">Hodi, F. S. et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. <i>J. Clin. Oncol.</i> <b>34</b>, 1510–1517 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2FJCO.2015.64.0391" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/JCO.2015.64.0391" data-track-item_id="10.1200/JCO.2015.64.0391">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXisFWjtr8%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26951310" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070547" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Evaluation%20of%20immune-related%20response%20criteria%20and%20RECIST%20v1.1%20in%20patients%20with%20advanced%20melanoma%20treated%20with%20pembrolizumab&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2015.64.0391&amp;volume=34&amp;pages=1510-1517&amp;publication_year=2016&amp;author=Hodi%2CFS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR30">Raja, R. et al. Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab. <i>Clin. Cancer Res.</i> <b>24</b>, 6212–6222 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F1078-0432.CCR-18-0386" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/1078-0432.CCR-18-0386" data-track-item_id="10.1158/1078-0432.CCR-18-0386">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXht1ait7rN" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30093454" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Early%20reduction%20in%20ctDNA%20predicts%20survival%20in%20patients%20with%20lung%20and%20bladder%20cancer%20treated%20with%20durvalumab&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-18-0386&amp;volume=24&amp;pages=6212-6222&amp;publication_year=2018&amp;author=Raja%2CR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR31">Goldberg, S. B. et al. Early assessment of lung cancer immunotherapy response via circulating tumor DNA. <i>Clin. Cancer Res.</i> <b>24</b>, 1872–1880 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F1078-0432.CCR-17-1341" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/1078-0432.CCR-17-1341" data-track-item_id="10.1158/1078-0432.CCR-17-1341">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXnslKmu7Y%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29330207" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5899677" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Early%20assessment%20of%20lung%20cancer%20immunotherapy%20response%20via%20circulating%20tumor%20DNA&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-17-1341&amp;volume=24&amp;pages=1872-1880&amp;publication_year=2018&amp;author=Goldberg%2CSB" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR32">Zou, W. et al. ctDNA predicts overall survival in patients with NSCLC treated with PD-L1 blockade or with chemotherapy. <i>JCO Precis. Oncol.</i> <b>5</b>, 827–838 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2FPO.21.00057" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/PO.21.00057" data-track-item_id="10.1200/PO.21.00057">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=34994614" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=ctDNA%20predicts%20overall%20survival%20in%20patients%20with%20NSCLC%20treated%20with%20PD-L1%20blockade%20or%20with%20chemotherapy&amp;journal=JCO%20Precis.%20Oncol.&amp;doi=10.1200%2FPO.21.00057&amp;volume=5&amp;pages=827-838&amp;publication_year=2021&amp;author=Zou%2CW" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR33">Vandekerkhove, G. et al. Plasma ctDNA is a tumor tissue surrogate and enables clinical–genomic stratification of metastatic bladder cancer. <i>Nat. Commun.</i> <b>12</b>, 184 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41467-020-20493-6" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41467-020-20493-6" data-track-item_id="10.1038/s41467-020-20493-6">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXht1Smu7c%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33420073" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794518" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Plasma%20ctDNA%20is%20a%20tumor%20tissue%20surrogate%20and%20enables%20clinical%E2%80%93genomic%20stratification%20of%20metastatic%20bladder%20cancer&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fs41467-020-20493-6&amp;volume=12&amp;publication_year=2021&amp;author=Vandekerkhove%2CG" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR34">Lee, J. H. et al. Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies. <i>JAMA Oncol.</i> <b>4</b>, 717–721 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1001%2Fjamaoncol.2017.5332" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1001/jamaoncol.2017.5332" data-track-item_id="10.1001/jamaoncol.2017.5332">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29423503" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5885201" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Association%20between%20circulating%20tumor%20DNA%20and%20pseudoprogression%20in%20patients%20with%20metastatic%20melanoma%20treated%20with%20anti-programmed%20cell%20death%201%20antibodies&amp;journal=JAMA%20Oncol.&amp;doi=10.1001%2Fjamaoncol.2017.5332&amp;volume=4&amp;pages=717-721&amp;publication_year=2018&amp;author=Lee%2CJH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR35">Bratman, S. V. et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. <i>Nat. Cancer</i> <b>1</b>, 873–881 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs43018-020-0096-5" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s43018-020-0096-5" data-track-item_id="10.1038/s43018-020-0096-5">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB38XjsFeisLg%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=35121950" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Personalized%20circulating%20tumor%20DNA%20analysis%20as%20a%20predictive%20biomarker%20in%20solid%20tumor%20patients%20treated%20with%20pembrolizumab&amp;journal=Nat.%20Cancer&amp;doi=10.1038%2Fs43018-020-0096-5&amp;volume=1&amp;pages=873-881&amp;publication_year=2020&amp;author=Bratman%2CSV" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR36">Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. <i>Nat. Rev. Cancer</i> <b>12</b>, 252–264 (2012).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnrc3239" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nrc3239" data-track-item_id="10.1038/nrc3239">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC38XksVegtrw%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=22437870" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856023" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20blockade%20of%20immune%20checkpoints%20in%20cancer%20immunotherapy&amp;journal=Nat.%20Rev.%20Cancer&amp;doi=10.1038%2Fnrc3239&amp;volume=12&amp;pages=252-264&amp;publication_year=2012&amp;author=Pardoll%2CDM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR37">Wolchok, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. <i>Clin. Cancer Res.</i> <b>15</b>, 7412–7420 (2009).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F1078-0432.CCR-09-1624" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/1078-0432.CCR-09-1624" data-track-item_id="10.1158/1078-0432.CCR-09-1624">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1MXhsFSnu7vN" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19934295" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Guidelines%20for%20the%20evaluation%20of%20immune%20therapy%20activity%20in%20solid%20tumors%3A%20immune-related%20response%20criteria&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-09-1624&amp;volume=15&amp;pages=7412-7420&amp;publication_year=2009&amp;author=Wolchok%2CJD" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR38">Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). <i>Eur. J. Cancer</i> <b>45</b>, 228–247 (2009).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.ejca.2008.10.026" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.ejca.2008.10.026" data-track-item_id="10.1016/j.ejca.2008.10.026">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:STN:280:DC%2BD1M%2Fgs12rug%3D%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19097774" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=New%20response%20evaluation%20criteria%20in%20solid%20tumours%3A%20revised%20RECIST%20guideline%20%28version%201.1%29&amp;journal=Eur.%20J.%20Cancer&amp;doi=10.1016%2Fj.ejca.2008.10.026&amp;volume=45&amp;pages=228-247&amp;publication_year=2009&amp;author=Eisenhauer%2CEA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR39">Bohnsack, O., Hoos, A. &amp; Ludajic, K. Adaptation and modification of the immune related response criteria (IRRC): IrRECIST (Abstract e22121). <i>J. Clin. Oncol.</i> <b>32</b>(15 Suppl.), e22121 (2014).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2Fjco.2014.32.15_suppl.e22121" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/jco.2014.32.15_suppl.e22121" data-track-item_id="10.1200/jco.2014.32.15_suppl.e22121">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Adaptation%20and%20modification%20of%20the%20immune%20related%20response%20criteria%20%28IRRC%29%3A%20IrRECIST%20%28Abstract%20e22121%29&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2Fjco.2014.32.15_suppl.e22121&amp;volume=32&amp;issue=15%20Suppl.&amp;publication_year=2014&amp;author=Bohnsack%2CO&amp;author=Hoos%2CA&amp;author=Ludajic%2CK" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR40">Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. <i>Biol. Blood Marrow Transplant.</i> <b>25</b>, 625–638 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.bbmt.2018.12.758" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.bbmt.2018.12.758" data-track-item_id="10.1016/j.bbmt.2018.12.758">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhs1aksbw%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30592986" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=ASTCT%20consensus%20grading%20for%20cytokine%20release%20syndrome%20and%20neurologic%20toxicity%20associated%20with%20immune%20effector%20cells&amp;journal=Biol.%20Blood%20Marrow%20Transplant.&amp;doi=10.1016%2Fj.bbmt.2018.12.758&amp;volume=25&amp;pages=625-638&amp;publication_year=2019&amp;author=Lee%2CDW" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR41">Zhang, Q. et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. <i>Cancer Discov.</i> <b>10</b>, 1842–1853 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2159-8290.CD-20-0047" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2159-8290.CD-20-0047" data-track-item_id="10.1158/2159-8290.CD-20-0047">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXktFWisL0%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32816849" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358981" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Prognostic%20and%20predictive%20impact%20of%20circulating%20tumor%20DNA%20in%20patients%20with%20advanced%20cancers%20treated%20with%20immune%20checkpoint%20blockade&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-20-0047&amp;volume=10&amp;pages=1842-1853&amp;publication_year=2020&amp;author=Zhang%2CQ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR42">Chiou, V. L. &amp; Burotto, M. Pseudoprogression and immune-related response in solid tumors. <i>J. Clin. Oncol.</i> <b>33</b>, 3541–3543 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2FJCO.2015.61.6870" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/JCO.2015.61.6870" data-track-item_id="10.1200/JCO.2015.61.6870">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XhtVakt7%2FL" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26261262" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622096" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Pseudoprogression%20and%20immune-related%20response%20in%20solid%20tumors&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2015.61.6870&amp;volume=33&amp;pages=3541-3543&amp;publication_year=2015&amp;author=Chiou%2CVL&amp;author=Burotto%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR43">Giacomo, A. M. D. et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. <i>Cancer Immunol. Immunother.</i> <b>58</b>, 1297–1306 (2009).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1007/s00262-008-0642-y" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1007/s00262-008-0642-y" data-track-item_id="10.1007/s00262-008-0642-y">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=19139884" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Therapeutic%20efficacy%20of%20ipilimumab%2C%20an%20anti-CTLA-4%20monoclonal%20antibody%2C%20in%20patients%20with%20metastatic%20melanoma%20unresponsive%20to%20prior%20systemic%20treatments%3A%20clinical%20and%20immunological%20evidence%20from%20three%20patient%20cases&amp;journal=Cancer%20Immunol.%20Immunother.&amp;doi=10.1007%2Fs00262-008-0642-y&amp;volume=58&amp;pages=1297-1306&amp;publication_year=2009&amp;author=Giacomo%2CAMD" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR44">Butler, M. O. et al. Abstract 517: Tebentafusp induces transient systemic inflammation and modifies the micro-environment to sensitize uveal melanoma tumors to cytotoxic CD8 cells. <i>Cancer Res.</i> <b>81</b>(13 Suppl.), 517 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F1538-7445.AM2021-517" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/1538-7445.AM2021-517" data-track-item_id="10.1158/1538-7445.AM2021-517">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Abstract%20517%3A%20Tebentafusp%20induces%20transient%20systemic%20inflammation%20and%20modifies%20the%20micro-environment%20to%20sensitize%20uveal%20melanoma%20tumors%20to%20cytotoxic%20CD8%20cells&amp;journal=Cancer%20Res.&amp;doi=10.1158%2F1538-7445.AM2021-517&amp;volume=81&amp;issue=13%20Suppl.&amp;publication_year=2021&amp;author=Butler%2CMO" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR45">Beylergil, V. et al. Abstract 819: Radiomic markers associated with clinical benefit in advanced uveal melanoma patients with radiographic progression on tebentafusp. <i>J. Immunother. Cancer</i> <b>9</b>(2 Suppl.), 819 (2021).</p><p class="c-reading-companion__reference-links"><a href="http://scholar.google.com/scholar_lookup?&amp;title=Abstract%20819%3A%20Radiomic%20markers%20associated%20with%20clinical%20benefit%20in%20advanced%20uveal%20melanoma%20patients%20with%20radiographic%20progression%20on%20tebentafusp&amp;journal=J.%20Immunother.%20Cancer&amp;volume=9&amp;issue=2%20Suppl.&amp;publication_year=2021&amp;author=Beylergil%2CV" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR46">Dercle, L. et al. Identification of non-small cell lung cancer sensitive to systemic cancer therapies using radiomics. <i>Clin. Cancer Res.</i> <b>26</b>, 2151–2162 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F1078-0432.CCR-19-2942" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/1078-0432.CCR-19-2942" data-track-item_id="10.1158/1078-0432.CCR-19-2942">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXitVyktb%2FI" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32198149" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239371" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Identification%20of%20non-small%20cell%20lung%20cancer%20sensitive%20to%20systemic%20cancer%20therapies%20using%20radiomics&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-19-2942&amp;volume=26&amp;pages=2151-2162&amp;publication_year=2020&amp;author=Dercle%2CL" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR47">Keller, L., Belloum, Y., Wikman, H. &amp; Pantel, K. Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond. <i>Br. J. Cancer</i> <b>124</b>, 345–358 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41416-020-01047-5" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41416-020-01047-5" data-track-item_id="10.1038/s41416-020-01047-5">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32968207" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Clinical%20relevance%20of%20blood-based%20ctDNA%20analysis%3A%20mutation%20detection%20and%20beyond&amp;journal=Br.%20J.%20Cancer&amp;doi=10.1038%2Fs41416-020-01047-5&amp;volume=124&amp;pages=345-358&amp;publication_year=2021&amp;author=Keller%2CL&amp;author=Belloum%2CY&amp;author=Wikman%2CH&amp;author=Pantel%2CK" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR48">Robertson, A. G. et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. <i>Cancer Cell</i> <b>32</b>, 204–220 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.ccell.2017.07.003" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.ccell.2017.07.003" data-track-item_id="10.1016/j.ccell.2017.07.003">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhtlClsbnJ" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28810145" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5619925" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Integrative%20analysis%20identifies%20four%20molecular%20and%20clinical%20subsets%20in%20uveal%20melanoma&amp;journal=Cancer%20Cell&amp;doi=10.1016%2Fj.ccell.2017.07.003&amp;volume=32&amp;pages=204-220&amp;publication_year=2017&amp;author=Robertson%2CAG" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR49">Shain, A. H. et al. The genetic evolution of metastatic uveal melanoma. <i>Nat. Genet.</i> <b>51</b>, 1123–1130 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41588-019-0440-9" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41588-019-0440-9" data-track-item_id="10.1038/s41588-019-0440-9">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXht1yktL7F" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31253977" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6632071" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20genetic%20evolution%20of%20metastatic%20uveal%20melanoma&amp;journal=Nat.%20Genet.&amp;doi=10.1038%2Fs41588-019-0440-9&amp;volume=51&amp;pages=1123-1130&amp;publication_year=2019&amp;author=Shain%2CAH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR50">Imbens, G. W. Nonparametric estimation of average treatment effects under exogeneity: a review. <i>Rev. Econ. Stat.</i> <b>86</b>, 4–29 (2004).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1162%2F003465304323023651" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1162/003465304323023651" data-track-item_id="10.1162/003465304323023651">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Nonparametric%20estimation%20of%20average%20treatment%20effects%20under%20exogeneity%3A%20a%20review&amp;journal=Rev.%20Econ.%20Stat.&amp;doi=10.1162%2F003465304323023651&amp;volume=86&amp;pages=4-29&amp;publication_year=2004&amp;author=Imbens%2CGW" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li></ol></div></div>
        </div>
    </div>
</aside>
</div>


    
        
    
    
        
            
        

        
            
        
    
    <script>
        window.dataLayer = window.dataLayer || [];
        window.dataLayer.push({
            page: {
                content: {
                    fundingWidget: "true",
                        }
                    }
                });
    </script>




<footer class="composite-layer" itemscope="" itemtype="http://schema.org/Periodical">
        <meta itemprop="publisher" content="Springer Nature">
        

        <div class="u-mt-16 u-mb-16">
    <div class="u-container">
        <div class="u-display-flex u-flex-wrap u-justify-content-space-between">
            

            <div class="c-meta u-ma-0 u-flex-shrink">
                <p class="c-meta__item c-meta__type u-mt-0">
                    <span itemprop="name">
                        Nature Medicine
                    </span>
                    (<i itemprop="alternateName">Nat Med</i>)
                </p>
                
    
        <p class="c-meta__item u-mt-0">
            <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop="issn">1546-170X</span> (online)
        </p>
    

                
    
        <p class="c-meta__item u-mt-0">
            <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop="issn">1078-8956</span> (print)
        </p>
    

            </div>
        </div>
    </div>
</div>

    <div class="c-footer">
        <div class="u-hide-print" data-track-component="footer">
    <h2 class="u-visually-hidden">nature.com sitemap</h2>
    <div class="c-footer__container">
        <div class="c-footer__grid c-footer__group--separator">
            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">About Nature Portfolio</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/npg_/company_info/index.html" data-track="click" data-track-action="about us" data-track-label="link">About us</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/npg_/press_room/press_releases.html" data-track="click" data-track-action="press releases" data-track-label="link">Press releases</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://press.nature.com/" data-track="click" data-track-action="press office" data-track-label="link">Press office</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://support.nature.com/support/home" data-track="click" data-track-action="contact us" data-track-label="link">Contact us</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Discover content</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/siteindex" data-track="click" data-track-action="journals a-z" data-track-label="link">Journals A-Z</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/subjects" data-track="click" data-track-action="article by subject" data-track-label="link">Articles by subject</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.protocols.io/" data-track="click" data-track-action="protocols.io" data-track-label="link">protocols.io</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.natureindex.com/" data-track="click" data-track-action="nature index" data-track-label="link">Nature Index</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Publishing policies</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/authors/editorial_policies" data-track="click" data-track-action="Nature portfolio policies" data-track-label="link">Nature portfolio policies</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nature-research/open-access" data-track="click" data-track-action="open access" data-track-label="link">Open access</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Author &amp; Researcher services</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/reprints" data-track="click" data-track-action="reprints and permissions" data-track-label="link">Reprints &amp; permissions</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/authors/research-data" data-track="click" data-track-action="data research service" data-track-label="link">Research data</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://authorservices.springernature.com/language-editing/" data-track="click" data-track-action="language editing" data-track-label="link">Language editing</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://authorservices.springernature.com/scientific-editing/" data-track="click" data-track-action="scientific editing" data-track-label="link">Scientific editing</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://masterclasses.nature.com/" data-track="click" data-track-action="nature masterclasses" data-track-label="link">Nature Masterclasses</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://solutions.springernature.com/" data-track="click" data-track-action="research solutions" data-track-label="link">Research Solutions</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Libraries &amp; institutions</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/tools-services" data-track="click" data-track-action="librarian service and tools" data-track-label="link">Librarian service &amp; tools</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/manage-your-account/librarianportal" data-track="click" data-track-action="librarian portal" data-track-label="link">Librarian portal</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/openresearch/about-open-access/information-for-institutions" data-track="click" data-track-action="open research" data-track-label="link">Open research</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/recommend-to-your-library" data-track="click" data-track-action="Recommend to library" data-track-label="link">Recommend to library</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Advertising &amp; partnerships</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/product/digital-advertising/" data-track="click" data-track-action="advertising" data-track-label="link">Advertising</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/" data-track="click" data-track-action="partnerships and services" data-track-label="link">Partnerships &amp; Services</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/media-kits/" data-track="click" data-track-action="media kits" data-track-label="link">Media kits</a>
                    </li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/product/branded-content-native-advertising/" data-track-action="branded content" data-track-label="link">Branded
                        content</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Professional development</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/naturecareers/" data-track="click" data-track-action="nature careers" data-track-label="link">Nature Careers</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://conferences.nature.com" data-track="click" data-track-action="nature conferences" data-track-label="link">Nature<span class="u-visually-hidden"> </span>
                        Conferences</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Regional websites</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/natafrica" data-track="click" data-track-action="nature africa" data-track-label="link">Nature Africa</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="http://www.naturechina.com" data-track="click" data-track-action="nature china" data-track-label="link">Nature China</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nindia" data-track="click" data-track-action="nature india" data-track-label="link">Nature India</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/natitaly" data-track="click" data-track-action="nature Italy" data-track-label="link">Nature Italy</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.natureasia.com/ja-jp" data-track="click" data-track-action="nature japan" data-track-label="link">Nature Japan</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nmiddleeast" data-track="click" data-track-action="nature middle east" data-track-label="link">Nature Middle East</a></li>
                </ul>
            </div>

        </div>
    </div>
    <div class="c-footer__container">
        <ul class="c-footer__links">
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/privacy" data-track="click" data-track-action="privacy policy" data-track-label="link">Privacy
                Policy</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/cookies" data-track="click" data-track-action="use of cookies" data-track-label="link">Use
                of cookies</a></li>
            <li class="c-footer__item">
                <button class="optanon-toggle-display c-footer__link" onclick="javascript:;" data-cc-action="preferences" data-track="click" data-track-action="manage cookies" data-track-label="link">Your privacy choices/Manage cookies
                </button>
            </li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/legal-notice" data-track="click" data-track-action="legal notice" data-track-label="link">Legal
                notice</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/accessibility-statement" data-track="click" data-track-action="accessibility statement" data-track-label="link">Accessibility
                statement</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/terms-and-conditions" data-track="click" data-track-action="terms and conditions" data-track-label="link">Terms &amp; Conditions</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/ccpa" data-track="click" data-track-action="california privacy statement" data-track-label="link">Your US state privacy rights</a></li>
            
        </ul>
    </div>
</div>


        <div class="c-footer__container">
    <a href="https://www.springernature.com/" class="c-footer__link">
        <img src="/static/images/logos/sn-logo-white-ea63208b81.svg" alt="Springer Nature" loading="lazy" width="200" height="20">
    </a>
    <p class="c-footer__legal" data-test="copyright">© 2025 Springer Nature Limited</p>
</div>

    </div>
    <div class="u-visually-hidden" aria-hidden="true">
    
    <!--?xml version="1.0" encoding="UTF-8"?--><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><defs><path id="a" d="M0 .74h56.72v55.24H0z"></path></defs><symbol id="icon-access" viewBox="0 0 18 18"><path d="m14 8c.5522847 0 1 .44771525 1 1v7h2.5c.2761424 0 .5.2238576.5.5v1.5h-18v-1.5c0-.2761424.22385763-.5.5-.5h2.5v-7c0-.55228475.44771525-1 1-1s1 .44771525 1 1v6.9996556h8v-6.9996556c0-.55228475.4477153-1 1-1zm-8 0 2 1v5l-2 1zm6 0v7l-2-1v-5zm-2.42653766-7.59857636 7.03554716 4.92488299c.4162533.29137735.5174853.86502537.226108 1.28127873-.1721584.24594054-.4534847.39241464-.7536934.39241464h-14.16284822c-.50810197 0-.92-.41189803-.92-.92 0-.30020869.1464741-.58153499.39241464-.75369337l7.03554714-4.92488299c.34432015-.2410241.80260453-.2410241 1.14692468 0zm-.57346234 2.03988748-3.65526982 2.55868888h7.31053962z" fill-rule="evenodd"></path></symbol><symbol id="icon-account" viewBox="0 0 18 18"><path d="m10.2379028 16.9048051c1.3083556-.2032362 2.5118471-.7235183 3.5294683-1.4798399-.8731327-2.5141501-2.0638925-3.935978-3.7673711-4.3188248v-1.27684611c1.1651924-.41183641 2-1.52307546 2-2.82929429 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.30621883.83480763 2.41745788 2 2.82929429v1.27684611c-1.70347856.3828468-2.89423845 1.8046747-3.76737114 4.3188248 1.01762123.7563216 2.22111275 1.2766037 3.52946833 1.4798399.40563808.0629726.81921174.0951949 1.23790281.0951949s.83226473-.0322223 1.2379028-.0951949zm4.3421782-2.1721994c1.4927655-1.4532925 2.419919-3.484675 2.419919-5.7326057 0-4.418278-3.581722-8-8-8s-8 3.581722-8 8c0 2.2479307.92715352 4.2793132 2.41991895 5.7326057.75688473-2.0164459 1.83949951-3.6071894 3.48926591-4.3218837-1.14534283-.70360829-1.90918486-1.96796271-1.90918486-3.410722 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.44275929-.763842 2.70711371-1.9091849 3.410722 1.6497664.7146943 2.7323812 2.3054378 3.4892659 4.3218837zm-5.580081 3.2673943c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-alert" viewBox="0 0 18 18"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-broad" viewBox="0 0 16 16"><path d="m6.10307866 2.97190702v7.69043288l2.44965196-2.44676915c.38776071-.38730439 1.0088052-.39493524 1.38498697-.01919617.38609051.38563612.38643641 1.01053024-.00013864 1.39665039l-4.12239817 4.11754683c-.38616704.3857126-1.01187344.3861062-1.39846576-.0000311l-4.12258206-4.11773056c-.38618426-.38572979-.39254614-1.00476697-.01636437-1.38050605.38609047-.38563611 1.01018509-.38751562 1.4012233.00306241l2.44985644 2.4469734v-8.67638639c0-.54139983.43698413-.98042709.98493125-.98159081l7.89910522-.0043627c.5451687 0 .9871152.44142642.9871152.98595351s-.4419465.98595351-.9871152.98595351z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 14 15)"></path></symbol><symbol id="icon-arrow-down" viewBox="0 0 16 16"><path d="m3.28337502 11.5302405 4.03074001 4.176208c.37758093.3912076.98937525.3916069 1.367372-.0000316l4.03091977-4.1763942c.3775978-.3912252.3838182-1.0190815.0160006-1.4001736-.3775061-.39113013-.9877245-.39303641-1.3700683.003106l-2.39538585 2.4818345v-11.6147896l-.00649339-.11662112c-.055753-.49733869-.46370161-.88337888-.95867408-.88337888-.49497246 0-.90292107.38604019-.95867408.88337888l-.00649338.11662112v11.6147896l-2.39518594-2.4816273c-.37913917-.39282218-.98637524-.40056175-1.35419292-.0194697-.37750607.3911302-.37784433 1.0249269.00013556 1.4165479z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-left" viewBox="0 0 16 16"><path d="m4.46975946 3.28337502-4.17620792 4.03074001c-.39120768.37758093-.39160691.98937525.0000316 1.367372l4.1763942 4.03091977c.39122514.3775978 1.01908149.3838182 1.40017357.0160006.39113012-.3775061.3930364-.9877245-.00310603-1.3700683l-2.48183446-2.39538585h11.61478958l.1166211-.00649339c.4973387-.055753.8833789-.46370161.8833789-.95867408 0-.49497246-.3860402-.90292107-.8833789-.95867408l-.1166211-.00649338h-11.61478958l2.4816273-2.39518594c.39282216-.37913917.40056173-.98637524.01946965-1.35419292-.39113012-.37750607-1.02492687-.37784433-1.41654791.00013556z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-right" viewBox="0 0 16 16"><path d="m11.5302405 12.716625 4.176208-4.03074003c.3912076-.37758093.3916069-.98937525-.0000316-1.367372l-4.1763942-4.03091981c-.3912252-.37759778-1.0190815-.38381821-1.4001736-.01600053-.39113013.37750607-.39303641.98772445.003106 1.37006824l2.4818345 2.39538588h-11.6147896l-.11662112.00649339c-.49733869.055753-.88337888.46370161-.88337888.95867408 0 .49497246.38604019.90292107.88337888.95867408l.11662112.00649338h11.6147896l-2.4816273 2.39518592c-.39282218.3791392-.40056175.9863753-.0194697 1.3541929.3911302.3775061 1.0249269.3778444 1.4165479-.0001355z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-sub" viewBox="0 0 16 16"><path d="m7.89692134 4.97190702v7.69043288l-2.44965196-2.4467692c-.38776071-.38730434-1.0088052-.39493519-1.38498697-.0191961-.38609047.3856361-.38643643 1.0105302.00013864 1.3966504l4.12239817 4.1175468c.38616704.3857126 1.01187344.3861062 1.39846576-.0000311l4.12258202-4.1177306c.3861843-.3857298.3925462-1.0047669.0163644-1.380506-.3860905-.38563612-1.0101851-.38751563-1.4012233.0030624l-2.44985643 2.4469734v-8.67638639c0-.54139983-.43698413-.98042709-.98493125-.98159081l-7.89910525-.0043627c-.54516866 0-.98711517.44142642-.98711517.98595351s.44194651.98595351.98711517.98595351z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-up" viewBox="0 0 16 16"><path d="m12.716625 4.46975946-4.03074003-4.17620792c-.37758093-.39120768-.98937525-.39160691-1.367372.0000316l-4.03091981 4.1763942c-.37759778.39122514-.38381821 1.01908149-.01600053 1.40017357.37750607.39113012.98772445.3930364 1.37006824-.00310603l2.39538588-2.48183446v11.61478958l.00649339.1166211c.055753.4973387.46370161.8833789.95867408.8833789.49497246 0 .90292107-.3860402.95867408-.8833789l.00649338-.1166211v-11.61478958l2.39518592 2.4816273c.3791392.39282216.9863753.40056173 1.3541929.01946965.3775061-.39113012.3778444-1.02492687-.0001355-1.41654791z" fill-rule="evenodd"></path></symbol><symbol id="icon-article" viewBox="0 0 18 18"><path d="m13 15v-12.9906311c0-.0073595-.0019884-.0093689.0014977-.0093689l-11.00158888.00087166v13.00506804c0 .5482678.44615281.9940603.99415146.9940603h10.27350412c-.1701701-.2941734-.2675644-.6357129-.2675644-1zm-12 .0059397v-13.00506804c0-.5562408.44704472-1.00087166.99850233-1.00087166h11.00299537c.5510129 0 .9985023.45190985.9985023 1.0093689v2.9906311h3v9.9914698c0 1.1065798-.8927712 2.0085302-1.9940603 2.0085302h-12.01187942c-1.09954652 0-1.99406028-.8927712-1.99406028-1.9940603zm13-9.0059397v9c0 .5522847.4477153 1 1 1s1-.4477153 1-1v-9zm-10-2h7v4h-7zm1 1v2h5v-2zm-1 4h7v1h-7zm0 2h7v1h-7zm0 2h7v1h-7z" fill-rule="evenodd"></path></symbol><symbol id="icon-audio" viewBox="0 0 18 18"><path d="m13.0957477 13.5588459c-.195279.1937043-.5119137.193729-.7072234.0000551-.1953098-.193674-.1953346-.5077061-.0000556-.7014104 1.0251004-1.0168342 1.6108711-2.3905226 1.6108711-3.85745208 0-1.46604976-.5850634-2.83898246-1.6090736-3.85566829-.1951894-.19379323-.1950192-.50782531.0003802-.70141028.1953993-.19358497.512034-.19341614.7072234.00037709 1.2094886 1.20083761 1.901635 2.8250555 1.901635 4.55670148 0 1.73268608-.6929822 3.35779608-1.9037571 4.55880738zm2.1233994 2.1025159c-.195234.193749-.5118687.1938462-.7072235.0002171-.1953548-.1936292-.1954528-.5076613-.0002189-.7014104 1.5832215-1.5711805 2.4881302-3.6939808 2.4881302-5.96012998 0-2.26581266-.9046382-4.3883241-2.487443-5.95944795-.1952117-.19377107-.1950777-.50780316.0002993-.70141031s.5120117-.19347426.7072234.00029682c1.7683321 1.75528196 2.7800854 4.12911258 2.7800854 6.66056144 0 2.53182498-1.0120556 4.90597838-2.7808529 6.66132328zm-14.21898205-3.6854911c-.5523759 0-1.00016505-.4441085-1.00016505-.991944v-3.96777631c0-.54783558.44778915-.99194407 1.00016505-.99194407h2.0003301l5.41965617-3.8393633c.44948677-.31842296 1.07413994-.21516983 1.39520191.23062232.12116339.16823446.18629727.36981184.18629727.57655577v12.01603479c0 .5478356-.44778914.9919441-1.00016505.9919441-.20845738 0-.41170538-.0645985-.58133413-.184766l-5.41965617-3.8393633zm0-.991944h2.32084805l5.68047235 4.0241292v-12.01603479l-5.68047235 4.02412928h-2.32084805z" fill-rule="evenodd"></path></symbol><symbol id="icon-block" viewBox="0 0 24 24"><path d="m0 0h24v24h-24z" fill-rule="evenodd"></path></symbol><symbol id="icon-book" viewBox="0 0 18 18"><path d="m4 13v-11h1v11h11v-11h-13c-.55228475 0-1 .44771525-1 1v10.2675644c.29417337-.1701701.63571286-.2675644 1-.2675644zm12 1h-13c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1h13zm0 3h-13c-1.1045695 0-2-.8954305-2-2v-12c0-1.1045695.8954305-2 2-2h13c.5522847 0 1 .44771525 1 1v14c0 .5522847-.4477153 1-1 1zm-8.5-13h6c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1 2h4c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-4c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-broad" viewBox="0 0 24 24"><path d="m9.18274226 7.81v7.7999954l2.48162734-2.4816273c.3928221-.3928221 1.0219731-.4005617 1.4030652-.0194696.3911301.3911301.3914806 1.0249268-.0001404 1.4165479l-4.17620796 4.1762079c-.39120769.3912077-1.02508144.3916069-1.41671995-.0000316l-4.1763942-4.1763942c-.39122514-.3912251-.39767006-1.0190815-.01657798-1.4001736.39113012-.3911301 1.02337106-.3930364 1.41951349.0031061l2.48183446 2.4818344v-8.7999954c0-.54911294.4426881-.99439484.99778758-.99557515l8.00221246-.00442485c.5522847 0 1 .44771525 1 1s-.4477153 1-1 1z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 20.182742 24.805206)"></path></symbol><symbol id="icon-calendar" viewBox="0 0 18 18"><path d="m12.5 0c.2761424 0 .5.21505737.5.49047852v.50952148h2c1.1072288 0 2 .89451376 2 2v12c0 1.1072288-.8945138 2-2 2h-12c-1.1072288 0-2-.8945138-2-2v-12c0-1.1072288.89451376-2 2-2h1v1h-1c-.55393837 0-1 .44579254-1 1v3h14v-3c0-.55393837-.4457925-1-1-1h-2v1.50952148c0 .27088381-.2319336.49047852-.5.49047852-.2761424 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.2319336-.49047852.5-.49047852zm3.5 7h-14v8c0 .5539384.44579254 1 1 1h12c.5539384 0 1-.4457925 1-1zm-11 6v1h-1v-1zm3 0v1h-1v-1zm3 0v1h-1v-1zm-6-2v1h-1v-1zm3 0v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-3-2v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-5.5-9c.27614237 0 .5.21505737.5.49047852v.50952148h5v1h-5v1.50952148c0 .27088381-.23193359.49047852-.5.49047852-.27614237 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.23193359-.49047852.5-.49047852z" fill-rule="evenodd"></path></symbol><symbol id="icon-cart" viewBox="0 0 18 18"><path d="m5 14c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm10 0c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm-10 1c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1 1-.4477153 1-1-.44771525-1-1-1zm10 0c-.5522847 0-1 .4477153-1 1s.4477153 1 1 1 1-.4477153 1-1-.4477153-1-1-1zm-12.82032249-15c.47691417 0 .88746157.33678127.98070211.80449199l.23823144 1.19501025 13.36277974.00045554c.5522847.00001882.9999659.44774934.9999659 1.00004222 0 .07084994-.0075361.14150708-.022474.2107727l-1.2908094 5.98534344c-.1007861.46742419-.5432548.80388386-1.0571651.80388386h-10.24805106c-.59173366 0-1.07142857.4477153-1.07142857 1 0 .5128358.41361449.9355072.94647737.9932723l.1249512.0067277h10.35933776c.2749512 0 .4979349.2228539.4979349.4978051 0 .2749417-.2227336.4978951-.4976753.4980063l-10.35959736.0041886c-1.18346732 0-2.14285714-.8954305-2.14285714-2 0-.6625717.34520317-1.24989198.87690425-1.61383592l-1.63768102-8.19004794c-.01312273-.06561364-.01950005-.131011-.0196107-.19547395l-1.71961253-.00064219c-.27614237 0-.5-.22385762-.5-.5 0-.27614237.22385763-.5.5-.5zm14.53193359 2.99950224h-13.11300004l1.20580469 6.02530174c.11024034-.0163252.22327998-.02480398.33844139-.02480398h10.27064786z"></path></symbol><symbol id="icon-chevron-less" viewBox="0 0 10 10"><path d="m5.58578644 4-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 -1 -1 0 9 9)"></path></symbol><symbol id="icon-chevron-more" viewBox="0 0 10 10"><path d="m5.58578644 6-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4.00000002c-.39052429.3905243-1.02368927.3905243-1.41421356 0s-.39052429-1.02368929 0-1.41421358z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"></path></symbol><symbol id="icon-chevron-right" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-circle-fill" viewBox="0 0 16 16"><path d="m8 14c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"></path></symbol><symbol id="icon-circle" viewBox="0 0 16 16"><path d="m8 12c2.209139 0 4-1.790861 4-4s-1.790861-4-4-4-4 1.790861-4 4 1.790861 4 4 4zm0 2c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"></path></symbol><symbol id="icon-citation" viewBox="0 0 18 18"><path d="m8.63593473 5.99995183c2.20913897 0 3.99999997 1.79084375 3.99999997 3.99996146 0 1.40730761-.7267788 2.64486871-1.8254829 3.35783281 1.6240224.6764218 2.8754442 2.0093871 3.4610603 3.6412466l-1.0763845.000006c-.5310008-1.2078237-1.5108121-2.1940153-2.7691712-2.7181346l-.79002167-.329052v-1.023992l.63016577-.4089232c.8482885-.5504661 1.3698342-1.4895187 1.3698342-2.51898361 0-1.65683828-1.3431457-2.99996146-2.99999997-2.99996146-1.65685425 0-3 1.34312318-3 2.99996146 0 1.02946491.52154569 1.96851751 1.36983419 2.51898361l.63016581.4089232v1.023992l-.79002171.329052c-1.25835905.5241193-2.23817037 1.5103109-2.76917113 2.7181346l-1.07638453-.000006c.58561612-1.6318595 1.8370379-2.9648248 3.46106024-3.6412466-1.09870405-.7129641-1.82548287-1.9505252-1.82548287-3.35783281 0-2.20911771 1.790861-3.99996146 4-3.99996146zm7.36897597-4.99995183c1.1018574 0 1.9950893.89353404 1.9950893 2.00274083v5.994422c0 1.10608317-.8926228 2.00274087-1.9950893 2.00274087l-3.0049107-.0009037v-1l3.0049107.00091329c.5490631 0 .9950893-.44783123.9950893-1.00275046v-5.994422c0-.55646537-.4450595-1.00275046-.9950893-1.00275046h-14.00982141c-.54906309 0-.99508929.44783123-.99508929 1.00275046v5.9971821c0 .66666024.33333333.99999036 1 .99999036l2-.00091329v1l-2 .0009037c-1 0-2-.99999041-2-1.99998077v-5.9971821c0-1.10608322.8926228-2.00274083 1.99508929-2.00274083zm-8.5049107 2.9999711c.27614237 0 .5.22385547.5.5 0 .2761349-.22385763.5-.5.5h-4c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm3 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-1c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm4 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238651-.5-.5 0-.27614453.2238576-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-close" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"></path></symbol><symbol id="icon-collections" viewBox="0 0 18 18"><path d="m15 4c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2h1c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-1v-1zm-4-3c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2v-9c0-1.1045695.8954305-2 2-2zm0 1h-8c-.51283584 0-.93550716.38604019-.99327227.88337887l-.00672773.11662113v9c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227zm-1.5 7c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-compare" viewBox="0 0 18 18"><path d="m12 3c3.3137085 0 6 2.6862915 6 6s-2.6862915 6-6 6c-1.0928452 0-2.11744941-.2921742-2.99996061-.8026704-.88181407.5102749-1.90678042.8026704-3.00003939.8026704-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6c1.09325897 0 2.11822532.29239547 3.00096303.80325037.88158756-.51107621 1.90619177-.80325037 2.99903697-.80325037zm-6 1c-2.76142375 0-5 2.23857625-5 5 0 2.7614237 2.23857625 5 5 5 .74397391 0 1.44999672-.162488 2.08451611-.4539116-1.27652344-1.1000812-2.08451611-2.7287264-2.08451611-4.5460884s.80799267-3.44600721 2.08434391-4.5463015c-.63434719-.29121054-1.34037-.4536985-2.08434391-.4536985zm6 0c-.7439739 0-1.4499967.16248796-2.08451611.45391156 1.27652341 1.10008123 2.08451611 2.72872644 2.08451611 4.54608844s-.8079927 3.4460072-2.08434391 4.5463015c.63434721.2912105 1.34037001.4536985 2.08434391.4536985 2.7614237 0 5-2.2385763 5-5 0-2.76142375-2.2385763-5-5-5zm-1.4162763 7.0005324h-3.16744736c.15614659.3572676.35283837.6927622.58425872 1.0006671h1.99892988c.23142036-.3079049.42811216-.6433995.58425876-1.0006671zm.4162763-2.0005324h-4c0 .34288501.0345146.67770871.10025909 1.0011864h3.79948181c.0657445-.32347769.1002591-.65830139.1002591-1.0011864zm-.4158423-1.99953894h-3.16831543c-.13859957.31730812-.24521946.651783-.31578599.99935097h3.79988742c-.0705665-.34756797-.1771864-.68204285-.315786-.99935097zm-1.58295822-1.999926-.08316107.06199199c-.34550042.27081213-.65446126.58611297-.91825862.93727862h2.00044041c-.28418626-.37830727-.6207872-.71499149-.99902072-.99927061z" fill-rule="evenodd"></path></symbol><symbol id="icon-download-file" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.5046024 4c.27614237 0 .5.21637201.5.49209595v6.14827645l1.7462789-1.77990922c.1933927-.1971171.5125222-.19455839.7001689-.0069117.1932998.19329992.1910058.50899492-.0027774.70277812l-2.59089271 2.5908927c-.19483374.1948337-.51177825.1937771-.70556873-.0000133l-2.59099079-2.5909908c-.19484111-.1948411-.19043735-.5151448-.00279066-.70279146.19329987-.19329987.50465175-.19237083.70018565.00692852l1.74638684 1.78001764v-6.14827695c0-.27177709.23193359-.49209595.5-.49209595z" fill-rule="evenodd"></path></symbol><symbol id="icon-download" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"></path></symbol><symbol id="icon-editors" viewBox="0 0 18 18"><path d="m8.72592184 2.54588137c-.48811714-.34391207-1.08343326-.54588137-1.72592184-.54588137-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400182l-.79002171.32905522c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274v.9009805h-1v-.9009805c0-2.5479714 1.54557359-4.79153984 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4 1.09079823 0 2.07961816.43662103 2.80122451 1.1446278-.37707584.09278571-.7373238.22835063-1.07530267.40125357zm-2.72592184 14.45411863h-1v-.9009805c0-2.5479714 1.54557359-4.7915398 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.40732121-.7267788 2.64489414-1.8254829 3.3578652 2.2799093.9496145 3.8254829 3.1931829 3.8254829 5.7411543v.9009805h-1v-.9009805c0-2.1155483-1.2760206-4.0125067-3.2099783-4.8180274l-.7900217-.3290552v-1.02400184l.6301658-.40892721c.8482885-.55047139 1.3698342-1.489533 1.3698342-2.51900785 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400184l-.79002171.3290552c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274z" fill-rule="evenodd"></path></symbol><symbol id="icon-email" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-.0049107 2.55749512v1.44250488l-7 4-7-4v-1.44250488l7 4z" fill-rule="evenodd"></path></symbol><symbol id="icon-error" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm2.8630343 4.71100931-2.8630343 2.86303426-2.86303426-2.86303426c-.39658757-.39658757-1.03281091-.39438847-1.4265779-.00062147-.39651227.39651226-.39348876 1.03246767.00062147 1.4265779l2.86303426 2.86303426-2.86303426 2.8630343c-.39658757.3965875-.39438847 1.0328109-.00062147 1.4265779.39651226.3965122 1.03246767.3934887 1.4265779-.0006215l2.86303426-2.8630343 2.8630343 2.8630343c.3965875.3965876 1.0328109.3943885 1.4265779.0006215.3965122-.3965123.3934887-1.0324677-.0006215-1.4265779l-2.8630343-2.8630343 2.8630343-2.86303426c.3965876-.39658757.3943885-1.03281091.0006215-1.4265779-.3965123-.39651227-1.0324677-.39348876-1.4265779.00062147z" fill-rule="evenodd"></path></symbol><symbol id="icon-ethics" viewBox="0 0 18 18"><path d="m6.76384967 1.41421356.83301651-.8330165c.77492941-.77492941 2.03133823-.77492941 2.80626762 0l.8330165.8330165c.3750728.37507276.8837806.58578644 1.4142136.58578644h1.3496361c1.1045695 0 2 .8954305 2 2v1.34963611c0 .53043298.2107137 1.03914081.5857864 1.41421356l.8330165.83301651c.7749295.77492941.7749295 2.03133823 0 2.80626762l-.8330165.8330165c-.3750727.3750728-.5857864.8837806-.5857864 1.4142136v1.3496361c0 1.1045695-.8954305 2-2 2h-1.3496361c-.530433 0-1.0391408.2107137-1.4142136.5857864l-.8330165.8330165c-.77492939.7749295-2.03133821.7749295-2.80626762 0l-.83301651-.8330165c-.37507275-.3750727-.88378058-.5857864-1.41421356-.5857864h-1.34963611c-1.1045695 0-2-.8954305-2-2v-1.3496361c0-.530433-.21071368-1.0391408-.58578644-1.4142136l-.8330165-.8330165c-.77492941-.77492939-.77492941-2.03133821 0-2.80626762l.8330165-.83301651c.37507276-.37507275.58578644-.88378058.58578644-1.41421356v-1.34963611c0-1.1045695.8954305-2 2-2h1.34963611c.53043298 0 1.03914081-.21071368 1.41421356-.58578644zm-1.41421356 1.58578644h-1.34963611c-.55228475 0-1 .44771525-1 1v1.34963611c0 .79564947-.31607052 1.55871121-.87867966 2.12132034l-.8330165.83301651c-.38440512.38440512-.38440512 1.00764896 0 1.39205408l.8330165.83301646c.56260914.5626092.87867966 1.3256709.87867966 2.1213204v1.3496361c0 .5522847.44771525 1 1 1h1.34963611c.79564947 0 1.55871121.3160705 2.12132034.8786797l.83301651.8330165c.38440512.3844051 1.00764896.3844051 1.39205408 0l.83301646-.8330165c.5626092-.5626092 1.3256709-.8786797 2.1213204-.8786797h1.3496361c.5522847 0 1-.4477153 1-1v-1.3496361c0-.7956495.3160705-1.5587112.8786797-2.1213204l.8330165-.83301646c.3844051-.38440512.3844051-1.00764896 0-1.39205408l-.8330165-.83301651c-.5626092-.56260913-.8786797-1.32567087-.8786797-2.12132034v-1.34963611c0-.55228475-.4477153-1-1-1h-1.3496361c-.7956495 0-1.5587112-.31607052-2.1213204-.87867966l-.83301646-.8330165c-.38440512-.38440512-1.00764896-.38440512-1.39205408 0l-.83301651.8330165c-.56260913.56260914-1.32567087.87867966-2.12132034.87867966zm3.58698944 11.4960218c-.02081224.002155-.04199226.0030286-.06345763.002542-.98766446-.0223875-1.93408568-.3063547-2.75885125-.8155622-.23496767-.1450683-.30784554-.4531483-.16277726-.688116.14506827-.2349677.45314827-.3078455.68811595-.1627773.67447084.4164161 1.44758575.6483839 2.25617384.6667123.01759529.0003988.03495764.0017019.05204365.0038639.01713363-.0017748.03452416-.0026845.05212715-.0026845 2.4852814 0 4.5-2.0147186 4.5-4.5 0-1.04888973-.3593547-2.04134635-1.0074477-2.83787157-.1742817-.21419731-.1419238-.5291218.0722736-.70340353.2141973-.17428173.5291218-.14192375.7034035.07227357.7919032.97327203 1.2317706 2.18808682 1.2317706 3.46900153 0 3.0375661-2.4624339 5.5-5.5 5.5-.02146768 0-.04261937-.0013529-.06337445-.0039782zm1.57975095-10.78419583c.2654788.07599731.419084.35281842.3430867.61829728-.0759973.26547885-.3528185.419084-.6182973.3430867-.37560116-.10752146-.76586237-.16587951-1.15568824-.17249193-2.5587807-.00064534-4.58547766 2.00216524-4.58547766 4.49928198 0 .62691557.12797645 1.23496.37274865 1.7964426.11035133.2531347-.0053975.5477984-.25853224.6581497-.25313473.1103514-.54779841-.0053975-.65814974-.2585322-.29947131-.6869568-.45606667-1.43097603-.45606667-2.1960601 0-3.05211432 2.47714695-5.50006595 5.59399617-5.49921198.48576182.00815502.96289603.0795037 1.42238033.21103795zm-1.9766658 6.41091303 2.69835-2.94655317c.1788432-.21040373.4943901-.23598862.7047939-.05714545.2104037.17884318.2359886.49439014.0571454.70479387l-3.01637681 3.34277395c-.18039088.1999106-.48669547.2210637-.69285412.0478478l-1.93095347-1.62240047c-.21213845-.17678204-.24080048-.49206439-.06401844-.70420284.17678204-.21213844.49206439-.24080048.70420284-.06401844z" fill-rule="evenodd"></path></symbol><symbol id="icon-expand"><path d="M7.498 11.918a.997.997 0 0 0-.003-1.411.995.995 0 0 0-1.412-.003l-4.102 4.102v-3.51A1 1 0 0 0 .98 10.09.992.992 0 0 0 0 11.092V17c0 .554.448 1.002 1.002 1.002h5.907c.554 0 1.002-.45 1.002-1.003 0-.539-.45-.978-1.006-.978h-3.51zm3.005-5.835a.997.997 0 0 0 .003 1.412.995.995 0 0 0 1.411.003l4.103-4.103v3.51a1 1 0 0 0 1.001 1.006A.992.992 0 0 0 18 6.91V1.002A1 1 0 0 0 17 0h-5.907a1.003 1.003 0 0 0-1.002 1.003c0 .539.45.978 1.006.978h3.51z" fill-rule="evenodd"></path></symbol><symbol id="icon-explore" viewBox="0 0 18 18"><path d="m9 17c4.418278 0 8-3.581722 8-8s-3.581722-8-8-8-8 3.581722-8 8 3.581722 8 8 8zm0 1c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9zm0-2.5c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5c2.969509 0 5.400504-2.3575119 5.497023-5.31714844.0090007-.27599565.2400359-.49243782.5160315-.48343711.2759957.0090007.4924378.2400359.4834371.51603155-.114093 3.4985237-2.9869632 6.284554-6.4964916 6.284554zm-.29090657-12.99359748c.27587424-.01216621.50937715.20161139.52154336.47748563.01216621.27587423-.20161139.50937715-.47748563.52154336-2.93195733.12930094-5.25315116 2.54886451-5.25315116 5.49456849 0 .27614237-.22385763.5-.5.5s-.5-.22385763-.5-.5c0-3.48142406 2.74307146-6.34074398 6.20909343-6.49359748zm1.13784138 8.04763908-1.2004882-1.20048821c-.19526215-.19526215-.19526215-.51184463 0-.70710678s.51184463-.19526215.70710678 0l1.20048821 1.2004882 1.6006509-4.00162734-4.50670359 1.80268144-1.80268144 4.50670359zm4.10281269-6.50378907-2.6692597 6.67314927c-.1016411.2541026-.3029834.4554449-.557086.557086l-6.67314927 2.6692597 2.66925969-6.67314926c.10164107-.25410266.30298336-.45544495.55708602-.55708602z" fill-rule="evenodd"></path></symbol><symbol id="icon-filter" viewBox="0 0 16 16"><path d="m14.9738641 0c.5667192 0 1.0261359.4477136 1.0261359 1 0 .24221858-.0902161.47620768-.2538899.65849851l-5.6938314 6.34147206v5.49997973c0 .3147562-.1520673.6111434-.4104543.7999971l-2.05227171 1.4999945c-.45337535.3313696-1.09655869.2418269-1.4365902-.1999993-.13321514-.1730955-.20522717-.3836284-.20522717-.5999978v-6.99997423l-5.69383133-6.34147206c-.3731872-.41563511-.32996891-1.0473954.09653074-1.41107611.18705584-.15950448.42716133-.2474224.67571519-.2474224zm-5.9218641 8.5h-2.105v6.491l.01238459.0070843.02053271.0015705.01955278-.0070558 2.0532976-1.4990996zm-8.02585008-7.5-.01564945.00240169 5.83249953 6.49759831h2.313l5.836-6.499z"></path></symbol><symbol id="icon-home" viewBox="0 0 18 18"><path d="m9 5-6 6v5h4v-4h4v4h4v-5zm7 6.5857864v4.4142136c0 .5522847-.4477153 1-1 1h-5v-4h-2v4h-5c-.55228475 0-1-.4477153-1-1v-4.4142136c-.25592232 0-.51184464-.097631-.70710678-.2928932l-.58578644-.5857864c-.39052429-.3905243-.39052429-1.02368929 0-1.41421358l8.29289322-8.29289322 8.2928932 8.29289322c.3905243.39052429.3905243 1.02368928 0 1.41421358l-.5857864.5857864c-.1952622.1952622-.4511845.2928932-.7071068.2928932zm-7-9.17157284-7.58578644 7.58578644.58578644.5857864 7-6.99999996 7 6.99999996.5857864-.5857864z" fill-rule="evenodd"></path></symbol><symbol id="icon-image" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm-3.49645283 10.1752453-3.89407257 6.7495552c.11705545.048464.24538859.0751995.37998328.0751995h10.60290092l-2.4329715-4.2154691-1.57494129 2.7288098zm8.49779013 6.8247547c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v13.98991071l4.50814957-7.81026689 3.08089884 5.33809539 1.57494129-2.7288097 3.5875735 6.2159812zm-3.0059397-11c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm0 1c-.5522847 0-1 .44771525-1 1s.4477153 1 1 1 1-.44771525 1-1-.4477153-1-1-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-info" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"></path></symbol><symbol id="icon-institution" viewBox="0 0 18 18"><path d="m7 16.9998189v-2.0003623h4v2.0003623h2v-3.0005434h-8v3.0005434zm-3-10.00181122h-1.52632364c-.27614237 0-.5-.22389817-.5-.50009056 0-.13995446.05863589-.27350497.16166338-.36820841l1.23156713-1.13206327h-2.36690687v12.00217346h3v-2.0003623h-3v-1.0001811h3v-1.0001811h1v-4.00072448h-1zm10 0v2.00036224h-1v4.00072448h1v1.0001811h3v1.0001811h-3v2.0003623h3v-12.00217346h-2.3695309l1.2315671 1.13206327c.2033191.186892.2166633.50325042.0298051.70660631-.0946863.10304615-.2282126.16169266-.3681417.16169266zm3-3.00054336c.5522847 0 1 .44779634 1 1.00018112v13.00235456h-18v-13.00235456c0-.55238478.44771525-1.00018112 1-1.00018112h3.45499992l4.20535144-3.86558216c.19129876-.17584288.48537447-.17584288.67667324 0l4.2053514 3.86558216zm-4 3.00054336h-8v1.00018112h8zm-2 6.00108672h1v-4.00072448h-1zm-1 0v-4.00072448h-2v4.00072448zm-3 0v-4.00072448h-1v4.00072448zm8-4.00072448c.5522847 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.4477153-1.00018112 1-1.00018112zm-12 0c.55228475 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.44771525-1.00018112 1-1.00018112zm5.99868798-7.81907007-5.24205601 4.81852671h10.48411203zm.00131202 3.81834559c-.55228475 0-1-.44779634-1-1.00018112s.44771525-1.00018112 1-1.00018112 1 .44779634 1 1.00018112-.44771525 1.00018112-1 1.00018112zm-1 11.00199236v1.0001811h2v-1.0001811z" fill-rule="evenodd"></path></symbol><symbol id="icon-location" viewBox="0 0 18 18"><path d="m9.39521328 16.2688008c.79596342-.7770119 1.59208152-1.6299956 2.33285652-2.5295081 1.4020032-1.7024324 2.4323601-3.3624519 2.9354918-4.871847.2228715-.66861448.3364384-1.29323246.3364384-1.8674457 0-3.3137085-2.6862915-6-6-6-3.36356866 0-6 2.60156856-6 6 0 .57421324.11356691 1.19883122.3364384 1.8674457.50313169 1.5093951 1.53348863 3.1694146 2.93549184 4.871847.74077492.8995125 1.53689309 1.7524962 2.33285648 2.5295081.13694479.1336842.26895677.2602648.39521328.3793207.12625651-.1190559.25826849-.2456365.39521328-.3793207zm-.39521328 1.7311992s-7-6-7-11c0-4 3.13400675-7 7-7 3.8659932 0 7 3.13400675 7 7 0 5-7 11-7 11zm0-8c-1.65685425 0-3-1.34314575-3-3s1.34314575-3 3-3c1.6568542 0 3 1.34314575 3 3s-1.3431458 3-3 3zm0-1c1.1045695 0 2-.8954305 2-2s-.8954305-2-2-2-2 .8954305-2 2 .8954305 2 2 2z" fill-rule="evenodd"></path></symbol><symbol id="icon-minus" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-newsletter" viewBox="0 0 18 18"><path d="m9 11.8482489 2-1.1428571v-1.7053918h-4v1.7053918zm-3-1.7142857v-2.1339632h6v2.1339632l3-1.71428574v-6.41967746h-12v6.41967746zm10-5.3839632 1.5299989.95624934c.2923814.18273835.4700011.50320827.4700011.8479983v8.44575236c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-8.44575236c0-.34479003.1776197-.66525995.47000106-.8479983l1.52999894-.95624934v-2.75c0-.55228475.44771525-1 1-1h12c.5522847 0 1 .44771525 1 1zm0 1.17924764v3.07075236l-7 4-7-4v-3.07075236l-1 .625v8.44575236c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-8.44575236zm-10-1.92924764h6v1h-6zm-1 2h8v1h-8z" fill-rule="evenodd"></path></symbol><symbol id="icon-orcid" viewBox="0 0 18 18"><path d="m9 1c4.418278 0 8 3.581722 8 8s-3.581722 8-8 8-8-3.581722-8-8 3.581722-8 8-8zm-2.90107518 5.2732337h-1.41865256v7.1712107h1.41865256zm4.55867178.02508949h-2.99247027v7.14612121h2.91062487c.7673039 0 1.4476365-.1483432 2.0410182-.445034s1.0511995-.7152915 1.3734671-1.2558144c.3222677-.540523.4833991-1.1603247.4833991-1.85942385 0-.68545815-.1602789-1.30270225-.4808414-1.85175082-.3205625-.54904856-.7707074-.97532211-1.3504481-1.27883343-.5797408-.30351132-1.2413173-.45526471-1.9847495-.45526471zm-.1892674 1.07933542c.7877654 0 1.4143875.22336734 1.8798852.67010873.4654977.44674138.698243 1.05546001.698243 1.82617415 0 .74343221-.2310402 1.34447791-.6931277 1.80315511-.4620874.4586773-1.0750688.6880124-1.8389625.6880124h-1.46810075v-4.98745039zm-5.08652545-3.71099194c-.21825533 0-.410525.08444276-.57681478.25333081-.16628977.16888806-.24943341.36245684-.24943341.58071218 0 .22345188.08314364.41961891.24943341.58850696.16628978.16888806.35855945.25333082.57681478.25333082.233845 0 .43390938-.08314364.60019916-.24943342.16628978-.16628977.24943342-.36375592.24943342-.59240436 0-.233845-.08314364-.43131115-.24943342-.59240437s-.36635416-.24163862-.60019916-.24163862z" fill-rule="evenodd"></path></symbol><symbol id="icon-plus" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-print" viewBox="0 0 18 18"><path d="m16.0049107 5h-14.00982141c-.54941618 0-.99508929.4467783-.99508929.99961498v6.00077002c0 .5570958.44271433.999615.99508929.999615h1.00491071v-3h12v3h1.0049107c.5494162 0 .9950893-.4467783.9950893-.999615v-6.00077002c0-.55709576-.4427143-.99961498-.9950893-.99961498zm-2.0049107-1v-2.00208688c0-.54777062-.4519464-.99791312-1.0085302-.99791312h-7.9829396c-.55661731 0-1.0085302.44910695-1.0085302.99791312v2.00208688zm1 10v2.0018986c0 1.103521-.9019504 1.9981014-2.0085302 1.9981014h-7.9829396c-1.1092806 0-2.0085302-.8867064-2.0085302-1.9981014v-2.0018986h-1.00491071c-1.10185739 0-1.99508929-.8874333-1.99508929-1.999615v-6.00077002c0-1.10435686.8926228-1.99961498 1.99508929-1.99961498h1.00491071v-2.00208688c0-1.10341695.90195036-1.99791312 2.0085302-1.99791312h7.9829396c1.1092806 0 2.0085302.89826062 2.0085302 1.99791312v2.00208688h1.0049107c1.1018574 0 1.9950893.88743329 1.9950893 1.99961498v6.00077002c0 1.1043569-.8926228 1.999615-1.9950893 1.999615zm-1-3h-10v5.0018986c0 .5546075.44702548.9981014 1.0085302.9981014h7.9829396c.5565964 0 1.0085302-.4491701 1.0085302-.9981014zm-9 1h8v1h-8zm0 2h5v1h-5zm9-5c-.5522847 0-1-.44771525-1-1s.4477153-1 1-1 1 .44771525 1 1-.4477153 1-1 1z" fill-rule="evenodd"></path></symbol><symbol id="icon-search" viewBox="0 0 22 22"><path d="M21.697 20.261a1.028 1.028 0 01.01 1.448 1.034 1.034 0 01-1.448-.01l-4.267-4.267A9.812 9.811 0 010 9.812a9.812 9.811 0 1117.43 6.182zM9.812 18.222A8.41 8.41 0 109.81 1.403a8.41 8.41 0 000 16.82z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-facebook" viewBox="0 0 24 24"><path d="m6.00368507 20c-1.10660471 0-2.00368507-.8945138-2.00368507-1.9940603v-12.01187942c0-1.10128908.89451376-1.99406028 1.99406028-1.99406028h12.01187942c1.1012891 0 1.9940603.89451376 1.9940603 1.99406028v12.01187942c0 1.1012891-.88679 1.9940603-2.0032184 1.9940603h-2.9570132v-6.1960818h2.0797387l.3114113-2.414723h-2.39115v-1.54164807c0-.69911803.1941355-1.1755439 1.1966615-1.1755439l1.2786739-.00055875v-2.15974763l-.2339477-.02492088c-.3441234-.03134957-.9500153-.07025255-1.6293054-.07025255-1.8435726 0-3.1057323 1.12531866-3.1057323 3.19187953v1.78079225h-2.0850778v2.414723h2.0850778v6.1960818z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-twitter" viewBox="0 0 24 24"><path d="m18.8767135 6.87445248c.7638174-.46908424 1.351611-1.21167363 1.6250764-2.09636345-.7135248.43394112-1.50406.74870123-2.3464594.91677702-.6695189-.73342162-1.6297913-1.19486605-2.6922204-1.19486605-2.0399895 0-3.6933555 1.69603749-3.6933555 3.78628909 0 .29642457.0314329.58673729.0942985.8617704-3.06469922-.15890802-5.78835241-1.66547825-7.60988389-3.9574208-.3174714.56076194-.49978171 1.21167363-.49978171 1.90536824 0 1.31404706.65223085 2.47224203 1.64236444 3.15218497-.60350999-.0198635-1.17401554-.1925232-1.67222562-.47366811v.04583885c0 1.83355406 1.27302891 3.36609966 2.96411421 3.71294696-.31118484.0886217-.63651445.1329326-.97441718.1329326-.2357461 0-.47149219-.0229194-.69466516-.0672303.47149219 1.5065703 1.83253297 2.6036468 3.44975116 2.632678-1.2651707 1.0160946-2.85724264 1.6196394-4.5891906 1.6196394-.29861172 0-.59093688-.0152796-.88011875-.0504227 1.63450624 1.0726291 3.57548241 1.6990934 5.66104951 1.6990934 6.79263079 0 10.50641749-5.7711113 10.50641749-10.7751859l-.0094298-.48894775c.7229547-.53478659 1.3516109-1.20250585 1.8419628-1.96190282-.6632323.30100846-1.3751855.50422736-2.1217148.59590507z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-youtube" viewBox="0 0 24 24"><path d="m10.1415 14.3973208-.0005625-5.19318431 4.863375 2.60554491zm9.963-7.92753362c-.6845625-.73643756-1.4518125-.73990314-1.803375-.7826454-2.518875-.18714178-6.2971875-.18714178-6.2971875-.18714178-.007875 0-3.7861875 0-6.3050625.18714178-.352125.04274226-1.1188125.04620784-1.8039375.7826454-.5394375.56084773-.7149375 1.8344515-.7149375 1.8344515s-.18 1.49597903-.18 2.99138042v1.4024082c0 1.495979.18 2.9913804.18 2.9913804s.1755 1.2736038.7149375 1.8344515c.685125.7364376 1.5845625.7133337 1.9850625.7901542 1.44.1420891 6.12.1859866 6.12.1859866s3.78225-.005776 6.301125-.1929178c.3515625-.0433198 1.1188125-.0467854 1.803375-.783223.5394375-.5608477.7155-1.8344515.7155-1.8344515s.18-1.4954014.18-2.9913804v-1.4024082c0-1.49540139-.18-2.99138042-.18-2.99138042s-.1760625-1.27360377-.7155-1.8344515z" fill-rule="evenodd"></path></symbol><symbol id="icon-subject-medicine" viewBox="0 0 18 18"><path d="m12.5 8h-6.5c-1.65685425 0-3 1.34314575-3 3v1c0 1.6568542 1.34314575 3 3 3h1v-2h-.5c-.82842712 0-1.5-.6715729-1.5-1.5s.67157288-1.5 1.5-1.5h1.5 2 1 2c1.6568542 0 3-1.34314575 3-3v-1c0-1.65685425-1.3431458-3-3-3h-2v2h1.5c.8284271 0 1.5.67157288 1.5 1.5s-.6715729 1.5-1.5 1.5zm-5.5-1v-1h-3.5c-1.38071187 0-2.5-1.11928813-2.5-2.5s1.11928813-2.5 2.5-2.5h1.02786405c.46573528 0 .92507448.10843528 1.34164078.31671843l1.13382424.56691212c.06026365-1.05041141.93116291-1.88363055 1.99667093-1.88363055 1.1045695 0 2 .8954305 2 2h2c2.209139 0 4 1.790861 4 4v1c0 2.209139-1.790861 4-4 4h-2v1h2c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2h-2c0 1.1045695-.8954305 2-2 2s-2-.8954305-2-2h-1c-2.209139 0-4-1.790861-4-4v-1c0-2.209139 1.790861-4 4-4zm0-2v-2.05652691c-.14564246-.03538148-.28733393-.08714006-.42229124-.15461871l-1.15541752-.57770876c-.27771087-.13885544-.583937-.21114562-.89442719-.21114562h-1.02786405c-.82842712 0-1.5.67157288-1.5 1.5s.67157288 1.5 1.5 1.5zm4 1v1h1.5c.2761424 0 .5-.22385763.5-.5s-.2238576-.5-.5-.5zm-1 1v-5c0-.55228475-.44771525-1-1-1s-1 .44771525-1 1v5zm-2 4v5c0 .5522847.44771525 1 1 1s1-.4477153 1-1v-5zm3 2v2h2c.5522847 0 1-.4477153 1-1s-.4477153-1-1-1zm-4-1v-1h-.5c-.27614237 0-.5.2238576-.5.5s.22385763.5.5.5zm-3.5-9h1c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-success" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm3.4860198 4.98163161-4.71802968 5.50657859-2.62834168-2.02300024c-.42862421-.36730544-1.06564993-.30775346-1.42283677.13301307-.35718685.44076653-.29927542 1.0958383.12934879 1.46314377l3.40735508 2.7323063c.42215801.3385221 1.03700951.2798252 1.38749189-.1324571l5.38450527-6.33394549c.3613513-.43716226.3096573-1.09278382-.115462-1.46437175-.4251192-.37158792-1.0626796-.31842941-1.4240309.11873285z" fill-rule="evenodd"></path></symbol><symbol id="icon-table" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587l-4.0059107-.001.001.001h-1l-.001-.001h-5l.001.001h-1l-.001-.001-3.00391071.001c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm-11.0059107 5h-3.999v6.9941413c0 .5572961.44630695 1.0058587.99508929 1.0058587h3.00391071zm6 0h-5v8h5zm5.0059107-4h-4.0059107v3h5.001v1h-5.001v7.999l4.0059107.001c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-12.5049107 9c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.22385763-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1.499-5h-5v3h5zm-6 0h-3.00391071c-.54871518 0-.99508929.44887827-.99508929 1.00585866v1.99414134h3.999z" fill-rule="evenodd"></path></symbol><symbol id="icon-tick-circle" viewBox="0 0 24 24"><path d="m12 2c5.5228475 0 10 4.4771525 10 10s-4.4771525 10-10 10-10-4.4771525-10-10 4.4771525-10 10-10zm0 1c-4.97056275 0-9 4.02943725-9 9 0 4.9705627 4.02943725 9 9 9 4.9705627 0 9-4.0294373 9-9 0-4.97056275-4.0294373-9-9-9zm4.2199868 5.36606669c.3613514-.43716226.9989118-.49032077 1.424031-.11873285s.4768133 1.02720949.115462 1.46437175l-6.093335 6.94397871c-.3622945.4128716-.9897871.4562317-1.4054264.0971157l-3.89719065-3.3672071c-.42862421-.3673054-.48653564-1.0223772-.1293488-1.4631437s.99421256-.5003185 1.42283677-.1330131l3.11097438 2.6987741z" fill-rule="evenodd"></path></symbol><symbol id="icon-tick" viewBox="0 0 16 16"><path d="m6.76799012 9.21106946-3.1109744-2.58349728c-.42862421-.35161617-1.06564993-.29460792-1.42283677.12733148s-.29927541 1.04903009.1293488 1.40064626l3.91576307 3.23873978c.41034319.3393961 1.01467563.2976897 1.37450571-.0948578l6.10568327-6.660841c.3613513-.41848908.3096572-1.04610608-.115462-1.4018218-.4251192-.35571573-1.0626796-.30482786-1.424031.11366122z" fill-rule="evenodd"></path></symbol><symbol id="icon-update" viewBox="0 0 18 18"><path d="m1 13v1c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-1h-1v-10h-14v10zm16-1h1v2c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-2h1v-9c0-.55228475.44771525-1 1-1h14c.5522847 0 1 .44771525 1 1zm-1 0v1h-4.5857864l-1 1h-2.82842716l-1-1h-4.58578644v-1h5l1 1h2l1-1zm-13-8h12v7h-12zm1 1v5h10v-5zm1 1h4v1h-4zm0 2h4v1h-4z" fill-rule="evenodd"></path></symbol><symbol id="icon-upload" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.85576936 4.14572769c.19483374-.19483375.51177826-.19377714.70556874.00001334l2.59099082 2.59099079c.1948411.19484112.1904373.51514474.0027906.70279143-.1932998.19329987-.5046517.19237083-.7001856-.00692852l-1.74638687-1.7800176v6.14827687c0 .2717771-.23193359.492096-.5.492096-.27614237 0-.5-.216372-.5-.492096v-6.14827641l-1.74627892 1.77990922c-.1933927.1971171-.51252214.19455839-.70016883.0069117-.19329987-.19329988-.19100584-.50899493.00277731-.70277808z" fill-rule="evenodd"></path></symbol><symbol id="icon-video" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-8.30912922 2.24944486 4.60460462 2.73982242c.9365543.55726659.9290753 1.46522435 0 2.01804082l-4.60460462 2.7398224c-.93655425.5572666-1.69578148.1645632-1.69578148-.8937585v-5.71016863c0-1.05087579.76670616-1.446575 1.69578148-.89375851zm-.67492769.96085624v5.5750128c0 .2995102-.10753745.2442517.16578928.0847713l4.58452283-2.67497259c.3050619-.17799716.3051624-.21655446 0-.39461026l-4.58452283-2.67497264c-.26630747-.15538481-.16578928-.20699944-.16578928.08477139z" fill-rule="evenodd"></path></symbol><symbol id="icon-warning" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-checklist-banner" viewBox="0 0 56.69 56.69"><path style="fill:none" d="M0 0h56.69v56.69H0z"></path><clipPath id="b"><use xlink:href="#a" style="overflow:visible"></use></clipPath><path d="M21.14 34.46c0-6.77 5.48-12.26 12.24-12.26s12.24 5.49 12.24 12.26-5.48 12.26-12.24 12.26c-6.76-.01-12.24-5.49-12.24-12.26zm19.33 10.66 10.23 9.22s1.21 1.09 2.3-.12l2.09-2.32s1.09-1.21-.12-2.3l-10.23-9.22m-19.29-5.92c0-4.38 3.55-7.94 7.93-7.94s7.93 3.55 7.93 7.94c0 4.38-3.55 7.94-7.93 7.94-4.38-.01-7.93-3.56-7.93-7.94zm17.58 12.99 4.14-4.81" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round"></path><path d="M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5m14.42-5.2V4.86s0-2.93-2.93-2.93H4.13s-2.93 0-2.93 2.93v37.57s0 2.93 2.93 2.93h15.01M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round;stroke-linejoin:round"></path></symbol><symbol id="icon-chevron-down" viewBox="0 0 16 16"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"></path></symbol><symbol id="icon-eds-i-arrow-right-medium" viewBox="0 0 24 24"><path d="m12.728 3.293 7.98 7.99a.996.996 0 0 1 .281.561l.011.157c0 .32-.15.605-.384.788l-7.908 7.918a1 1 0 0 1-1.416-1.414L17.576 13H4a1 1 0 0 1 0-2h13.598l-6.285-6.293a1 1 0 0 1-.082-1.32l.083-.095a1 1 0 0 1 1.414.001Z"></path></symbol><symbol id="icon-eds-i-check-circle-medium" viewBox="0 0 24 24"><path d="M12 1c6.075 0 11 4.925 11 11s-4.925 11-11 11S1 18.075 1 12 5.925 1 12 1Zm0 2a9 9 0 1 0 0 18 9 9 0 0 0 0-18Zm5.125 4.72a1 1 0 0 1 .156 1.405l-6 7.5a1 1 0 0 1-1.421.143l-3-2.5a1 1 0 0 1 1.28-1.536l2.217 1.846 5.362-6.703a1 1 0 0 1 1.406-.156Z"></path></symbol><symbol id="icon-eds-i-chevron-down-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-chevron-down-small" viewBox="0 0 16 16"><path d="M13.692 5.278a1 1 0 0 1 .03 1.414L9.103 11.51a1.491 1.491 0 0 1-2.188.019L2.278 6.692a1 1 0 0 1 1.444-1.384L8 9.771l4.278-4.463a1 1 0 0 1 1.318-.111l.096.081Z"></path></symbol><symbol id="icon-eds-i-chevron-right-medium" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-eds-i-chevron-right-small" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-eds-i-chevron-up-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-close-medium" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-copy-link" viewBox="0 0 24 24"><path fill-rule="evenodd" clip-rule="evenodd" d="M19.4594 8.57015C19.0689 8.17963 19.0689 7.54646 19.4594 7.15594L20.2927 6.32261C20.2927 6.32261 20.2927 6.32261 20.2927 6.32261C21.0528 5.56252 21.0528 4.33019 20.2928 3.57014C19.5327 2.81007 18.3004 2.81007 17.5404 3.57014L16.7071 4.40347C16.3165 4.794 15.6834 4.794 15.2928 4.40348C14.9023 4.01296 14.9023 3.3798 15.2928 2.98927L16.1262 2.15594C17.6673 0.614803 20.1659 0.614803 21.707 2.15593C23.2481 3.69705 23.248 6.19569 21.707 7.7368L20.8737 8.57014C20.4831 8.96067 19.85 8.96067 19.4594 8.57015Z"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M18.0944 5.90592C18.4849 6.29643 18.4849 6.9296 18.0944 7.32013L16.4278 8.9868C16.0373 9.37733 15.4041 9.37734 15.0136 8.98682C14.6231 8.59631 14.6231 7.96314 15.0136 7.57261L16.6802 5.90594C17.0707 5.51541 17.7039 5.5154 18.0944 5.90592Z"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M13.5113 6.32243C13.9018 6.71295 13.9018 7.34611 13.5113 7.73664L12.678 8.56997C12.678 8.56997 12.678 8.56997 12.678 8.56997C11.9179 9.33006 11.9179 10.5624 12.6779 11.3224C13.438 12.0825 14.6703 12.0825 15.4303 11.3224L16.2636 10.4891C16.6542 10.0986 17.2873 10.0986 17.6779 10.4891C18.0684 10.8796 18.0684 11.5128 17.6779 11.9033L16.8445 12.7366C15.3034 14.2778 12.8048 14.2778 11.2637 12.7366C9.72262 11.1955 9.72266 8.69689 11.2637 7.15578L12.097 6.32244C12.4876 5.93191 13.1207 5.93191 13.5113 6.32243Z"></path><path d="M8 20V22H19.4619C20.136 22 20.7822 21.7311 21.2582 21.2529C21.7333 20.7757 22 20.1289 22 19.4549V15C22 14.4477 21.5523 14 21 14C20.4477 14 20 14.4477 20 15V19.4549C20 19.6004 19.9426 19.7397 19.8408 19.842C19.7399 19.9433 19.6037 20 19.4619 20H8Z"></path><path d="M4 13H2V19.4619C2 20.136 2.26889 20.7822 2.74705 21.2582C3.22434 21.7333 3.87105 22 4.5451 22H9C9.55228 22 10 21.5523 10 21C10 20.4477 9.55228 20 9 20H4.5451C4.39957 20 4.26028 19.9426 4.15804 19.8408C4.05668 19.7399 4 19.6037 4 19.4619V13Z"></path><path d="M4 13H2V4.53808C2 3.86398 2.26889 3.21777 2.74705 2.74178C3.22434 2.26666 3.87105 2 4.5451 2H9C9.55228 2 10 2.44772 10 3C10 3.55228 9.55228 4 9 4H4.5451C4.39957 4 4.26028 4.05743 4.15804 4.15921C4.05668 4.26011 4 4.39633 4 4.53808V13Z"></path></symbol><symbol id="icon-eds-i-download-medium" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-info-filled-medium" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-institution-medium" viewBox="0 0 24 24"><g><path fill-rule="evenodd" clip-rule="evenodd" d="M11.9967 1C11.6364 1 11.279 1.0898 10.961 1.2646C10.9318 1.28061 10.9035 1.29806 10.8761 1.31689L2.79765 6.87C2.46776 7.08001 2.20618 7.38466 2.07836 7.76668C1.94823 8.15561 1.98027 8.55648 2.12665 8.90067C2.42086 9.59246 3.12798 10 3.90107 10H4.99994V16H4.49994C3.11923 16 1.99994 17.1193 1.99994 18.5V19.5C1.99994 20.8807 3.11923 22 4.49994 22H19.4999C20.8807 22 21.9999 20.8807 21.9999 19.5V18.5C21.9999 17.1193 20.8807 16 19.4999 16H18.9999V10H20.0922C20.8653 10 21.5725 9.59252 21.8667 8.90065C22.0131 8.55642 22.0451 8.15553 21.9149 7.7666C21.7871 7.38459 21.5255 7.07997 21.1956 6.86998L13.1172 1.31689C13.0898 1.29806 13.0615 1.28061 13.0324 1.2646C12.7143 1.0898 12.357 1 11.9967 1ZM4.6844 8L11.9472 3.00755C11.9616 3.00295 11.9783 3 11.9967 3C12.015 3 12.0318 3.00295 12.0461 3.00755L19.3089 8H4.6844ZM16.9999 16V10H14.9999V16H16.9999ZM12.9999 16V10H10.9999V16H12.9999ZM8.99994 16V10H6.99994V16H8.99994ZM3.99994 18.5C3.99994 18.2239 4.2238 18 4.49994 18H19.4999C19.7761 18 19.9999 18.2239 19.9999 18.5V19.5C19.9999 19.7761 19.7761 20 19.4999 20H4.49994C4.2238 20 3.99994 19.7761 3.99994 19.5V18.5Z"></path></g></symbol><symbol id="icon-eds-i-mail-medium" viewBox="0 0 24 24"><path d="m19.462 0c1.413 0 2.538 1.184 2.538 2.619v12.762c0 1.435-1.125 2.619-2.538 2.619h-16.924c-1.413 0-2.538-1.184-2.538-2.619v-12.762c0-1.435 1.125-2.619 2.538-2.619zm.538 5.158-7.378 6.258a2.549 2.549 0 0 1 -3.253-.008l-7.369-6.248v10.222c0 .353.253.619.538.619h16.924c.285 0 .538-.266.538-.619zm-.538-3.158h-16.924c-.264 0-.5.228-.534.542l8.65 7.334c.2.165.492.165.684.007l8.656-7.342-.001-.025c-.044-.3-.274-.516-.531-.516z"></path></symbol><symbol id="icon-eds-i-menu-medium" viewBox="0 0 24 24"><path d="M21 4a1 1 0 0 1 0 2H3a1 1 0 1 1 0-2h18Zm-4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h14Zm4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h18Z"></path></symbol><symbol id="icon-eds-i-search-medium" viewBox="0 0 24 24"><path d="M11 1c5.523 0 10 4.477 10 10 0 2.4-.846 4.604-2.256 6.328l3.963 3.965a1 1 0 0 1-1.414 1.414l-3.965-3.963A9.959 9.959 0 0 1 11 21C5.477 21 1 16.523 1 11S5.477 1 11 1Zm0 2a8 8 0 1 0 0 16 8 8 0 0 0 0-16Z"></path></symbol><symbol id="icon-eds-i-user-single-medium" viewBox="0 0 24 24"><path d="M12 1a5 5 0 1 1 0 10 5 5 0 0 1 0-10Zm0 2a3 3 0 1 0 0 6 3 3 0 0 0 0-6Zm-.406 9.008a8.965 8.965 0 0 1 6.596 2.494A9.161 9.161 0 0 1 21 21.025V22a1 1 0 0 1-1 1H4a1 1 0 0 1-1-1v-.985c.05-4.825 3.815-8.777 8.594-9.007Zm.39 1.992-.299.006c-3.63.175-6.518 3.127-6.678 6.775L5 21h13.998l-.009-.268a7.157 7.157 0 0 0-1.97-4.573l-.214-.213A6.967 6.967 0 0 0 11.984 14Z"></path></symbol><symbol id="icon-eds-i-warning-filled-medium" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-expand-image" viewBox="0 0 18 18"><path d="m7.49754099 11.9178212c.38955542-.3895554.38761957-1.0207846-.00290473-1.4113089-.39324695-.3932469-1.02238878-.3918247-1.41130883-.0029047l-4.10273549 4.1027355.00055454-3.5103985c.00008852-.5603185-.44832171-1.006032-1.00155062-1.0059446-.53903074.0000852-.97857527.4487442-.97866268 1.0021075l-.00093318 5.9072465c-.00008751.553948.44841131 1.001882 1.00174994 1.0017946l5.906983-.0009331c.5539233-.0000875 1.00197907-.4486389 1.00206646-1.0018679.00008515-.5390307-.45026621-.9784332-1.00588841-.9783454l-3.51010549.0005545zm3.00571741-5.83449376c-.3895554.38955541-.3876196 1.02078454.0029047 1.41130883.393247.39324696 1.0223888.39182478 1.4113089.00290473l4.1027355-4.10273549-.0005546 3.5103985c-.0000885.56031852.4483217 1.006032 1.0015506 1.00594461.5390308-.00008516.9785753-.44874418.9786627-1.00210749l.0009332-5.9072465c.0000875-.553948-.4484113-1.00188204-1.0017499-1.00179463l-5.906983.00093313c-.5539233.00008751-1.0019791.44863892-1.0020665 1.00186784-.0000852.53903074.4502662.97843325 1.0058884.97834547l3.5101055-.00055449z" fill-rule="evenodd"></path></symbol><symbol id="icon-github" viewBox="0 0 100 100"><path fill-rule="evenodd" clip-rule="evenodd" d="M48.854 0C21.839 0 0 22 0 49.217c0 21.756 13.993 40.172 33.405 46.69 2.427.49 3.316-1.059 3.316-2.362 0-1.141-.08-5.052-.08-9.127-13.59 2.934-16.42-5.867-16.42-5.867-2.184-5.704-5.42-7.17-5.42-7.17-4.448-3.015.324-3.015.324-3.015 4.934.326 7.523 5.052 7.523 5.052 4.367 7.496 11.404 5.378 14.235 4.074.404-3.178 1.699-5.378 3.074-6.6-10.839-1.141-22.243-5.378-22.243-24.283 0-5.378 1.94-9.778 5.014-13.2-.485-1.222-2.184-6.275.486-13.038 0 0 4.125-1.304 13.426 5.052a46.97 46.97 0 0 1 12.214-1.63c4.125 0 8.33.571 12.213 1.63 9.302-6.356 13.427-5.052 13.427-5.052 2.67 6.763.97 11.816.485 13.038 3.155 3.422 5.015 7.822 5.015 13.2 0 18.905-11.404 23.06-22.324 24.283 1.78 1.548 3.316 4.481 3.316 9.126 0 6.6-.08 11.897-.08 13.526 0 1.304.89 2.853 3.316 2.364 19.412-6.52 33.405-24.935 33.405-46.691C97.707 22 75.788 0 48.854 0z"></path></symbol><symbol id="icon-springer-arrow-left"><path d="M15 7a1 1 0 000-2H3.385l2.482-2.482a.994.994 0 00.02-1.403 1.001 1.001 0 00-1.417 0L.294 5.292a1.001 1.001 0 000 1.416l4.176 4.177a.991.991 0 001.4.016 1 1 0 00-.003-1.42L3.385 7H15z"></path></symbol><symbol id="icon-springer-arrow-right"><path d="M1 7a1 1 0 010-2h11.615l-2.482-2.482a.994.994 0 01-.02-1.403 1.001 1.001 0 011.417 0l4.176 4.177a1.001 1.001 0 010 1.416l-4.176 4.177a.991.991 0 01-1.4.016 1 1 0 01.003-1.42L12.615 7H1z"></path></symbol><symbol id="icon-submit-open" viewBox="0 0 16 17"><path d="M12 0c1.10457 0 2 .895431 2 2v5c0 .276142-.223858.5-.5.5S13 7.276142 13 7V2c0-.512836-.38604-.935507-.883379-.993272L12 1H6v3c0 1.10457-.89543 2-2 2H1v8c0 .512836.38604.935507.883379.993272L2 15h6.5c.276142 0 .5.223858.5.5s-.223858.5-.5.5H2c-1.104569 0-2-.89543-2-2V5.828427c0-.530433.210714-1.039141.585786-1.414213L4.414214.585786C4.789286.210714 5.297994 0 5.828427 0H12Zm3.41 11.14c.250899.250899.250274.659726 0 .91-.242954.242954-.649606.245216-.9-.01l-1.863671-1.900337.001043 5.869492c0 .356992-.289839.637138-.647372.637138-.347077 0-.647371-.285256-.647371-.637138l-.001043-5.869492L9.5 12.04c-.253166.258042-.649726.260274-.9.01-.242954-.242954-.252269-.657731 0-.91l2.942184-2.951303c.250908-.250909.66127-.252277.91353-.000017L15.41 11.14ZM5 1.413 1.413 5H4c.552285 0 1-.447715 1-1V1.413ZM11 3c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Zm0 2c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Z" fill-rule="nonzero"></path></symbol></svg>
</div>
</footer>




    


    

<div class="c-site-messages message u-hide u-hide-print c-site-messages--nature-briefing c-site-messages--nature-briefing-email-variant c-site-messages--nature-briefing-redesign-2020 sans-serif c-site-messages--nature-briefing-transres" data-component-id="nature-briefing-banner" data-component-expirydays="30" data-component-trigger-scroll-percentage="15" data-track="in-view" data-track-action="in-view" data-track-category="nature briefing" data-track-label="Briefing banner visible: TranslationalResearch">

    
    <div class="c-site-messages__banner-large">

        
<div class="c-site-messages__close-container">
    <button class="c-site-messages__close" data-track="click" data-track-category="nature briefing" data-track-label="Briefing banner dismiss: TranslationalResearch">
        <svg width="25px" height="25px" focusable="false" aria-hidden="true" viewBox="0 0 25 25" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
            <title>Close banner</title>
            <defs></defs>
            <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd">
                <rect opacity="0" x="0" y="0" width="25" height="25"></rect>
                <path d="M6.29679575,16.2772478 C5.90020818,16.6738354 5.90240728,17.3100587 6.29617427,17.7038257 C6.69268654,18.100338 7.32864195,18.0973145 7.72275218,17.7032043 L12,13.4259564 L16.2772478,17.7032043 C16.6738354,18.0997918 17.3100587,18.0975927 17.7038257,17.7038257 C18.100338,17.3073135 18.0973145,16.671358 17.7032043,16.2772478 L13.4259564,12 L17.7032043,7.72275218 C18.0997918,7.32616461 18.0975927,6.68994127 17.7038257,6.29617427 C17.3073135,5.89966201 16.671358,5.90268552 16.2772478,6.29679575 L12,10.5740436 L7.72275218,6.29679575 C7.32616461,5.90020818 6.68994127,5.90240728 6.29617427,6.29617427 C5.89966201,6.69268654 5.90268552,7.32864195 6.29679575,7.72275218 L10.5740436,12 L6.29679575,16.2772478 Z" fill="#ffffff"></path>
            </g>
        </svg>
        <span class="visually-hidden">Close</span>
    </button>
</div>


        <div class="c-site-messages__form-container">

            <div class="grid grid-12 last">
                <div class="grid grid-4">
                    <img alt="Nature Briefing: Translational Research" src="/static/images/logos/nature-briefing-logo-transres-white-1245a3c374.svg" width="213" height="40">
                    <p class="c-site-messages--nature-briefing__strapline extra-tight-line-height">Sign up for the <em>Nature Briefing: Translational Research</em> newsletter — top stories in biotechnology, drug discovery and pharma.</p>
                </div>
                <div class="grid grid-8 last">
                    <form action="https://www.nature.com/briefing/translational_research" method="post" data-location="banner" data-track="signup_nature_briefing_banner" data-track-action="transmit-form" data-track-category="nature briefing" data-track-label="Briefing banner submit: TranslationalResearch">
                        <input id="briefing-banner-signup-form-input-track-originReferralPoint" type="hidden" name="track_originReferralPoint" value="TransResBriefingBanner">
                        <input id="briefing-banner-signup-form-input-track-formType" type="hidden" name="track_formType" value="DirectEmailBanner">

                        <input type="hidden" value="false" name="gdpr_tick" id="gdpr_tick_banner">
                        <input type="hidden" value="false" name="marketing" id="marketing_input_banner">
                        <input type="hidden" value="false" name="marketing_tick" id="marketing_tick_banner">
                        <input type="hidden" value="TransResBriefingBanner" name="brieferEntryPoint" id="brieferEntryPoint_banner">

                        <label class="nature-briefing-banner__email-label" for="emailAddress">Email address</label>

                        <div class="nature-briefing-banner__email-wrapper">
                            <input class="nature-briefing-banner__email-input box-sizing text14" type="email" id="emailAddress" name="emailAddress" value="" placeholder="e.g. jo.smith@university.ac.uk" required="" data-test-element="briefing-emailbanner-email-input">
                            
                            <input type="hidden" value="true" name="N:translational_research" id="defaultNewsletter_banner">
                            <button type="submit" class="nature-briefing-banner__submit-button box-sizing text14" data-test-element="briefing-emailbanner-signup-button">Sign up</button>
                        </div>

                        <div class="nature-briefing-banner__checkbox-wrapper grid grid-12 last">
                            <input class="nature-briefing-banner__checkbox-checkbox" id="gdpr-briefing-banner-checkbox" type="checkbox" name="gdpr" value="true" data-test-element="briefing-emailbanner-gdpr-checkbox" required="">
                            <label class="nature-briefing-banner__checkbox-label box-sizing text13 sans-serif block tighten-line-height" for="gdpr-briefing-banner-checkbox">I agree my information will be processed in accordance with the <em>Nature</em> and Springer Nature Limited <a href="https://www.nature.com/info/privacy">Privacy Policy</a>.</label>
                        </div>
                    </form>
                </div>
            </div>

        </div>

    </div>

    
    <div class="c-site-messages__banner-small">

        
<div class="c-site-messages__close-container">
    <button class="c-site-messages__close" data-track="click" data-track-category="nature briefing" data-track-label="Briefing banner dismiss: TranslationalResearch">
        <svg width="25px" height="25px" focusable="false" aria-hidden="true" viewBox="0 0 25 25" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
            <title>Close banner</title>
            <defs></defs>
            <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd">
                <rect opacity="0" x="0" y="0" width="25" height="25"></rect>
                <path d="M6.29679575,16.2772478 C5.90020818,16.6738354 5.90240728,17.3100587 6.29617427,17.7038257 C6.69268654,18.100338 7.32864195,18.0973145 7.72275218,17.7032043 L12,13.4259564 L16.2772478,17.7032043 C16.6738354,18.0997918 17.3100587,18.0975927 17.7038257,17.7038257 C18.100338,17.3073135 18.0973145,16.671358 17.7032043,16.2772478 L13.4259564,12 L17.7032043,7.72275218 C18.0997918,7.32616461 18.0975927,6.68994127 17.7038257,6.29617427 C17.3073135,5.89966201 16.671358,5.90268552 16.2772478,6.29679575 L12,10.5740436 L7.72275218,6.29679575 C7.32616461,5.90020818 6.68994127,5.90240728 6.29617427,6.29617427 C5.89966201,6.69268654 5.90268552,7.32864195 6.29679575,7.72275218 L10.5740436,12 L6.29679575,16.2772478 Z" fill="#ffffff"></path>
            </g>
        </svg>
        <span class="visually-hidden">Close</span>
    </button>
</div>


        <div class="c-site-messages__content text14">
            <span class="c-site-messages--nature-briefing__strapline strong">Get what matters in translational research, free to your inbox weekly.</span>
            <a class="nature-briefing__link text14 sans-serif" data-track="click" data-track-category="nature briefing" data-track-label="Small-screen banner CTA to site" data-test-element="briefing-banner-link" target="_blank" rel="noreferrer noopener" href="/briefing/translational-research/?brieferEntryPoint=TransResBriefingBanner">Sign up for Nature Briefing: Translational Research
            </a>
        </div>

    </div>

</div>

    




<noscript>
    <img hidden src="https://verify.nature.com/verify/nature.png" width="0" height="0" style="display: none" alt="">
</noscript>




<script src="//content.readcube.com/ping?doi=10.1038/s41591-022-02015-7&amp;format=js&amp;last_modified=2022-10-13" async=""></script>

<xhm-udpeiyyunrpk></xhm-udpeiyyunrpk><div data-cc-ghost="" style="height: 352px;"></div><script type="text/javascript" id="fetch-contextual-ads-campaign-data" charset="">(function(){var g=function(a){a=new CustomEvent("campaignDataLoaded",{detail:a});document.dispatchEvent(a)},b=google_tag_manager["rm"]["50443292"](18);if(b){var k=1500;b=google_tag_manager["rm"]["50443292"](19);b="link"===b?google_tag_manager["rm"]["50443292"](20):google_tag_manager["rm"]["50443292"](21);var m=function(a,c){var h=!1,l=setTimeout(function(){h=!0;c(null)},k),d=new XMLHttpRequest;d.onload=function(){var e=null,f=[];if(200===d.status){try{e=JSON.parse(d.responseText)}catch(p){e={}}f=e.campaigns||[]}h||(clearTimeout(l),c(f.length?f.join(","):null))};d.open("GET",
"/platform/contextual?doi\x3d"+a);d.send()},n=function(a,c){a&&-1===a.indexOf("not set")?m(a,c):setTimeout(c,1)};n(b,function(a){window.campaignsForContextualAds=a;g(a);window.dataLayer.push({content:{article:{campaignID:a}}})})}else window.campaignsForContextualAds="",g(null)})();</script>
<script type="text/javascript" id="gtm-setup-accessdetailsloaded-handler" charset="">document.addEventListener("accessdetailsloaded",function(a){a=a.detail||{};var b={event:"update-access-details"};a.institutional_business_partner_ids&&a.resolved_by||console.log("BPID data could not be retrieved from /exposed-details");a.logged_in_to_sn_profile||console.log("logged_in_to_sn_profile could not be retrieved from /exposed-details");var c=a.institutional_business_partner_ids&&a.institutional_business_partner_ids.join?a.institutional_business_partner_ids.join(";"):"",d=a.resolved_by&&a.resolved_by.join?
a.resolved_by.join(";"):"",e=a.personal_business_partner_id_found,f=a.logged_in_to_sn_profile,g=a.snid;b.user={};b.user.profile={};b.user.profile.profileInfo={resolvedBy:d||null,bpid:c||null,personal:e||null,logged_in_to_sn_profile:f,snid:g||null};b.session={};b.session.authentication={};b.session.authentication.token=a.token||null;b.session.authentication.legacy={};window.dataLayer.push(b);window.idpUserDataLoaded=!0},!1);window.dataLayer.push({event:"accessdetailsloaded-handler-added"});
window.accessDetailsLoadedHandlerAdded=!0;</script><script type="text/javascript" id="gtm-mediatrust" charset="">var s=document.getElementsByTagName("script")[0],p=document.createElement("script");p.async="async";p.src="https://scripts.webcontentassessor.com/scripts/93dabb8d80079a87fec7bb6f67b807fce90e1688f8957ad7ad152bfd58ea01c2";s.parentNode.insertBefore(p,s);</script><script id="crossmark-script" text="" charset="" type="text/javascript" src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script><script type="text/javascript" id="polyfill-matches" charset="">Element.prototype.matches||(Element.prototype.matches=Element.prototype.matchesSelector||Element.prototype.mozMatchesSelector||Element.prototype.msMatchesSelector||Element.prototype.oMatchesSelector||Element.prototype.webkitMatchesSelector||function(a){a=(this.document||this.ownerDocument).querySelectorAll(a);for(var b=a.length;0<=--b&&a.item(b)!==this;);return-1<b});</script><script type="text/javascript" id="fetch-idp-user-data" charset="">(function(a){if("function"===typeof window.CustomEvent)return!1;var c=function(d,b){b=b||{};var e=document.createEvent("CustomEvent");e.initCustomEvent(d,b.bubbles||!1,b.cancelable||!1,b.detail||a);return e};c.prototype=window.Event.prototype;window.CustomEvent=c})();var parse=function(a,c){try{return 200===a?JSON.parse(c):null}catch(d){return null}},dispatch=function(a){a=new CustomEvent("accessdetailsloaded",{detail:a});document.dispatchEvent(a)},site=google_tag_manager["rm"]["50443292"](59),idpUrl;
switch(site){case "nature":idpUrl=-1<window.location.hostname.indexOf("local-www")||-1<window.location.hostname.indexOf("test-www")?"https://staging-idp.nature.com/exposed-details":"https://idp.nature.com/exposed-details";break;case "link":idpUrl=-1<window.location.hostname.indexOf("link-qa")?"https://staging-idp.springer.com/exposed-details":"https://idp.springer.com/exposed-details";break;case "springer":idpUrl=-1<window.location.hostname.indexOf("local-www")||-1<window.location.hostname.indexOf("test-www")?
"https://staging-idp.springer.com/exposed-details":"https://idp.springer.com/exposed-details"}if(void 0!==idpUrl){var transport=new XMLHttpRequest;transport.open("GET",idpUrl,!0);transport.withCredentials=!0;transport.onreadystatechange=function(){4===transport.readyState&&dispatch(parse(transport.status,transport.responseText))};transport.send()}else dispatch(null);</script><script src="https://verify.nature.com/verify/nature.min.js"></script><script type="text/javascript" id="create-ad-slots" charset="">function createAndLoadAds(){function h(b){"nature"===a&&google_tag_manager["rm"]["50443292"](87)(b);"bmc"!==a&&"springeropen"!==a||google_tag_manager["rm"]["50443292"](99)(b);("link"===a&&"oscar"===google_tag_manager["rm"]["50443292"](100)||"springer"===a||"link"===a&&!0===google_tag_manager["rm"]["50443292"](101))&&google_tag_manager["rm"]["50443292"](126)(b);"link"===a&&"bunsen"===google_tag_manager["rm"]["50443292"](127)&&google_tag_manager["rm"]["50443292"](152)(b);"link"===a&&"Core"===google_tag_manager["rm"]["50443292"](153)&&google_tag_manager["rm"]["50443292"](165)(b)}window.googletag=window.googletag||{cmd:[]};var a=google_tag_manager["rm"]["50443292"](166),e=google_tag_manager["rm"]["50443292"](168);
if(-1===window.location.search.indexOf("hide_ads\x3dtrue"))if(window.adSlots&&0!==Object.keys(window.adSlots).length)console.log("Ads previously loaded. Will not update ad slots until next page load.");else{window.adSlots||(window.adSlots={});window.getAd=function(b,f){for(var c in window.adSlots)if(-1<c.indexOf(b)){if("object"===f)return adSlots[c];if("slot"===f)return adSlots[c].slot}};googletag.cmd.push(function(){googletag.pubads().setPrivacySettings({limitedAds:e});console.log("limitedAds is ",
e);googletag.pubads().setRequestNonPersonalizedAds(google_tag_manager["rm"]["50443292"](170));googletag.pubads().enableSingleRequest();googletag.pubads().disableInitialLoad()});for(var g=document.querySelectorAll("[data-gpt]"),d=0;g[d];++d)h(g[d]);googletag.cmd.push(function(){googletag.enableServices()})}}createAndLoadAds();</script>
</body></html>